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SUMMARY 
 
SUMMARY 
Conditional gene expression systems are valuable tools for herpesviral research. As yet, all 
available expression systems base on two features: first, an expression cassette with responsive 
elements and second, the inducer, i.e. a chemical compound or a protein. In this study, a novel 
inducible expression system has been developed, that bases on intrinsic features of herpesviruses, 
thus conditional expression is turned on by wild type virus infection. This has been achieved by 
exploiting the herpesvirus origin of lytic replication (oriLyt) of the murine Cytomegalovirus 
(MCMV) to activate the expression of adjacent genes. Cell lines carrying an episomal vector, with 
a reporter or transgene combined with the oriLyt were constructed. These oriLyt-based replicon 
vectors were silenced in uninfected cells; however, virus infection liberated the plasmids from 
histone-deacetylase-induced inactivation. Replication of the episome after infection led to a very 
strong induction of gene expression by up to 1.000-fold. This virus-inducible expression system 
opened a wide range of application possibilities. 
 A variety of diseases attributed to herpesvirus infections in livestock has a high 
economical impact. Vaccines have been developed; but several disadvantages limit their general 
application. Intracellular immunization is discussed as an option to vaccination. Hereby a viral 
dominant–negative protein is used to prevent herpesvirus dissemination in the animal cell. 
Previous attempts were unsuccessful due to strong side effects of the constitutively expressed 
transgenic dominant-negative proteins. An important step towards the implementation was 
achieved by constructing the replicon vector system, as transgene expression is activated by a 
wild type virus infection itself without using chemicals or genetically modified viruses. The results 
of the present study show that viral infection specifically activated the expression of a dominant-
negative transgene, which in turn inhibited viral growth. 
 The trans-complementation of late herpesviral proteins is very demanding. Incorrect 
expression timing and insufficient transgene amounts hamper the successful production of trans-
complemented viruses. Furthermore, isolated and high expression of viral proteins can be toxic 
for the cell. These problems were overcome with the replicon vector system. Using glycoprotein 
O and the transmembrane protein M50 it was demonstrated in this study that the system even 
enables the expression of toxic proteins. 
  Furthermore, the replicon vector was used to generate a transgenic mouse line (VIOLA). 
This mouse line expressed the reporter gene only upon infection with MCMV. The expression 
was inducible in explant cultures of the mouse but not in vivo. This interesting property of the 
VIOLA mice might be used to study herpesvirus-induced chromatin remodeling. 
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ZUSAMMENFASSUNG 
Konditionale Expressionssysteme sind wertvolle Werkzeuge für die Forschung an Herpesviren. 
Bisher hatten alle erhältlichen Expressionssysteme eine gemeinsame Eigenschaft. Sie basieren auf 
zwei Bestandteilen: erstens einer Expressionskassette mit schaltbaren Elementen und zweitens 
einem induzierenden Molekül oder Protein. In dieser Arbeit wurde ein neuartiges induzierbares 
Expressionssytem entwickelt, dass auf natürlichen Eigenschaften von Herpesviren zurückgreift 
und damit durch eine Infektion mit Wildtyp-Viren angeschaltet werden kann. Dafür wurde der 
herpesvirale Ursprung der lytischen DNA-Replikation (oriLyt) des murinen Zytomegalievirus 
verwendet, um benachbarte Gene zu aktivieren. Zell-Linien wurden erzeugt, die ein Trans- oder 
Reportergen mit dem oriLyt auf einem episomalen Vektor enthalten. Diese oriLyt-basierenden 
Replikonvektoren wurden in nichtinfizierten Zellen inaktiviert; aber durch Virusinfektion 
konnten die Plasmide von der Histone-Deacetylase- abhängigen Stilllegung befreit werden. Die 
gleichzeitige Replikation des Vektors führte zu einer sehr starken Induktion der Genexpression 
um das tausendfache. Dieses neue Virus-induzierbare Expressionsystem eröffnet eine weite 
Reihe von Anwendungsmöglichkeiten. 
 Herpesviren sind wichtige Pathogene, die sowohl Mensch als Tier befallen. Durch 
Herpesviren hervorgerufene Erkrankungen verursachen erheblichen ökonomischen Schaden in 
der Nutztierhaltung. Impfstoffe für Nutztiere wurden entwickelt; mehrere Nachteile schränken 
jedoch ihre allgemeine Anwendung ein. Als Alternative ist das Konzept der intrazellulären 
Immunisierung denkbar. Hierbei wird in den tierischen Zellen ein virales, dominant-negatives 
(DN) Transgen verwendet, das die Ausbreitung der Infektion verhindern soll. Bisherige Versuche 
schlugen aufgrund der starken Nebeneffekte der konstitutiv exprimierten transgenen DN 
Proteine fehl. Ein wichtiger Schritt zur Implementierung wurde durch die Konstruktion der 
Replikonvektoren erreicht, da die Transgene durch die Infektion mit dem Wildtyp-Virus aktiviert 
werden, ohne die Notwendigkeit chemische Verbindungen oder genetisch modifizierte Viren zu 
benutzen. Die Ergebnisse dieser Studie zeigen, dass eine Infektion die dominant-negativen 
Transgene spezifisch anschaltet und dabei die Ausbreitung des Virus verhindert. 
 Die Trans-Komplementierung von späten herpesviralen Proteinen stellt eine 
Herausforderung dar. Die erfolgreiche Produktion von trans-komplementierten Viren wird durch 
mangelnde Transgene Menge und falsche Expressionszeitpunkte beeinträchtigt. Außerdem kann 
die isolierte und hohe Expression von viralen Proteinen toxisch für die Zelle sein. Diese 
Probleme wurden durch das Replikonvektor-System gelöst. Mit Hilfe des Glycoproteins O und 
des transmembranen Proteins M50 konnte in dieser Arbeit gezeigt werden, dass das 
Replikonsystem sogar die Expression von toxischen Proteinen ermöglicht.  
ZUSAMMENFASSUNG 
 
Schließlich wurde der Vektor zur Erzeugung einer transgenen Mauslinie (VIOLA) verwendet, die 
das Reportergen Luciferase abhängig von der viralen Infektion mit MCMV exprimiert. Die 
Expression war in Explant-Kulturen, aber nicht in der lebenden Maus induzierbar. Diese 
bemerkenswerte Eigenschaft der VIOLA-Maus könnte eventuell zur Untersuchung von 
Herpesvirus-bedingter Chromatin Umstrukturierungen dienen. 
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1 INTRODUCTION 
1.1 Herpesviruses 
Herpesviruses comprise a very large class of double-stranded DNA viruses, with over 200 
different species identified so far. They possess a broad host spectrum, as almost if not all 
vertebrates and even some invertebrates analyzed to date harbor at least one specific herpesvirus 
[1]. Still, a common feature of herpesviruses is their primary association with one particular host 
species. The ongoing identification of new virus species led to a re-classification of herpesviruses 
by the International Committee on Taxonomy of Viruses in 2009. The old family of 
herpesviridae is now split into three families and incorporated in the new order herpesvirales [2] 
(Figure 1). 
 
 
Figure 1: Taxonomy of herpesviruses 
Due to newly identified species the herpesvirus taxonomy has been updated in 2009 [2]. The order of herpesvirales is 
now divided into three families. The most important family, the herpesviridae, is grouped in three distinct 
subfamilies. For each of the subfamilies viruses infecting humans have been identified. Shown are also species 
infecting mice with the exception of the species MuHV-3, MuHV-5 and MuHV-6, which are not assigned to any 
subfamily yet. Up to date no alpha-herpesvirus infecting mice were isolated. 
 
 The ability to establish a life-long latency after primary infection is a hallmark of 
herpesvirus infection [3]. Recurrent infection can emerge by reactivation from this silent state, in 
which only few herpesviral genes are expressed. Herpesvirus infection, in general, leads to a mild, 
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asymptomatic course through the long evolutionary adaptation of virus and host immune system 
[4]. However, severe manifestations of disease can arise in case of primary infection, re-infection 
or reactivation of immunocompromised hosts, as elderly, during pregnancy or 
immunosuppression in correlation with solid or bone marrow transplantation. Moreover, some 
herpesviruses possess also oncogenic potential [5].  
 The medical and economically most relevant family is the family of herpesviridae that 
infects mammals, birds and reptiles. The herpesviridae are divided into three major subfamilies, 
namely α-, β- and γ-herpesvirinae. Herpesviruses infecting and causing disease in humans can be 
found in any of these subfamilies. These are herpes simplex virus 1(HSV-1; above all herpes 
labialis, encephalitis, keratoconjunctivitis), herpes simplex virus 2 (HSV-2; herpes genitalis), 
varicella-zoster virus (VZV; chicken pox, zoster/shingles), human cytomegalovirus (HCMV; 
hepatitis, pneumonia, leucopenia, gastrointestinal disease, retinitis),  human herpesvirus 6 (HHV-
6; Roseola infantum), human herpesvirus 7 (HHV-7, Roseola infantum), Epstein-Barr virus 
(EBV; infectious mononucleosis, Burkitt’s lymphoma) and Kaposi’s sarcoma-associated virus 
(KSHV; Kaposi’s sarcoma, morbus Castleman). The grouping to one of the subfamilies is largely 
based on their tissue tropism as well as characteristics of productive infection [5]. The members 
of the α-herpesvirinae possess a broad cell tropism and reside in their latent stage mainly in 
sensory neurons of trigeminal ganglia [6]. They can infect several host cell cultures in vitro and 
possess a short and effective replication cycle leading to rapid destruction of infected cells [1]. γ-
herpesvirinae infect fewer cell types productively and reside primarily in lymphoid and myeloid 
cells in their latent stage causing lymphoproliferativ diseases [7]. Characteristic for the β- 
subfamily is a long replication cycle and relatively broad cell tropism. Latently infected cells are 
often found in cells derived from the myeloid lineage [8], but many other cell types seem to 
harbor latent genomes as well [9]. A subgroup of the β-herpesviruses, the cytomegaloviruses 
(CMV), is of major clinical importance. CMV’s are named in accordance with the appearance of 
greatly enlarged cells with intracellular and intranuclear inclusion bodies. Human CMV (HCMV) 
plays an important role in infection of immunocompromised individuals such as transplant or 
AIDS patients, and infection of the fetus or newborn. Congenital infection leads to long-lasting 
health problems in 50 % of the cases as mental retardation, hearing or vision loss, growth 
problems and others [10]. Hence, calculating the cost of congenital acquired HCMV disease to 
the health care system and the threat to human health, the Institute of Medicine selected HCMV 
to the most needed viral vaccine [11].  
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1.2 Herpesvirus morphology 
All herpesviruses share the same morphology with an icosahedral capsid embedded in a 
proteinaceous layer called the tegument and are surrounded by a lipid envelope covered by 
several glycoproteins (Figure 2). The linear double-stranded DNA (ranging from 124-230 kb in 
length) is packed in form of a torus [12] and encodes between 70 - 230 genes, depending on the 
subfamily. The icosahedral capsid is about 100 nm in size, and consists of 162 capsomers. Four 
proteins shape the capsid. The major capsid protein (MCP) forms pentons and hexons that are 
connected by trimers, which are built by the minor capsid protein and minor capsid binding 
protein [13]. These are then decorated by the smallest capsid protein (SCP), which is the least 
conserved of the capsid proteins [14]. While SCP is essential in β-herpesvirinae it is dispensable in 
other subfamilies.  
 
Figure 2: Morphology of a herpesvirus virion 
A) Schematic illustration and B) positive stain electron microscopic picture of a herpesvirus virion. (modified from 
[15]). C) Reconstitution of a herpesvirus capsid from cryo-electromicroscopy. The position of the small capsid 
protein (SCP) on the tips of hexon and penton bases is depicted in dark grey (modified from [16]). 
 
 The capsid is surrounded by the tegument, a protein layer that consists of several 
proteins (and some RNA), and might possess an ordered layered structure [17]. These proteins 
modulate host functions without the need of prior viral protein synthesis. They help the virus to 
evade the immune system and to start its own gene expression [18]. Herpesviruses acquire their 
final envelope, which is covered with a plethora of different glycoproteins and – complexes [19]. 
The number, amount and type of glycoproteins varies between different herpesviruses. In total 
the mature virion reaches a size of 120 – 260 nm.  
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1.3 Herpesvirus replication cycle 
Herpesviruses enter the cell by different ways and therefore not only one specific but many 
receptors have been identified that might play a role in attachment [20, 21]. Furthermore, fusion 
of the envelope with the plasma membrane or a membrane of the endosome can be used 
depending on the cell type to be infected [22, 23]. Right after entry, the tegument proteins hide 
the virus from the immune system, fend off apoptotic mechanisms and, in some cases, shut off 
host protein synthesis [4]. Using other tegument proteins, capsids travel along microtubules to 
the microtubule organizing center (MTOC), from where they are further transported to nuclear 
pores. There, capsids partially disassemble and inject the viral DNA into the nucleus [24]. Inside 
the nucleus either latent or lytic replication cycle is started. In the lytic cycle, immediate early 
proteins are expressed stimulated by proteins brought by the virion [25] or are directly 
transcribed by the host RNA polymerase II [26]. These immediate early proteins start the cascade 
of a precisely regulated gene expression [27].  Early gene products are triggered by immediate 
early viral transcription factors and thus are not or little transcribed without the presence of these 
viral factors. 
 Early gene expression leads a. o. to amplification of the viral DNA producing long and 
branched concatemeric DNA (see chapter 1.4). Recently, the dogma of the mechanism of 
herpesviral DNA replication has been challenged. At present, it is unclear whether linear or 
circularized genomes serve as templates. After viral DNA replication has started expression of 
true-late genes is induced [28, 29]. The concatemeric DNA is cleaved in unit length genomes and 
is immediately packed into the freshly assembled capsids. Capsids egress from the nucleus by 
budding through the nuclear membrane ― the first envelopment and de-envelopment process 
[19]. In the cytoplasm, the tegument assembles around the capsids and gain their final 
glycoprotein covered envelope by budding into the TGN [19]. Mature virions are released by 
fusion with the plasma membrane (see Figure 3). 
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Figure 3: Schematic model of a herpesvirus replication cycle. 
(1) Herpesvirus particles bind via glycoproteins to largely undefined receptors at the cell membrane. (2) Entry 
follows after fusion of the envelope with the plasma membrane (in fibroblasts) or via receptor mediated endocytosis 
(not depicted here). (3) Capsids travel via microtubules to the MTOC and then to nuclear pores, where the viral 
genome is released into the nucleus after partial destabilization of the capsid. (4) The viral genome circularizes and 
the cascade of gene expression starts with immediate early genes being transcribed, (5) which in turn activate early 
genes. Early gene products drive a. o. (6) the viral DNA replication and subsequently late gene expression is started. 
At the beginning viral genomes are amplified via a theta-replication or a recombination dependent replication. 
Replication continues probably by rolling circle amplification. (7) Long branched concatemers are finally produced. 
(8) Several late proteins build the viral capsids that (9) are packed with linear unique length genomes. (10) Nuclear 
capsid bud through the inner nuclear membrane, (11) leading to enveloped capsids in the perinuclear space, which 
are (12) released into the cytoplasm by a de-envelopment step. (13) Tegument proteins assemble around the capsid in 
the cytoplasm and particles are targeted to the TGN, where they acquire their final envelope covered with viral 
glycoproteins. (14) Exocytotic vesicles fuse with the plasma membrane and thereby (15) release the mature 
enveloped virion into the extracellular space. 
 
1.4 DNA replication of herpesviruses 
As herpesviruses have two alternative lifecycles (latent and lytic), their DNA replication has 
adapted to these different needs. During lytic replication a high number of viral genomes is 
produced. Many viral as well as some cellular proteins are actively involved in the replication of 
viral DNA, which is initiated from the origin of lytic DNA replication (oriLyt). Most knowledge 
of the mechanism of herpesviral DNA amplification arises from work on HSV-1, while little 
information is available about this mechanism in other herpesviruses. In general the DNA 
replication follows two essential steps. The initiation of DNA replication is the first step. A 
variety of mechanisms to recognize the origin of replication, to dissociate and open the double 
helix, and to recruit the replication proteins are exploited by herpesviruses. The second part, the 
DNA synthesis step however seems to be conserved. 
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Figure 4: Types of DNA replication 
Three types of DNA replication are discussed for herpesvirus genome amplification. A) Rolling Circle Amplification. 
The DNA strand is nicked and new DNA is synthesized on the 3’ end, while the 5’ end is displaced from the 
heteroduplex. The complementary strand is synthesized with the displaced strand as template. This type of 
replication can produce long concatemeric genomes. B) Theta-replication. At an origin of replication specialized 
protein initiate unwinding of DNA. Replication of the DNA is bi-directional. Thereby two circular daughter 
genomes are produced. C) D-loop (or Displacement-loop) Replication. A DNA strand invades the double helix and 
replaces the complementary strand, resulting in a short stretch of a triple helix. This serves as a primer for DNA 
synthesis. A second replication origin is activated as the D-loop expands and synthesizes the complementary strand. 
Two circular genomes are produced by the D-loop like replication. 
 
 The commonly accepted model for herpesvirus DNA amplification involves the 
formation of circular genomes after entry of the genome into the cell. Theta-replication and 
subsequent rolling circle amplification are thought to generate highly concatemeric and branched 
genome intermediates [30]. While the existence of head-to tail concatemers and the ability to 
amplify oriLyt-containing plasmids provide proof for the existence of a rolling circle 
amplification phase, there is no experimental evidence to support the theta-replication mode [31] 
(for comparison of the replication types see Figure 4). However, this theory explains the 
dependence on cellular topoisomerase II at the early amplification stages and the non-linear 
kinetics [32]. Rolling circle amplification alone cannot explain the highly branched viral 
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concatemeric genomes. Theoretical explanations could be redundant initiation, recombination 
intermediates or strand evasion; however unambiguous evidence for these mechanism is lacking 
[31]. While data are conflicting, most experimental evidence points to circular genomes as 
templates for DNA replication [32]. Wilkinson and Weller proposed the involvement of 
homologous recombination and D-loop formation as a model for DNA initiation followed by 
rolling circle amplification [33], which better explains the observed branched structures then the 
old model. 
1.4.1 Proteins required for herpesviral DNA replication 
The core machinery of the lytic DNA replication consisting of six proteins is conserved in all 
herpesviruses and resembles functional analogues of eukaryotic replication proteins [34]. These 
are a DNA polymerase with a processivity factor, three proteins building a helicase-primase 
complex and one single-stranded DNA binding protein. However, the initiation of lytic DNA 
replication and the sequences and structures of oriLyts are highly diverse between the 
subfamilies. Furthermore, the mechanisms of initiation of DNA replication seem to be as diverse 
as the replication origins themselves. Origin binding or origin activating proteins (OBP) are also 
not conserved ― speaking for a co-evolution of activating proteins and origin sequences [35, 36]. 
Remarkably, the core set of replication proteins can be exchanged by herpesviruses of another 
class, yet, the origin binding/activating protein and the origin of replication must belong to the 
same herpesvirus [36]. 
1.4.2 Structure of herpesviral replication origins and initiation of DNA replication 
1.4.2.1  Structure of replication origins of α-herpesviruses 
Not only the structure, but also the number of replication origins is variable among the 
subfamilies. Herpesviruses of the α-subfamily possess three replication origins, according to their 
positioning in the genomic segment. It is unclear, why α-herpesviruses harbor three origins, as 
any of these origins suffices for replication and reactivation from latency [37-39]. In contrast, β-
herpesvirinae harbor only one oriLyt and γ-herpesviruses encode 2 to 3 replication origins. 
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Figure 5: Structure of various herpesviral genomes and position of replication origins 
Depicted is the overall organization of various α-, β- and γ- herpesviral genomes. Terminal Repeats (TR), Internal 
Repeat (IR), Unique Region /long /short (U, UL, US), Repeat ( R). 
  
 All three origins of α- herpesviruses represent compact short palindromic sequences. 
The two oriS are identical, whereby one of them might have been acquired due to duplication of 
the terminal sequence. Moreover, most of the α-herpesviruses use the conserved sequence 
GTTCGCAC as binding site for the origin binding protein. This motif can be found in high 
affinity binding sites (Box I) and low affinity binding sites (Box II and Box III). The first step in 
HSV-1 origin licensing, meaning origin activation, is the binding of protein OBP (UL9) as a 
dimer to 10 bp motifs in Boxes I,II and III [40]. Although UL9 contains a helicase domain, ATP-
dependent unwinding of DNA could not been shown on long double-stranded DNA stretches 
[34]. UL9 works rather in a corporate fashion with the single-strand DNA binding protein UL29 
(alias ICP8) and forms a hairpin structure by complementary base-pairing of Box I and Box III 
[34, 41]. The binding of UL9 might thereby result in bending, distortion and destabilization of 
the superhelicity of the origin [41]. Changes in the conformation and the strand separation could 
then allow binding of the helicase/primase complex UL5/UL52/UL8 to the origin, as well as the 
recruitment of the other replication enzymes [42](Figure 6). Leading and lagging strand synthesis 
is then facilitated by the herpesvirus encoded DNA polymerase, which can be specifically 
blocked with nucleoside analogous like phosphonoacetic acid [43]. 
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Figure 6: Model of herpes simplex virus type-1 DNA replication ( from [44]) 
1–3: successive binding, looping, and distortion of oriS by the UL9 protein (UL9). Boxes I, II, represent the UL9 
protein recognition sites. The converging arrows indicate the relative orientation of Boxes I and II. The diverging 
arrows indicate transcription from the ICP4 and ICP22/47 promoters. 4: binding of ICP8 to the UL9 protein and 
distorted DNA. 5: ATP-dependent DNA unwinding that generates ICP8-coated DNA strands. 6A: recruitment of 
DNA helicase-primase (UL8-5/52) by UL9 protein followed by primer synthesis (curved line) and dissociation of UL9 
protein. 6B: recruitment of DNA polymerase -primase (Pol α-Primase) by UL9 protein followed by primer synthesis 
(curved line) and elongation, and dissociation of UL9 protein and DNA polymerase-primase. 7: Unwinding of the 
DNA replication fork and lagging-strand priming by the DNA helicase-primase. Leading- and lagging-strand DNA 
synthesis promoted by the HSV-1 DNA polymerase (Pol/UL42). The arrows indicate the direction of translocation 
of the DNA replication proteins or that of the DNA.  
 
1.4.2.2 Structure of replication origins of β-herpesviruses 
With respect to their replication origins the subfamily of β-herpesviruses is divided into the 
roseoloviruses (HHV6 and HHV7) and CMVs. While the roseoloviruses encode an OBP and the 
respective recognition site homologous to the α-subfamily, CMVs harbor a unique replication 
origin with no homology to any herpesviral replication origin of the other subfamilies. 
Furthermore, no classical OBP could be identified. Compared to the minimal sequence of the 
replication origins of HSV-1 of 45 bp or 144 bp respectively, the minimal length for CMVs 
oriLyt sequences are much larger, with 1.4 kb for HCMV [45], 1.7 kb for murine cytomegalovirus 
(MCMV) [46] or 1.3 kb for simian cytomegalovirus (SCMV) [47]. In HCMV, additional 
sequences flanking the oriLyt up to 4 kb in total length increase the replication efficiency in vitro 
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[45-48]. The analysis of sequence requirements of the HCMV oriLyt in the viral context 
furthermore revealed that besides this quite large minimal oriLyt sequence the accessory regions 
in the viral genome are absolutely required to produce infectious viruses [49].  
 The overall organization of the CMV oriLyt sequence is asymmetric and at least two 
domains can be distinguished. In domain I a high number of direct (DR) and indirect repeats 
(IR), as well as palindromic sequences and A/T rich regions of varying length can be found. It 
also contains an unrepeated essential stretch of pyrimidine residues, coined the Y-block [48, 50]. 
Furthermore, the oriLyt sequences includes several consensus motifs for cellular transcription 
factor binding sites (Sp1, CRE, MLTF/USF) [48]. The most extensively studied CMV oriLyt, the 
HCMV oriLyt, was shown to include an essential promoter element that is responsive to the IE2 
and UL84 protein [51, 52]. This element can be substituted by an SV40 early promoter, indicating 
that transcription is important for the functionality of the oriLyt [52]. The promoter element was 
suggested to be bidirectional as the orientation relative to the second domain was not relevant for 
activity of the oriLyt. Domain II is less complex and very G/C rich. Moreover, the HCMV oriLyt 
harbors a stable DNA/RNA hybrid structure with stem loops [53], which are bound by the UL84 
protein [54]. Binding of UL84 was proposed to change the conformation of this area [54]. This 
resembles the UL9 induced hairpin-formation and duplex-distortion of HSV-1. The function and 
necessity of UL84 is discussed controversially, as in some experimental set ups and virus strains 
the presence of UL84 was essential [55] and in others not [56]. 
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Figure 7: Organization of the MCMV replication origin 
Depicted is the overall organization of the MCMV oriLyt. A) GC-content of the minimal oriLyt region (nt position 
according to pSM3fr).The Y-block has been annotated according to sequence alignment with RCMV and HCMV.  
B)The oriLyt of MCMC harbors many indirect (IR) and direct repeats (DR) and palindromic sequences (P). C) The 
oriLyt contains many transcription factor binding sites e.g. for AP2, AP3, C/REB and TBP (predicted by the 
program PROMO [57]. 
 The oriLyt sequence of MCMV harbors many direct and indirect repeats, palindromic 
sequences and transcription factor binding sites. These are structural elements which are also 
present in HCMV, yet there is no sequence homology between MCMV and HCMV oriLyt. The 
proteins necessary for oriLyt-dependent DNA replication of MCMV are not yet identified. 
Although it has been proposed that it might be the homologue of HCMV, there is no 
experimental evidence. However, the core replication components are conserved. Concerns arise, 
whether the M84 protein of MCMV is a real homologue to UL84 as it is only distantly related 
and not essential for replication in cell culture [58, 59]. However, no other MCMV protein shares 
significant homology to UL84 either. The question if the MCMV oriLyt harbors a RNA/DNA 
hybrid like the human one has not been addressed so far.  
 
INTRODUCTION 
12 
 
1.4.2.3 Structure of replication origins of γ-herpesviruses 
In contrast to α- and β-herpesviruses, most γ-herpesviruses have clearly specialized replication 
origins for their latent or lytic replication. The most studied γ-herpesvirus is the Epstein-Barr-
Virus (EBV). Its latent replication origin oriP leads to a one-per-cell-cycle replication of the 
circular EBV plasmid, mediated by the viral protein EBNA-1 and the cellular replication 
machinery. Additionally, the EBV genome encodes two lytic replication origins. Similar to HSV-1 
the reason for several lytic replication origins is not clear. The mechanisms of latent and lytic 
replication have little in common and possess independent cis- and trans-activating factors 
pointing to separate mechanisms [60]. There is no sequence homology of the oriLyt of EBV to 
those of the α-herpesvirus subfamily, but some features resemble structures of the β-herpesvirus 
subfamily. 
 The murine herpesvirus 68 (MHV68) serves as a mouse model for γ-herpesvirus 
infection. MHV68 does not encode a classical oriP but harbors two different lytic replication 
origins. A 1.25 kbp minimal oriLyt sequence is located at the right end of the linear genome 
within the M5 - M6 region [61], whereas the second one is 600 bp in length and locates in the 
M10 locus on the left side of the genome [62, 63]. The homologous elements of both oriLyt 
sequences revealed several essential CCAAT boxes, as well as auxiliary 40 bp GC-rich repeats at 
the 3’ end and an AT-rich palindrome [62]. Proteins necessary for the activation of MHV68 
oriLyts have not been identified, yet. 
1.5 Genetic tools to study herpesvirus biology  
Cloning the herpesvirus genomes into bacterial artificial chromosomes (BAC) has paved the way 
for modern herpesvirus genetics [64] (see Figure 8). Thus modifications to the herpesviral 
genome can be prepared in the bacterial cell and ongoing improvements to the reverse genetic 
tool set enable now any mutation to be introduced into the herpesviral genome.  
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Figure 8: Methods of herpesvirus mutagenesis.  
A) Site-directed mutagenesis in eukaryotic cells. A linear DNA fragment containing the mutation and a marker gene 
(red box) flanked by sequences homologous to the viral target sequence, is transfected into virus-infected cells. By 
homologous recombination (dashed lines) the marker gene is inserted into the viral genome. Recombinant viruses 
and wild-type viruses need further separation. B) The cosmid approach. Overlapping fragments spanning the entire 
virus genome are cloned as cosmids. A mutation is introduced into one fragment (red box). After transfection into 
permissive cells, the virus genome is reassembled by several homologous recombination events generation the 
mutant virus progeny. C) The principle of viral bacterial artificial chromosome (BAC) mutagenesis. The viral genome 
is maintained as a BAC in E.coli. Mutant viral BACs can be generated using various mutagenesis approaches /red 
arrow). Recombinant viral BAC DNA is transfected into cells and the mutant virus progeny is reconstituted. (from 
[65]) 
 
 Observing phenotypes caused by mutation of herpesviral genes and comparison to wt 
allow delineating their function. To correlate a phenotype to the introduced mutation needs 
always the controls of reverted mutants to exclude that the observed phenotype is due to 
unwanted side effects during the cloning procedure. At the moment, routine sequencing of a 
complete herpesviral genome is not cost-effective and restriction pattern analysis and southern 
blotting may not allow the detection of all mutations [66]. Therefore, the reversion of the 
introduced mutation, which should lead to the wt phenotype, is an appropriate method. Various 
complementation methods have been developed for this purpose (see figure Figure 9). Cis-
complementation, whether it takes place in bacteria or the host cell, exchanges the mutant allel 
with the wt allel on its original position. This bears some risks if other genetic elements span the 
region of interest. Non-annotated overlapping genes, which might have been destroyed by the 
mutation, will be corrected by this way as well; therefore this procedure does not absolutely allow 
the correlation of the mutation and the phenotype, but helps to exclude spontaneous mutation 
on other positions in the genome.  
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Figure 9: Different approaches for confirmation of the mutation-phenotype connection. 
 A) Cis—complementation in cells allows reversion of the mutation to the wild type (wt) sequence. By transfection 
of cells with the mutant BAC genome (I) or infection with the mutant virus (II) and co-transfection of a DNA 
fragment carrying the wt sequence and appropriate viral homologies, the mutation (M) can be reverted to the wt 
sequence. Since revertant and mutant viruses need further separation, this approach only works efficiently if one can 
select for the revertant, e.g., if it has a growth advantage over the mutant virus. B) Cis-complementation of viral 
BACs in E. coli is best performed by shuttle plasmid mutagenesis. The shuttle plasmid carrying the wt sequence and 
appropriate homologies is introduced into E. coli carrying the mutant BAC plasmid. By RecA-mediated homologous 
recombination, the wt sequence is inserted at the mutation site without leaving any operational sequences. After 
transfection of the revertant BAC genome into permissive cells, a homogenous revertant population is gained 
without any further need for selection against mutant viruses. C) Protein trans-complementation in cells. Cells that 
express the viral wt gene product permanently (I) or transiently by an additional expression vector (II) are 
superinfected with the mutant virus. This allows transient complementation of the mutant phenotype if the 
expression times and levels of the wt gene product are appropriate. D) Ectopic cis-complementatin using viral 
BACS. (from [66]) 
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 Ectopic cis-complementation, meaning the insertion of the gene on another position in 
the genome prevents this problem [66]. However, knowledge of the position where this gene 
should be introduced needs to be collected first. Otherwise, again phenotypes can be falsely 
attributed. The best option is to trans-complement the protein by growth on complementing cell 
lines. Trans-complementation is still a difficult task, especially for late herpesvirus proteins. 
Incorrect timing, aberrant intracellular distribution due to missing viral interaction partners and 
incorrect expression levels of the viral protein may explain poor complementation results. 
Toxicity of the gene products and suitable cell lines limit the approach even more [66]. 
 Several trans-complementing cell lines constitutively expressing the viral proteins have 
been described. Nevertheless, many viral proteins need to be expressed conditionally to 
circumvent the above mentioned problems. Today, systems for inducible gene expression 
typically require the use of small chemical compounds such as tetracyclin or doxycyclin (as in the 
case of Tet-on/Tet-off systems)[67] or rapamycin (for FKBP12-based systems)[68]. In these 
systems, gene expression is activated synchronously and irrespective of the state of virus 
replication in all cells [69]. This could again limit the usage, as the protein is expressed at incorrect 
times regarding the viral life cycle. To adjust the timing problem, transcription activators can be 
cloned into the herpesviral genome under control of a promoter, which is activated at the desired 
time point [70].  Similarly, recombination systems like Cre/loxP and FLP/FRT can be used. 
However, this alternative needs always the manipulation of the viral genome.  
 Trans-complemented viruses are not only interesting for research purposes, but there is 
also an increasing market for spread-deficient or so called single-cycle vaccines. In these vaccines 
an essential gene is deleted, which needs to be compensated by growth on complementing cell 
lines [71]. Thereby the vaccine can infect the cell only once and thereby induce an immune 
response. Yet, without the essential protein further virus spread is inhibited. For vaccine 
development it is not desired that the vector includes bacterial sequences, therefore the above 
mentioned conditional expression systems cannot be applied. Production of sufficient trans-
complemented virus is therefore a limiting step in the application of these viruses. 
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1.6 Vaccination against herpesvirus disease 
Studies on human and animal vaccination against herpesvirus infection and disease began in the 
1970s. Since then, several vaccination concepts have been tested or realized. These can be 
classified in five general types: inactivated virus vaccines, subunit vaccines, DNA vaccines, 
attenuated virus vaccines, and markerless vaccines. Several vaccines against animal-herpesviruses 
are on the market, but there is only one licensed vaccine against a human herpesviruses, namely 
against varicella zoster virus. 
 Inactivated virus vaccines although helpful to contain diverse virus infections, have not 
been very successful in case of herpesviruses [72, 73]. Subunit vaccines contain isolated antigens 
of major virus components such as glycoproteins or structural proteins. Some of these vaccines 
showed good results in the prevention of herpesvirus-associated diseases due to a high 
neutralizing antibody response [74]. However, subunit vaccines are prone to failure due to 
different virus serotypes or virus mutations. Furthermore, several doses and adjuvants are 
typically necessary to obtain sufficient immune responses [75]. Modified live attenuated vaccines, 
possess usually a good immunogenicity as they express most of the antigen subsets and can 
replicate in the host, without causing disease. In the classical approaches virus strains were 
attenuated by several passages in cell culture. The adaptation to the cell culture conditions usually 
led to loss of gene functions that were necessary for virus pathogenesis in vivo. Many licensed 
vaccines have been generated by this way, as measles, mumps and rubella vaccine[76]. Yet, the 
mutations that arise are uncontrolled and the cause for attenuation is not always clear. The only 
herpesvirus vaccine on the market is a life-attenuated vaccine, namely the OKA-strain against 
varicella-zoster virus [77]. Attempts to create life-attenuated vaccines by similar procedures failed 
for other human herpesvirus. The right balance between immunogenicity and attenuation is hard 
to obtain. Thus, several vaccine trials were stopped, as they were either causing disease symptoms 
or did not prevent infection and disease of wt infection [78]. Thus, recent strategies involve the 
targeted attenuation of herpesvirus by reverse-genetics methods.  The highest safety level coupled 
with strong immunogenicity is achieved by single-cycle /spread-deficient vaccines. These 
vaccines lack one or several essential genes for virus replication but possess most of the antigen 
repertoire of the wild type (wt) virus. As proof of principle the vaccine MCMV-∆M94 
demonstrated that the immune response elicited by the first target cells is sufficient to control 
MCMV disease [71]. A drawback of these vaccines is the necessity to culture them on trans-
complementing cell lines and with this the poor efficacy of vaccine production. 
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1.7 Animal Herpesviruses  
1.7.1 Vaccination against animal herpesviruses 
The class of herpesviruses is very large (see chapter 1.1) and of course comprises many subtypes 
infecting domestic and livestock animals. Important pathogens among these are pseudo rabies 
virus (PRV), which leads to Aujeszky’s disease in pigs, bovine herpesvirus 1 (BHV-1), causing e.g. 
infectious rhinotracheitis and infectious pustular vulvovaginitis, Marek’s disease virus (MDV) and 
gallid herpesvirus 1 infecting poultry, and cyprinide herpesvirus affecting the increasing industry 
of fish farms. Symptoms of herpesvirus infection of animals share common features with those 
infecting human reaching from localized vesicular eruptions of surface epithelia, to diffuse and 
widespread damage of the mucosa of the respiratory, digestive and genital tracts, damage of the 
vascular epithelium and necrosis of liver, lymphoid and other tissues, as well as specific neuron 
damage such as diffuse meningo-encephalitis [79]. An exception to the strict species specificity of 
one herpesviruses to one natural host is seen with PRV. The transmission of PRV to cattle, 
sheep, goats, dogs, cats, foxes, rats and mice causes neuropathologic diseases and is irretrievably 
fatal [79, 80]. As in humans, fetuses and newborns are more susceptible to severe or lethal 
outcomes through herpesvirus infection, while infection of adult animals is typically less severe. 
Still the infection causes big economic losses to animal husbandry through loss of weight, 
decrease of milk or egg production and also restrictions in the international livestock trade [72]. 
As herpesvirus infections can lead to abortion and infertility, animal reproduction is also affected. 
Due to the nature of herpesvirus infection, latently infected animals can spread the virus in the 
herds upon reactivation.   
 For many animal species complete prevention of disease by attenuated herpesvirus 
vaccines has been reported [72, 81, 82]. Unfortunately, they generally keep some residual 
virulence and stay latently in the host. Furthermore, they cannot prevent infection with wt virus 
and establishment of latent wt virus infection [83, 84]. Furthermore, recombination of wt and 
vaccine virus towards new serotypes has been reported [85]. This is alarming, as in case of MDV 
the transmission of wt virus in the vaccinated flocks has led to more virulent strains and thus to 
the failure of vaccines [86]. The general policy in Europe has thus changed to an eradication 
program for BHV-1 and PRV-1, which includes a test and slaughter policy or test and removal 
program [87]. Upon these terms sero-positive herds have to be culled. Furthermore, marker 
vaccines and the so-called DIVA (differentiating infected from vaccinated animal) strategy 
contributed to the success of the eradication programs and many countries, Germany included, 
are now free of BHV-1 or PRV-1. As a further safety step, vaccination in these countries is even 
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prohibited. However, the eradication programs and the related vaccination prohibition keep the 
risk, that infections of non-immune herds can occur at any time through transmission from wild 
life animals, like BHV infections of dairy cows by dear, or pigs by PRV infected wild sows [88, 
89]. Testing of wild life animals revealed the underestimation of wild life infection and the risk of 
spill over infections. Also the restructuring of farming procedures towards an animal friendly 
breeding in outside cages opens the door for re-infection of healthy herds by contacts with wild 
life.  
 As vaccination against herpesviruses always resulted in the persistence of the wt virus in 
vaccinated animals, a better solution to eradicate the virus is certainly needed. The usage of 
intracellular immunization to protect livestock from infection and disease might be an alternative 
provided that necessary acceptance among consumers is gained. 
 
1.7.2 Intracellular Immunization against herpesviruses 
The term ‛intracellular immunization’ was coined by Baltimore in 1988 [90] and describes the 
expression of dominant-negative proteins (DN) in cells to inhibit viral replication. A cell that 
carries a transgenic DN protein should thus be rendered resistant to virus infection. DN proteins 
are protein mutants that exert a null-phenotype even in the presence of a functional wt protein 
(reviewed in [91], see 1.8 ). The idea of intracellular immunization was postulated in response to 
the finding of Friedmann and colleagues, that a truncated transcription activator VP16 of HSV-1, 
which was inserted into the cellular genome can provide DN resistance against HSV-1 infection 
in cell culture [92].  
 Based on this concept, other groups have tried to transfer this in vitro phenotype to 
mouse models. A dominant negative ICP4 mutant (X25) of HSV-1 that sequesters functional 
ICP4 monomers into nonfunctional heterodimeric complexes was used to generate the first 
transgenic mouse carrying an DN mutant against a herpesvirus [93, 94]. Four transgenic mouse 
lines were generated by microinjection of linearized DNA fragments encoding the X25 mutant 
under control of its own viral promoter. Copy numbers of the transgene ranged from 2 to 10 per 
cell in mouse lines. Although the general principle could be proven, only the mouse line with the 
highest copy number showed a relevant reduction of viral titer in the range of 5-13 fold [93]. In in 
vitro experiments a copy number of 40 per cell was necessary to inhibit plaque formation by the 
factor of 38 [94]. A higher copy number of the transgene was proposed to be necessary to 
achieve resistance. Unfortunately, although X25 expression was driven by the viral ICP4 
promoter and therefore should be activated in infected cells, also in uninfected cells expression of 
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X25 was observed. Furthermore, strong side effects were routinely observed in all the transgenic 
mouse lines, with one mouse line having only a third of the normal weight of non-transgenic 
weaning siblings [93]. As ICP4 operates by forming a complex with the TATA-binding protein 
and TFIIB to activate or repress transcription, it is possible that the DN protein still has some 
intrinsic potential to interact with cellular proteins and thereby disturbs host cell transcription [91, 
95].  
 Another group implemented intracellular immunization to PRV. In this case the DN 
protein consisted of a chimeric protein consisting of the DNA binding domain of IE180 of PRV 
and the tail-truncated VP16 of HSV-1, lacking the transcription activation domain [96]. Infection 
of transgenic cell lines with PRV-1 and HSV-1 revealed specific inhibition of PRV by the IE180 
DN protein [97]. One transgenic mouse line expressing the chimeric DN under control of the 
interferon inducible Mx-1 promoter could be obtained that transferred the transgene to the F1 
generation. This line carried five copies of the transgene and could successfully inhibit lethal PRV 
infection. In particular 15 of 18 control mice died upon challenge with PRV LD50 whereas 16 of 
18 transgenic mice survived the challenge [98]. Low constitutive expression of the transgene was 
observed, although the Mx-1 promoter should drive expression only by induction with interferon 
α and β [98]. Again, mice exhibited severe side effects as seen with the X25 mutant, namely heavy 
weight loss, dwarf phenotype, bad reproduction and a high ratio of females at birth. Therefore, 
intracellular immunization against herpesviruses is possible but seems to need a tight control of 
the DN protein in the uninfected state as well as an appropriate target protein that does not 
influence host cell functions. This goal, however, is demanding as the inducible systems generally 
used today need either administration of small chemical compounds or genetic modification of 
the virus. Neither system is not appropriate for livestock applications, as the drug would not be 
administered before the start of disease symptoms and infection occurs with wt virus. An 
efficient intracellular immunization should inhibit virus spread already in the first infected target 
cells, so that manifestation of the disease does not even occur. Therefore, a successful and safe 
implementation of intracellular immunization calls for an inducible system that is tight and in 
same time is activated by the wild type virus (only). 
 Thus a suitable method to construct stable cell lines and animals is pivotal in order to 
test such inducible systems and an appropriate DN protein in cell culture and that furthermore 
allows the transfer of the technology to livestock.  
INTRODUCTION 
20 
 
1.8 Dominant-negative herpesviral proteins 
Dominant-negative proteins are mutants capable to inhibit the wt protein in a cell in the way that 
it causes the cell to be deficient in the function of the gene product [91]. Meaning the wt protein 
cannot fulfill its full function in the presence of the DN protein.  Dominant-negative (DN) 
proteins can be used for the identification of protein function, identification of pathways and for 
the inhibition of viral replication by intracellular immunization. Several DN proteins of 
herpesviruses have been reported, some which were found by chance others which were 
generated by purpose. The development of a random insertional mutagenesis protocol by 
transpon based insertions facilitated the screening of any herpesviral gene for DN mutations [99].  
Three MCMV genes were subjected to such a DN screen in the past [99-101]. Interestingly in all 
proteins at least one mutation could be found that possessed DN activity. The strength of 
individual DN proteins was found to be diverse. The DN mutants of the protein M50 and M94 
were in general rather weak in their ability to inhibit viral proliferation, if they were encoded in 
the viral genome. DN mutants of the protein M53, were found to block viral spread completely. 
  An attempt to tag the small capsid protein SCP of MCMV with the green fluorescent 
protein (GFP) led to a fusion protein (GFPSCP) that elicits a strong DN effect on capsid export 
from the nucleus [102]. Viruses encoding the GFPSCP protein accumulate capsids in nuclear 
speckles and were unable to spread to neighboring cells in vitro [103]. In mice infected with an 
MCMV mutant, encoding a Tet-regulated GFPSCP, viral titers were markedly reduced e.g. in 
lungs reaching three orders of magnitude [103]. Thus GFPSCP is very useful as a model DN, as 
it exhibits a strong DN effect and additionally it can be easily monitored by its fluorescence. 
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1.9 The non-viral episomal vector pEPI for the generation of stable cell 
lines and transgenic animal  
The construction of transgenic cell lines is a fundamental tool for life science research to 
characterize proteins, to produce biological compounds like monoclonal antibodies, and also to 
complement virus deletion mutants. Several techniques have been established over time to 
manipulate the cell genome to express a foreign gene. In principle two approaches can be 
differentiated. Either the gene is integrated into the host genome, at a certain position or 
randomly, or it is maintained extrachromosomally as an episome.  
 A non-viral episomal self-replicating vector has been described that bases on a surface 
matrix attachment region (S/MAR) and a functional eukaryotic or viral origin of replication [104]. 
S/MAR elements are eukaryotic sequences that flexibly anchor the genome in loops to the 
nuclear matrix [105]. They are typically A/T rich (up to 70 %), enriched in DNA topoisomerase 
II binding sites, and do not harbor recognizable consensus sequences [106]. They are often 
associated with chromosomal origins of bidirectional replication [104] and are thought to elicit 
duplex strand destabilization,  a necessary function for DNA replication and transcription [106]. 
 An S/MAR element of the human β-interferon gene [107] was identified being 
sufficient to allow a stable episomal maintenance and once-per-cell cycle replication of a vector 
without the need of antibiotic selection pressure [108-111]. Due to its episomal maintenance the 
vector was termed pEPI-1. Although an SV40 origin of replication is included in this pEPI 
vector, its episomal persistence is independent of the large T antigen [104] and can be replaced by 
other replication origins [112]. As a prerequisite for episomal maintenance of pEPI, the direction 
of transcription needs to run into the S/MAR, most likely to generate an accessible chromatin 
structure. In the original pEPI vector an egfp gene under control of the human CMV immediate 
early promoter is thus positioned before the S/MAR site, without a transcription termination 
signal prior to the S/MAR element. The A/T rich S/MAR site itself contains also two AATAA 
signals that serve as minimal polyA sites. Furthermore a cryptic transcription termination signal is 
present 1500- 1700 bp inside the S/MAR element [113]. 
 In immunoprecipitation studies pEPI was associated with the cellular scaffold 
attachment factor A (SAF-A) [114]. SAF-A is typically involved in partitioning eukaryotic 
genomes into independent chromatin loops by attaching DNA via S/MAR regions to the nuclear 
scaffold or matrix [115]. The S/MAR element was taken from the human β-interferon gene [107], 
however artificial MAR elements, containing the SAF-A binding site, can also replace the 
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eukaryotic element [112]. Vector numbers in transfected cells were usually in the range of 2 to 10 
copies per cell [104, 111]. The vector pEPI was found to replicate synchronously once-per-cell 
cycle in early S-phase and components of the origin recognition complex could be precipitated in 
CHIP assays, such as Orc1, Orc2 and Mcm3 [116]. Interestingly, replication can start from any 
position of the plasmid [116]. Fluorescence in situ hybridization (FISH) revealed the attachment 
of pEPI vectors to metaphase chromosomes. However, they are not covalently bound as they 
can be separated from the chromosomes by higher shear forces during preparation of the 
metaphase spread [111].  
 The vector pEPI was used in a variety of different cell lines in vitro and supports a 
constitutive transgene expression in e.g. CHO, K562, HaCat cell lines and others [109, 112, 117]. 
Remarkably, the transgene expression was silenced in cells of murine origin, such as in the 
murine erythroleukemia cell line (MEL) [118], murine fibroblasts (NIH3T3) [119], immortalized 
murine embryonic fibroblasts (IMEF ) [120] but also in the human cell lines HEK293 [119] and 
HCT116 [120]. Interestingly, the episome could also be maintained episomally in the silenced 
status [118].  
 The vector attributes can also function in vivo. Transgenic pig fetuses were generated by 
sperm mediated gene transfer expressing GFP from the pEPI vector [121]. In 12 of 18 fetuses 
episomal pEPI vectors were isolated with less than 10 copies per cell. However, only 9 of 12 
fetuses with episomal plasmids expressed the transgene, but then in all analyzed tissues [121].
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1.10 Aim of the thesis 
In this work a novel gene expression system had to be constructed that had to fulfill several 
criteria: 
1. It should be inducible by viral infection without the need of modifying the virus genome. 
2. It should allow a temporally high expression of the transgenic protein. 
3. It should be activated under ‘late’ expression kinetics. 
 
The newly generated replicon vector system had to be tested for several applications. 
1. Intracellular Immunization 
 Previous studies on intracellular immunization revealed the absolute necessity of a strict 
control of the DN gene, as transgenic mice suffered from uncontrolled transgene expression (see 
chapter 1.7.2). Using the dominant-negative viral fusion protein GFPSCP, the suitability of the 
replicon system for the implementation of intracellular immunization should be evaluated. 
2. Trans-complementation of late herpesviral proteins 
 Correct expression kinetics and expression strength are important for successful trans-
complementation of viruses lacking essential late proteins. With two model proteins, the 
glycoprotein O and the toxic transmembrane protein M50, the efficacy of the replicon system to 
trans-complement the corresponding deletion viruses should be tested. 
3. Possibility to use the expression system in vivo 
 In order to analyze whether the newly generated expression system is compatible with in 
vivo applications, transgenic mouse lines had to be created and analyzed. 
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2 MATERIAL 
2.1 Devices 
Bacterial shaker ISF- 1- W Kühner, Birsfelden, CH 
Bio-Photometer  Eppendorf, Hamburg, D 
Centrifuges:  
5417 R  Eppendorf, Hamburg, D 
AvantiTM J-20xp  Beckman Coulter, Krefeld, D 
8-55M ultracentrifuge Beckman Coulter, Krefeld, D 
Multifuge 3 S-R Heraeus Instruments, Gera, D 
Confocal microscope Axiovert 200M Zeiss, Jena, D 
Developing-machine Optimax TR MS Laborgeräte, Wiesloch, D 
Fluorescence microscope 1x71 Olympus, Hamburg, D  
Flow cytometer Epics XL-MCL  Beckman Coulter, Krefeld, D 
Gene PulserTM Bio-Rad, Munich, D 
Hybridization Oven Unitherm 6/12 Uniequib, Planegg, D 
Incubator B5050E  Heraeus Instruments, Hanau, D 
Incubator BB16CU Haraeus Instruments, Hanau, D 
Incubator Shaker ISF-1-W Kühner, Birsfelden, CH 
Light microscope Axiovert 25 Zeiss Carl, D 
Microplate luminometer LB960 Berthold, Bad-Wildbad, D 
Mini-PROTEAN3 Cell Bio-Rad, Munich, D 
ND-1000 Spectrophotometer Nanodrop, USA  
PerfectBlueTM, electrophoresis system Peqlab, Erlangen, D 
Photo documentation apparatus EagleEye Bio-Rad, Munich, D 
Roller mixer SRT Stuart, Staffordshire, UK 
Semi-Dry-Transfer Cell Trans-BlotSD  Bio-Rad, Munich, D 
Sonifier-bath SONOREX SUPER RK 103H Bandelin, Berlin, D 
TGradient, PCR Machine Biometra, Göttingen, D 
Thermomixer 5436  Eppendorf, Hamburg, D 
Tissue cell culture lamina flow BDK, Sonnenbühl-Genkingen, D 
UV-Crosslinker  Vilbour-Lourmat, Eberhardzell, D 
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Vortex-Mixer Bender/Hobein, Zürich, CH 
Water Bath F10  Julabo, Seelbach D  
Shaking water bath GFL 1090 Gesellschaft für Labortechnik, Burgwedel, D 
2.2 Consumables 
Cell culture dishes (20 cm2; 55 cm2; 145 cm2) Becton Dickinson, Heidelberg, D 
Cell culture plates (6-, 12-, 24-, 48-, 96-well) Becton Dickinson, Heidelberg, D 
Cell culture flasks (25cm2, 75cm2) Becton Dickinson, Heidelberg, D 
Cell scrapers (25-, 39 cm) Costar, Bodenheim, D  
Cryotubes  Nunc, Thermo Fisher Scientific, Langenselbold, D 
Chemiluminoscence film HyperfilmTMECL GE Healthcare Bioscience, Freiburg, D 
Combitips plus (5 mL, 10 mL) Eppendorf, Hamburg, D 
Electroporation cuvettes  Bio-Rad, Munich, D 
Falcon conical tubes (15 mL, 50 mL) Becton Dickinson, Heidelberg, D 
Hybond-P membrane GE Healthcare Bioscience, Freiburg, D 
Hybond-N+ membrane GE Healthcare Bioscience, Freiburg, D 
Nylon-Membrane, positively charged Roche, Mannheim, D 
Pipettes (5 mL, 10 mL, 25 mL) Sarstedt, Nümbrecht, D 
Reaction tubes (1.5 mL, 2 mL) Eppendorf, Hamburg, D 
Whatman paper  Macherey-Nagel, Düren, D  
Ultracentrifugation tubes Beckman Coulter, Krefeld, D 
2.3  Reagents 
All common chemicals were obtained by Roth (Karlsruhe D), Sigma-Aldrich (Deisenhofen, D), 
Becton Dickinson (Heidelberg, D), Invitrogen (Karlsruhe, D), Merk (Darmstadt, D) or Fluka 
(Karlsruhe, D) unless otherwise specified. 
Restriction cloning enzymes and their buffers were purchased from NEB (Frankfurt/Main, D). 
2.4 Commercial Kits 
Crimson Taq, PCR system NEB, Frankfurt/Main, D 
DNeasy Blood and Tissue Kit Qiagen, Hilden, D 
DIG Nucleic Acid Detection Kit Roche Diagnostics, Mannheim, D 
Dual-Luciferase assay system Promega, Madison, USA 
ECL plus western blotting detection system GE Healthcare, Freiburg, D 
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Expand high fidelity PCR system Roche Diagnostics, Mannheim, D 
Gel extraction kit Qiagen, Hilden, D 
GFX micro plasmid purification kit GE Healthcare Bioscience, Freiburg, D 
Nucleobond PC100 Macherey-Nagel, Düren, D  
PCR purification kit Qiagen, Hilden; D 
PCR DIG Probe Synthesis Kit Roche Diagnostics, Mannheim, D 
Taqman 1000 RxN PCR Core Reagents Applied Biosystems, Foster City, USA 
 
2.5 Antibodies 
antibody species application source 
Α-GFP (ab290) rabbit polyclonal  WB 1:2500 Abcam, Cambridge, USA 
α-dig-Fluorescein-Fab sheep FISH Roche, Mannheim, D 
Avidin-Cy3.5 not applicable FISH Rockland, Gilbertsville, 
USA 
α-IE1/3 (CHROMA 101) mouse polyclonal  WB 1:1000 
IF: 1:500 
Stipan Jonjic, Rijeka, 
Croatia 
α- HA (3F10) rat WB: 1:1000 Roche, Mannheim, D 
α-actin (20-33) rabbit WB: 1:1000 Sigma- Aldrich, Hamburg, 
D 
2.6 Bacterial strains 
strain genotype application source 
DH10B F– mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ 
∆M15 ∆lacX74 recA1 endA1 araD139 ∆(ara leu) 
7697 galU galK rpsL nupG λ– (Strep R) 
Maintenance of BACs Invitrogen 
Karlsruhe, D 
PIR1 F- ∆lac169 rpoS(am) robA1 creC510 hsdR514 
endA recA1 uidA(∆Mlu I)::pir-116 
Maintenance of vectors with 
R6Kγ origin of replication 
Invitrogen 
Karlsruhe, D 
SCS110 rpsL (Strr) thr leu endA thi-1 lacY galK  tonA 
tsx dam dcm supE44 ∆(lac-proAB) [F´ traD36 
proAB 
Generation of dcm/dam 
methylation free DNA. 
Stratagene, Cedar 
Creek, USA 
XL1-
blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac[F´ proAB lacIqZ∆M15 Tn10 (Tetr)] 
Routine cloning of plasmid 
DNA 
Stratagene Cedar 
Creek, USA 
NEB10- 
beta 
araD139 ∆(ara-leu)7697 fhuA lacX74 galK (Φ80 
∆(lacZ)M15) mcrA galU recA1 endA1 nupG 
rpsL (StrR) ∆(mrr-hsdRMS-mcrBC) 
Efficient transformation of 
methylated DNA from 
eukaryotic sources 
NEB, 
Frankfurt/Main, 
D 
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2.7 Eukaryotic cell lines 
cell line type origin 
NIH3T3 murine fibroblasts (ATCC®: CRL-1658™) 
M2-10B4 murine bone marrow stromal cells (ATCC®: CRL-1972™) 
MHEC-5T murine heart endothelial cells [122] 
SVEC4-10 murine lymphoid endothelial cell line (SV40 
transformed) 
[123] 
mES E14 Murine embryonic stem cell line [124] 
2.8 Viruses 
Virus name reconstituted from origin 
wt-MCMV pSM3fr-MCK-2fl [125] 
MCMV-gfp pSM3fr-∆m157-egfp [126] 
MCMV-luc pSM3fr-∆m157-luc [126] 
MCMV-mCherry pSM3fr-∆1-16gfpscpIRESmCherry kindly provided by Zsolt Ruzsics, Max 
von Pettenkofer Institut, LMU 
MCMV-∆M50 pSM3fr-∆1-
16∆M50:gfp/gfpscpIRESmCherry 
kindly provided by Zsolt Ruzsics, Max 
von Pettenkofer Institut, LMU 
 
2.9 Oligonucleotides 
primer  sequence application 
H5-MCMV-orilyt-
ori6kan-for 
5’-GGCGGGAGCGACGGGGGCGAGCTGGAGA 
GATCGTCGTCCGCCATGCTAGCACGCGTGCCA
GTGTTACAACCAATTAACC -3’ 
pick-up cloning of MCMV-
oriLyt 
H3-MCMV-oriLyt-
ori6kan-rev 
5′-GAACGACCCCCGCTCCTGTATAATTTCGAT 
GCCGGGGAGGTCGCCACGCGTCTGAAGATC 
AGCAGTTCAACCTGTT-3′ 
pick-up cloning of MCMV-
oriLyt 
bsr-for-taqman 5′-CCTCATTGAAAGAGCAACGGCTAC-3′ qPCR Detection of bsr  
bsr-rev-taqman 5′-GCACCACGAGTTCTGCACAAGGT-3′ qPCR Detection of bsr 
LBR-for 5′-GGAAGTTTGTTGAGGGTGAAGTGGT-3′ qPCR Detection of lbr 
LBR-rev 5′-CCAGTTCGGTGCCATCTTTGTATTT-3′ qPCR Detection of lbr 
M54-for  5′-ATCATCCGTTGCATCTCGTTG-3′ PCR detection of M54 
M54-rev 5′-CGCCATCTGTATCCGTCCAT-3′ PCR detection of M54 
M74-for 5′-TCCGGACAACGTCTTTCCC-3′ PCR detection of M74 
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M74-rev 5′-ATCATCCGTTGCATCTCGTTG-3′ PCR detection of M74 
P(SV40) probe-for 5′-TACCGAGCTCTTACGCGTGC-3′ PCR detection of luc, VIOLA 
genotyping, Southern probe 
pA(SV40)-probe-
rev 
5′-TAAGATACATTGATGAGTTTGGA-3′ PCR detection of luc, VIOLA 
genotyping, Southern probe 
P(M143)-HindIII-
rev 
5′-CCAAGACAAGCTTCGCGCACG-3′ Cloning of Promoter M143 into 
pEpibo-luc 
P(M143)-KpnI-for 5′-CCAAGACAAGCTTCGCGCACG-3′ Cloning of Promoter M143 into 
pEpibo-luc 
P(M53)-KpnI-for 5′-CAGCTGGTACCGACCATGGCG-3′ Cloning of Promoter M53 into 
pEpibo-luc 
P(M53)-HindIII-rev 5′-
GGCTCCTAATAAGCTTACTTCTCGACGGTGAA
G-3′ 
Cloning of Promoter M53 into 
pEpibo-luc 
P(CMVie)-KpnI-for 5′-TTACAATTTACGGTACCAGCGCGCGTTG-3′ Cloning of Promoter CMVie 
into pEpibo-luc 
P(CMVie)-HindIII-
rev 
5′-
TTAGCCAAAGCTTGAGAGCTCTGCTTATATAG-
3′ 
Cloning of Promoter CMVie 
into pEpibo-luc 
P(M94)-KpnI-for 5′-TTCGCATCAGGTACCGGTTCGCCGTGATC-3′ Cloning of Promoter M94 into 
pEpibo-luc 
P(M94)-HindIII-rev 5′-GTCGCCATAAGCTTGGTCTACCTGCAGCTG-
3′ 
Cloning of Promoter M94 into 
pEpibo-luc 
bsr-for-FISH 5′-ATGGCCAAGCCTTTGTCTCA-3′ Generation of a bsr FISH probe  
bsr-rev-FISH 5′-AGATCGAGAAGCACCTGTCG-3′ Generation of a bsr FISH probe 
gfpscp-for-FISH 5′- AGCAAGGGCGAGGAGCTGTT -3′ Generation of a GFPSCP FISH 
probe 
gfpscp-rev-FISH 5′-TAGCGATCGAGAGCATCCGC-3′ Generation of a GFPSCP FISH 
probe 
 
2.10 Plasmids and bacterial artificial chromosomes 
plasmid name features origin 
p06kan Cloning vector with kanamycin cassette 
and R6K origin of replication 
kindly provided by Brigitte Rupp, Max 
von Pettenkofer-Institute, LMU 
pCR3 Cloning vector, encoding for the human 
CMVie promoter 
Invitrogen, Karlsruhe, D 
pkD46 L-Arabinose inducible expression of 
recombinases red α, -β, -γ and temperature 
sensitive replication origin oriR101 
[127] 
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pGL3-control Luciferase reporter vector: 
Firefly luciferase under control of 
SV40minimal promoter 
Promega, Mannheim, D 
pTK-RL Luciferase reporter vector: 
Renilla luciferase under control of 
Thymidin Kinase promoter 
Promega, Mannheim, D 
pHSB5 Hyperactive Sleeping Beauty kindly provided by A. Erhardt, Max von 
Pettenkofer- Institute, LMU 
pMSB5 Mutated Sleeping Beauty kindly provided by A. Erhardt, Max von 
Pettenkofer- Institute, LMU 
pTMCS Transposon vector for Sleeping Beauty kindly provided by A. Erhardt, Max von 
Pettenkofer- Institute, LMU 
pGPSie1/ie3-ie2 Plasmid encoding entire ie-1/2 and ie3 
locus 
kindly provided by K. Eisenächer, 
Medizinische Klinik und Poliklinik, TMU 
 
Table 1: Newly generated plasmids 
plasmid name features 
pT-mOrange Transposon for Sleeping Beauty containing Hygromycin 
resistance gene (hyg) and mOrange gene driven by the human 
CMVie promoter flanked by inverted repeats (IR)  
pT-gfpscp Transposon for Sleeping Beauty containing hyg and dominant-
negative gfpscp driven by the human CMVie promoter gene 
flanked by IR 
B45-gfpscp Episomal papillomavirus vector with gfpscp under control of the 
methallotheonein promoter, Kan, NeoR 
p06kan-MCMVoriLyt p06kan harbouring a 3824bp region of the oriLyt of MCMV, 
KanR  
pEpibo-luc Episomal plasmid with firefly luciferase gene (luc) under control 
of the SV40 minimal promoter, BSR 
pEpibo-P(CMVie)-luc Episomal plasmid with firefly luciferase gene (luc) under control 
of the human CMVie promoter, BSR 
pEpibo-P(M143)-luc Episomal plasmid with gene under control of the M143 
promoter (904 bp; [128]),BSR 
pEpibo-P(M53)-luc Episomal plasmid with luc under control of the M53 promoter 
(502 bp ), BSR 
pEpibo-P(M94)-luc Episomal plasmid with luc under control of the M94 promoter 
(600bp), BSR 
pEpibo-luc-ori Episomal plasmid with luc under SV40 minimal control and the 
MCMV oriLyt, BSR 
pEpibo-gfpscp-ori Episomal plasmid with gfpscp under SV40 minimal control and 
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the MCMV oriLyt, BSR 
pEpibo-gO-ori Episomal plasmid with gO under SV40 minimal control and the 
MCMV oriLyt, BSR 
pEpiNo-M50-ori Episomal plasmid with M50 under SV40 minimal control and the 
MCMV oriLyt, BSR 
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3 METHODS 
3.1 Microbiological methods 
3.1.1  Cultivation of Escherichia coli 
According to the intended application, different E. coli strains were used. All E. coli cultures were 
grown in low-salt Luria Broth (LB) medium at 37 °C. Single colonies were achieved by dispersing 
bacteria on petri dishes on LB-agar medium with appropriate antibiotics. Liquid cultures were 
grown in LB-medium with appropriate antibiotics under constant shaking at 180 rpm at 37 °C. 
To conserve E. coli strains, equal volumes of an o.n. culture and 50 % (v/v) sterile glycerol were 
mixed and stored at -80 °C.  
LB-medium(low salt)  antibiotics 
10 g Bacto Tryptone 100 µg/ml Ampicillin  
  5 g yeast extract 100 µg/ml Blasticidin S 
  5 g NaCl   25 µg/ml Chloramphenicol 
Add H2O to 1l   50 µg/ml Kanamycin 
     30 µg/ml Zeocin 
 
LB-agar 
7.5 g Agar per 500ml LB-Medium 
3.1.2 Preparation of electrocompetent E. coli 
To generate electrocompetent cells, 200 ml pre-warmed LB-medium was inoculated with 5 ml of 
an o.n. culture and cultivated until bacteria reached an OD600 of 0.45 . All subsequent steps were 
performed at 4 °C with sterile pre-chilled buffers and equipment. After incubation on ice for 30 
min, bacteria were centrifuged at 5000 × g for 10 min. Supernatants were completely discarded 
and the pellet resuspended in 150 ml ddH2O. Centrifugation steps were repeated three times 
while washing the bacteria with 150 ml 10 % (v/v) glycerol. After the last centrifugation step the 
pellet was resuspended in 1 ml 10 % (v/v) glycerol and aliquots of 50 µl were snap-frozen in 
liquid nitrogen and stored at -80 °C.  
3.1.3 Transformation of E. coli by electroporation 
Aliquots of electrocompetent cells were thawed on ice and  approx. 25 - 50 ng vector DNA was 
added directly. The mixture was then transferred to pre-chilled electroporation cuvettes (0.2 mm). 
METHODS 
32 
 
DNA transfer into bacteria was achieved by a short high-voltage electrical discharge of 2.5 kV, 
25 µF and 400 Ω. Immediately after the pulse, 1 ml pre-warmed SOC-Medium was added and 
the culture was transferred to round-bottom culture tubes for 1 h incubation at 37 °C at 180 rpm. 
Cells were plated on LB-agar with selective antibiotics in appropriate dilutions and cultured o.n. 
at 37 °C. Typical transformation efficiencies of 108-109cfu/µg control vector pUC19 were 
achieved. 
SOC-Medium: 
2 %    Tryptone 
0.5 % Yeast Extract 
10 mM NaCl  
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose (freshly added)  
 
 
3.2 Molecular biological methods 
3.2.1 Isolation of nucleic acid from bacteria 
3.2.1.1 Small scale isolation of nucleic acid from bacteria 
Plasmids: 
Isolation of plasmid DNA from E. coli has was performed from 2 ml liquid o.n. culture with the 
GFX Micro Plasmid Kit according to manufacturer’s instructions.  
BACs:  
Due to the size of BACs coding for the MCMV genome (~ 230 kb), small scale column-based 
purification with commercial plasmid purification kits was not suitable. Therefore, an alkaline 
lysis procedure with subsequent phenol-chloroform extraction and DNA precipitation by 
isopropanol was performed.  Briefly, a single clone was picked and cultured in 10 ml of LB-
medium with appropriate antibiotics at 37 °C o.n.. Cells were centrifuged at 3500 rpm for 15 min 
at RT and the bacterial pellet was then resupended in 200 µl cold resuspension buffer. For 
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alkaline lysis, 200 µl lysis buffer was added and solutions mixed by gentle inversions. Precipitation 
of proteins and chromosomal DNA was achieved by adding 400 µl neutralization buffer. After 
10 min incubation on ice, precipitates were sedimented by centrifugation at 20,000 × g  for 
10 min. Supernatants were transferred into a fresh 2 ml reaction tube and BAC DNA extracted 
by addition of 1 ml phenol/chloroform and centrifugation at 20,000 × g  for 5 min. BAC DNA, 
in the upper phase, was than precipitated with 1 ml isopropanol at 20,000 × g  for 30 min. Salts 
were removed by washing the DNA pellet with 70 % (v/v) EtOH and another centrifugation at 
20,000 × g  for 10 min. The supernatant was discarded, pellet allowed to air-dry and the BAC 
DNA was then dissolved in 100 µl 10 mM Tris-HCl pH 7.5.  
Resuspension Buffer pH 8.0 Lysis Buffer  Neutralization Buffer pH 4.8 
 25 mM Tris/HCl 200 mM NaOH 3 M KAc 
10 mM EDTA 1 % (w/v) SDS 
100 mg/l RNase A,  
 
3.2.1.2 Large scale isolation of nucleic acid from bacteria  
Isolation of plasmids and BACs in large scale volume was performed with Nucleobond PC100 
Kit according to manufacturer’s instructions. 
Concentration and purity of the isolated nucleic acids were determined by UV extinction 
measurement with the Nanodrop spectrometer and agarose gel electrophoresis. Correctness of 
mutagenesis on plasmids and BACs were verified by restriction fragment analysis and sequencing. 
3.2.2 Isolation of nucleic acid from eukaryotic cells 
3.2.2.1 Extraction of genomic DNA for molecular biological assays  
Extraction of genomic DNA from cultured cell lines as well as from murine tissues have been 
performed with the Qiagen DNeasy Blood & Tissue Kit according to manufacturer’s 
instructions, with the exception that vortexing was avoided to minimize shearing of genomic 
DNA.   
3.2.2.2  Extraction of genomic DNA from mouse tails for genotyping 
VIOLA mice progeny were bred as heterozygotes and were genotyped for the presence of the luc 
gene. To this end, 0.5 -1 cm mouse tails pieces were digested o.n. with 500 µl proteinase K buffer 
supplemented with 19,2 µg proteinase K at 55 °C under constant shaking. The next day, samples 
were vortexed for 30 s and residual debris removed by centrifugation at 20,000 × g for 2 min at 
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RT. The supernatants were transferred into a fresh tube, mixed with 500 µl isopropanol and 
DNA was pelleted by centrifugation at 20,000 × g for 20 min at RT. Next, the pellet was washed 
with 500 µl 70 % EtOH to remove salts by another centrifugation for 10 min. Supernatants were 
aspired, the genomic DNA dried at 37 °C and finally resuspended in 100 µl 10 mM Tris-HCl, 
pH 7.5. Typically 2 µl of the digest were used for genotyping via PCR (see 3.2.4.2.1). 
Proteinase K-Buffer: 
200 mM  NaCL 
100 mM Tris pH 8 
    5 mM EDTA 
1 % (w/v) SDS 
 
3.2.3 Cloning Techniques 
3.2.3.1 Restriction enzyme digest 
Restriction fragment analysis as well as the preparation of linear DNA fragments was performed 
with restriction endonucleases. For analytical analysis 1 µg of plasmid DNA was digested with 
5 U restriction enzyme for 1 h. Preparative digests 10 µg DNA were digested with 25 U 
restriction enzyme for 3 h. Temperature and buffers were adjusted according to manufacturer’s 
instructions. Digestion of genomic DNA was performed with at least 8 U restriction enzyme/µg 
DNA o.n. 
3.2.3.2 DNA precipitation 
For concentration or removal of reaction components DNA was precipitated from solution by 
addition of 1/10 volume 3 M sodium acetate (pH 5.3) and three volumes 100 % ethanol. The 
solution was mixed and either incubated at -80 °C for 20 min or on ice for 1 h. DNA was 
subsequently precipitated by centrifugation at 20,000 × g at 4 °C for 30 min. The DNA pellet 
was washed with 70 % ethanol. After another centrifugation at 20,000 × g at 4 °C for 10 min, the 
pellet was dried at 45 °C. DNA was subsequently resuspended in 10 mM Tris-HCl, pH 7.5.  
3.2.3.3 Blunting of DNA overhangs by Klenow polymerase 
For cloning fragments with incompatible restriction sites, fragments were subjected to Klenow 
Polymerase that fills in 5´ overhangs and removes 3´ overhangs of digested restriction sites to 
form blunt ends. The reaction was performed in 1 × NEB 2 buffer supplemented with dNTP to 
a final concentration of 33 µM. One unit Klenow Polymerase per µg DNA was added in a total 
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volume of 50 µl. After 15 min incubation at RT, the reaction was stopped by addition of 2 µl 
0.5 M EDTA prior to heat inactivation at 75 °C for 20 min. Before using the blunted fragment in 
further cloning steps, DNA was purified via QIAquick PCR Purification Kit according to 
manufacturer’s instructions. 
3.2.3.4 Dephosphorylation of DNA fragments 
To avoid re-circularization of restriction enzyme digested vector DNA, fragments were 
dephosphorylated with 1 U/µg Antarctic phosphatase for 1 h at 37 °C. The enzyme was 
inactivated at 65 °C for 10 min and linearized fragments were purified via QIAquick PCR 
Purification Kit according to manufacturer’s instructions. 
3.2.3.5 Purification of DNA from agarose gels 
For isolation of DNA fragments from agarose gels (3.2.4.1), fragments were excised on a trans-
illuminator with longwave UV light and purified with the QIAquick Gel Extraction Kit according 
to manufacturer’s instructions.  
3.2.3.6 Ligation of DNA fragments 
DNA fragments were ligated using T4 DNA ligase with a molar ratio of 1:3 between vector 
(100 ng) and insert. Ligation was performed in a total reaction volume of 20 µl with 400 U T4 
DNA ligase in 1× T4 DNA Ligase buffer in a water bath at 16 °C o.n. In control reactions, insert 
fragments were replaced with the same volume water. Typically 50 µl electrocompetent bacteria 
were transformed with 4 µl of the ligation reaction.  
3.2.3.7 Manipulation of bacterial artificial chromosomes by homologous recombination 
Due to the big size of BACs coding for the entire herpesviral genomes, standard cloning 
procedures are not feasible [66]. To generate herpesviral mutants, homologous recombination of 
linear fragments with the BAC DNA was applied according to the protocol established by 
Wagner and colleagues [129]. 
 In this work, a kanamycin selection cassette was inserted next to the origin of replication 
(see Figure 15) by homologous recombination. To this end, a linear fragment (containing a 
kanamycin selection marker, the bacterial origin of replication R6K and 40 bp sequences 
homologues to the viral genome on both sites) was amplified from the plasmid p06kan by PCR 
with the primer H3-MCMVori-ori6kan-for and H5-MCMVori-ori6kan-rev. The fragment was 
purified by DNA precipitation (see 3.2.3.2) and electrocompetent L-Arabinose induced DH10B 
bacteria harbouring pSM3fr and pKD46 were transformed with 1.5 µg. By induction with L-
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Arabinose, recombinases were expressed in a controlled manner and mediated the recombination 
of the linear fragment and the homologous region on the BAC during 2 h incubation at 37 °C. 
Bacteria containing an insertion of the kanamycin cassette were selected by growing on LB-
CAM-KAN-agar plates. Correct insertion was confirmed by RFLP analysis of the candidate 
pSM3fr-ori6kan BAC clones.  
3.2.4 Analyzing nucleic acid 
3.2.4.1 Agarose gel electrophoresis 
For analysis of restriction fragments, digested DNA was separated by agarose gel electrophoresis. 
Plasmid DNA solutions in 1 × loading dye were analyzed in 1 or 2 % agarose/TAE gels, whereas 
0.8 % agarose/TBE gels were used for restriction fragments of BAC DNA. Voltage and duration 
of electrophoresis were adjusted to the length of the fragments to be analyzed. Before pouring 
the gels, ethidium bromide was added to a final concentration of 0.005 % (v/v) allowing the 
visualization of the DNA under UV-light with the Eagle-Eye imaging system. 
TAE-buffer (1 ×), pH 7.3 TBE-Buffer (1 ×), pH 8.3 10 × Loading Dye 
40 mM Tris-Acetate 90 mM Tris-HCl 15 % (w/v) Ficoll 
  1 mM EDTA 90 mM boric acid 50 mM Tris-HCl, pH 7.5 
   1 mM EDTA 2.5 mg/ml Orange G 
 
3.2.4.2  Polymerase chain reaction 
3.2.4.2.1 Touch-down PCR 
Polymerase chain reaction (PCR) allows the amplification of DNA and was used for different 
purposes, like genotyping cell clones and mice strains, subcloning genes by introduction of 
mutated sequences or restriction sites, creating linear fragments for homologous recombination 
and labeling of DNA with modified nucleotides. In all cases, the amplification of the target DNA 
was based on a touch-down PCR having the following program conditions (Figure 10). 
 
Figure 10: Schematic diagram of a touch-down PCR 
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 An elongation temperature of 72 °C was used to amplify high quality DNA for labeling 
probes or further subcloning with the Expand High Fidelity PCR System (Roche). Genotyping 
has been performed with the more robust PCR system Crimson Taq using an elongation 
temperature of 68 °C. Reaction conditions were used according to manufacturer’s instruction. If 
needed Mg2+ concentration has been adjusted or 5 % DMSO added for complex structured 
templates. 
3.2.4.2.2 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was performed with the TaqMan technology. In this case, 
amplification of the template was detected by a fluorescence resonance energy transfer (FRET) 
based probe. Single stranded probes 5’-FAM (Fluorophore) and 3’-TAMRA (Quencher) labeled- 
were designed complementary to the amplicon of the murine lamin B receptor gene (lbr) and the 
Blasticidin S resistance gene (bsr) (Table 2).  
Table 2: TaqMan –Probes 
probe sequence feature 
5’ FAM-lbr-sense-TAMRA 3’ CTGAGCCACGACAACAAATCCCAGCTCT
AC 
binds within the sense strand of 
the lbr gene 
5’FAM-bsr-sense-TAMRA 3’ CATCTCTGAAGACTACAGCGTCGCCA binds within the sense strand of 
the bsr gene 
  
Table 3: qPCR Reaction Set up 
reagents volume program 
Forward-Primer [8 µM] 2.5 µl  
Reverse-Primer [8 µM] 2,5 µl 
Taqman-Probe [2 µM] 5 µl 
buffer A [10x] 5 µl 
MgCl2 [25 mM] 8 µl 
dXTP-Mix [2.5 & 5 mM] 4 µl 
UNG [1 U/µl] 0.5 µl 
AmpliTaqGold [5 U/µl] 0.25 µl 
ddH2O (ROTH) 12.25 µl 
 Template 10 µl  
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 To estimate the copies of transgene in stable cell lines or mice, amplification of the bsr 
gene was correlated relative to the endogenous lbr gene. PCR was set up with the Taqman 1000 
RXN core reagents in triplicates (Table 3). This includes the labeling of PCR-amplicons with 
Uracil and its degradation in following PCRs by adding the heat-instable enzyme uracil-DNA-
glycosylase to minimize carry over contamination. 
3.2.4.3 Southern Blot 
Southern blot experiments were performed to analyze the status of transgenes in stable cell lines 
or mice. The technique bases on the protocol established by Edward Southern [130]. 
Electrophoretically separated restriction fragments of genomic DNA were transferred onto a 
nylon membrane and hybridized with labeled probes.  
3.2.4.3.1 PCR labeling of probes for Southern Blot analysis 
Probes for Southern blot analysis (3.2.4.3) were generated by PCR amplification with 
digoxigenin-labeled dUTPs with the PCR DIG Probe-Synthesis kit according to manufacturer’s 
instructions. Dot blot analysis and agarose gel electrophoresis was used to verify sufficient 
incorporation of digoxigenin into the probe. Optimal concentration of probes for hybridization 
in Southern blot experiments was evaluated empirically. 
3.2.4.3.2 Agarose electrophoresis for Southern blot 
Genomic DNA (gDNA) was prepared according to the protocol described in section 3.2.2. 10 µg 
was digested with an appropriate restriction enzyme o.n. DNA was loaded with 1 × GelPilot 
Loading Dye (Qiagen, Hilden, D) on a 0.5 % TAE-agarose gel and electrophoresis was 
performed at 80 V for 16 h. The gel was stained afterwards in an ethidium bromide bath and 
photographed with a fluorescent ruler to determine the running distance of the marker 
fragments. Subsequently, the gel was destained in water before continuing with capillary transfer. 
3.2.4.3.3 Capillary transfer of gDNA 
 Electrophoretically separated gDNA must be pretreated to be efficiently transferred to a 
positively charged nylon membrane (Roche). As the target DNA fragments were in general over 
10 kb in size, the DNA was depurinated by submerging the gel in 0.25 N HCl until the 
bromphenol-blue contained in the loading dye turned yellow. Thereby the fragments break into 
smaller pieces. After a short wash in ddH2O, DNA fragments were denatured in 0.5 N NaOH/ 
1.5 M NaCl until the color of bromphenol changed back to blue. The pH of the gel was 
neutralized by submerging the gel in 1M Tris /1.5 M NaCl (pH 7.4) for 15 min. In the meantime 
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the nylon membrane was submerged in ddH2O and than equilibrated in 20 × SSC. The capillary 
transfer was set up as depicted in Figure 11.  
 
 
 
 
 
 
Figure 11: Upward Capillary transfer modified from Sambrook and Russel [131] 
Transfer of the DNA was carried out by capillary forces from 20 × SSC transfer buffer that is drawn from the 
reservoir through the gel onto the membrane. The paper towels and weight help to maintain a constant stream of 
buffer. 
 Capillary transfer was performed at RT o.n. Then, the DNA was crosslinked onto the 
wet nylon membrane in an UV-linker by 0.125 Joule/cm2. Salt crystals from the 20 × SSC were 
removed by rinsing the membrane with ddH2O. Thereupon, the DNA was air-dried before 
continuing with the hybridization procedure. 
20 × SSC pH 7.0 
   3 M NaCl 
0.3 M Na-Citrate 
 
3.2.4.3.4 Vacuum transfer 
Vacuum transfer of DNA was performed alternatively to capillary transfer. This method is able 
to create sharper bands and can be accomplished in a shorter time. To this end, the vacuum 
blotter was set up with agarose gel, nylone membrane and Whatman paper. Each soaked in 20 × 
SSC according to manufacturer’s instructions. Depurination was performed directly on the 
vacuum blot, by soaking 0.25 N HCl through the gel while applying constant pressure of 0.2 bar 
until the indicator bromphenolblue of the loading dye turned yellow. Excess solution was 
removed before addition of 0.5 N NaOH/ 1.5 M NaCl to denature the genomic DNA until the 
indicator turned blue. Neutralization solution (1 M Tris /1.5 M NaCl pH 7.4) was added for 10 
min. Final transfer of gDNA was achieved by soaking 20 × SSC buffer through the gel for 1.5 h. 
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Crosslinking of the DNA and preparation of the nylon membrane was performed as described 
previously ( see section 3.2.4.3.3).   
3.2.4.3.5 Hybridization of probe 
To minimize unspecific binding of probe to gDNA, the nylon membrane was pre-hybridized 
with DIG-Easy Hyb solution. At least 20 ml of the pre-hybridization solution were added to the 
membrane in roller-bottles. Incubation was performed at a defined hybridization temperature for 
2-3 h. The success of a southern blot analysis is strongly dependent on the right hybridization 
temperature and probe concentration. The latter one was evaluated empirically ― not exceeding 
25 ng/ml―. A starting point to find the optimal hybridization conditions can be calculated with 
following equation:  
Tm= 49.82 + 0.41 × % GC - (600/l)  
Thyb = Tm- (20 °C to 25 °C) 
(with Tm = melting temperatue; Thyb = hybridization temperature, % GC = percent GC-content, l = length of probe) 
 
Table 4: Conditions of Southern blot probes 
probe optimal hybridization temperature optimal concentration 
S2-luc-dig 37 °C 20 ng/ml 
S3-gfpscp-dig 47 °C 15 ng/ml 
 
 The probe was first diluted in 50 µl ddH2O, boiled 5 min at 95 °C, immediately put on 
ice to achieve single stranded DNA and then added to 20 ml pre-warmed DIG-easy hyb solution. 
The probe was carefully mixed in the solution and then added to the membrane. Hybridization 
was performed for 16 - 24 h. Unbound probe was removed by two washes with a low-stringency 
buffer ( 2 × SSC, 0.1 % SDS) at 37 °C or RT for 30 min and 10 min respectively, followed by 
two washes with a high-stringency buffer (0.5 x SSC, 0.1 % SDS) at  65 °C for 10 min each. 
3.2.4.3.6 Detection of labeled target DNA  
For detection of the labeled target DNA an alkaline phosphatase conjugated anti-DIG-antibody 
that specifically hydrolyzes the chemiluminescent substrate CDP-star was used allowing detection 
of emitted light on an X-ray film (Hyperfilm ECL, GE Healthcare). The DIG luminescence 
detection kit and CDP-Star were used according to manufacturer’s instruction.  
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3.2.4.4 Fluorescence in situ hybridization (FISH) 
Fluorescence in situ hybridization (FISH) is a technique to visualize the locus of a DNA 
sequence in the genome. Basic steps involve the preparation of metaphase spreads, generation of 
specific probes and their hybridization to the chromosomes, as well as detection of the probes by 
immunofluorescence-labeling.  
3.2.4.4.1 Preparation of metaphase chromosome spreads 
FISH hybridization was performed on condensed metaphase chromosomes. NIH3T3 were split 
one day before preparation on a 10 cm2 plate at a ratio of 1:3. Demecolcin (Sigma-Aldrich) was 
added to a final concentration of 0.1 µg/ml to the cell culture medium to yield a maximum of 
metaphase cells. After 2 h incubation found herein to be optimal for NIH3T3, rounded and 
detached metaphase cells were harvested into a 15 ml falcon tube. After centrifugation at 300 × g 
for 5 min, cells were washed with pre-warmed PBS (37 °C) and finally resuspended in 0.5 ml 
PBS. At a minimal vortex speed, 10 ml of 37 °C warm hypotonic solution was added dropwise 
and cells swelled during the following 15 min incubation in a 37 °C water bath. Than 1 ml 
fixative was added, the suspension was carefully inverted and incubated at RT for another 15 
min. Cells were centrifuged at 300 × g at RT for 5 min, supernatants discarded, carefully 
resuspended in 1 ml of residual solution and finally resolved in 7 ml fixative. This step was 
repeated three times at 4 °C. Afterwards, the cells were resuspended in 1 ml fixative and 
incubated at -20 °C for at least 10 min. Three to four drops of this suspension was dropped from 
at least 40 cm distance onto ice cold water covered slides that were purified by sonification and 
pre-chilled to 0 °C. Slides were incubated on a 40 °C hot plate with high humidity and finally 
dried at RT. After one week of incubation at RT in the dark, metaphase spreads were further 
processed.  
Hypotonic Solution 
0.91 % (w/v) tri-sodiumcitrate-dihydrate 
pre-warmed to 37 °C, freshly prepared 
Fixative 
3 volumes methanol : 1  volume glacial acid  
pre-chilled to  -20 °C, freshly prepared 
 
3.2.4.4.2 Probe preparation 
Efficient labeling of probes is very important for successful FISH analysis to achieve a good 
signal to noise ratio. Probes were either directly labeled by incorporation of 
Diethylamincoumarin-dUTP (DEAC-dUTP) or were labeled with digoxigenin-dUTP or biotin-
dATP allowing indirect detection via fluorescence coupled antibodies, i.e. anti-dig-Fab or anti-
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biotin-Fab. The incorporation of the modified nucleotides was performed by PCR or 
nicktranslation. The optimal length for probes is 300 – 500 bp. Longer PCR fragments were 
digested with appropriate restriction enzyme or digested with DNase I. Probes were denatured 
with 1/10 volume of 3 M NaAc, 2.5 volumes of 100 % EtOH and 1 µl salmon sperm DNA, to 
prevent unspecific binding. The mixture was centrifuged at 20,000 × g for 20 min, supernatant 
was discarded and the DNA pellet was washed with 150 µl ice-cold 70 % EtOH. After another 
centrifugation step, the pellet was dried in a vacuum-centrifuge at 65 °C for 5 min. Probes (for 
one hybridization window with 25 µl) were dissolved in 5 µl 100 % formamide and denatured in 
a 37 °C waterbath for 30 min. Renaturation of the single stranded probe was inhibited by 
addition of 5 µl 40 % dextransulfate in 2 × SSC. The mixture was further incubated at 72 °C for 
5 min to improve denaturation and subsequently incubated at 37 °C for 30 min. This mix was 
stored at      - 20 °C until use and applied without further treatment. 
 The commercial available mouse-pancentromeric FISH probe mouse-Pan-Cy3 (BioCat, 
Heidelberg, D), was used as control and directly applied for hybridization after denaturation at 
72 °C for 10 min.  
3.2.4.4.3 Hybridization of FISH probes 
Before hybridization, metaphase spreads were treated with pepsin and RNAse to remove cell 
debris.  To this end, the previously prepared metaphase slides were washed with 2 × SSC for 5 
min at RT. Then 200 µl RNAse solution (0.2 mg/ml RNAse A in 2 × SSC) was added to the 
coverslide. After 30 min incubation in a dark moist chamber at 37 °C, slides were washed three 
times with 2 × SSC. For the pepsin digest, prewarmed 50 ml ddH2O to 37 °C was mixed with 
100 µl 5 N HCl and 15 µl 10 % pepsin. Slides were incubated therein for 70 s, to allow the 
digestion of cytoplasmic proteins without destroying the chromosome structures. Immediately 
afterwards, slides were washed two times with PBS for 5 min at RT and then with an ascending 
ethanol row of 70 %, 90 % and 100 % respectively at 4 °C for 3 min each. Subsequently, slides 
were air-dried in a dark chamber.  
 To denature the chromosomal DNA, slides were put into a 72 °C hot denaturation 
solution (70 % Formamide/ 2 × SSC) for 105 s and immediately transferred to -20 °C pre-chilled 
70 % EtOH. Slides were dehydrated by putting them into an increasing -20 °C chilled ethanol 
row for 5 min each (70 %, 90 %, 100 % ethanol). Finally, slides were air-dried in a dark chamber. 
 For the hybridization, a 10 µl drop of the probe mixture (3.2.4.4.2) was set on the slide 
and covered by an 18 mm × 18 mm cover slip by sealing the edges with the rubber glue 
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Fixogum. Slides were heated to 72 °C for 2 min, then transferred to 37 °C water bath in a closed 
metal chamber and incubated for 2 - 3 days. 
3.2.4.4.4 Fluorescence-Immunodetection 
Hardened fixogum was removed and coverslides carefully removed by dipping slides into 2 × 
SSC 0.2 % Tween-20. All following steps were performed under light protection of the slides. 
Slides were washed three times with 2 × SSC 0.2 % Tween-20 at 42 °C for 5 min, three times 
with 0.75 × SSC at 60 °C for 5min and once again at 42 °C for 5 min with 2 × SSC 0.2 % 
Tween-20. Unspecific binding sites for antibodies were blocked with 3 % BSA for 30 min at 
37 °C. Slides were washed again at 42 °C with 2 × SSC 0.2 % Tween-20 for 5 min.  
 Immunolabeling of the probes was achieved by adding anti-biotin-Cy3.5 (1 : 3000 in 
1 % BSA) binding to the biotin labeled probes and anti-dig-fluorescein antibody (1 : 150 in 1 % 
BSA). Incubation was performed for 45 min at 37 °C in a humidified chamber. Excessive 
antibodies were washed away by incubating slides three times at 42 °C in 2 × SSC for 5 min. 
DNA was counterstained with 0.05 µg/ml DAPI in 2 × SSC solution for 2 min in a dark moist 
chamber and washed with ddH2O for 5 min. Slides were air-dried afterwards. To minimize fading 
of the fluorescence marker phenylendiamindihydrochlorid was added to the slides and covered 
by a cover slide.  
3.3 Tissue culture techniques 
3.3.1 Culturing eukaryotic cell lines 
All mammalian primary cells and cell lines were cultured under sterile conditions at 37 °C, 95 % 
humidity and 7 % CO2. Cell lines were passaged on a regular basis. To this end, old medium was 
removed from adherent cells and cells were washed with PBS. After detachment with 0.25 % 
Trypsin/EDTA (Gibco, Karlsruhe, D), cells were resuspended in 10 ml culture medium and a 
portion of the cells was transferred on a new culture plate with fresh medium according to the 
split ratio in shown in Table 5. 
Table 5: Culture conditions of used cell lines 
cell line type medium split ratio antibiotics for  selection 
NIH3T3 continuous murine 
fibroblast cell line 
DMEM, 10 % FCS, 1% 
Pen/Strep 
1:6 
every 3-4 days 
200 µg/ml G418 
  10 µg/ml BS 
  50 µg/ml Hygromycin 
MHEC-5T continuous murine 
heart endothelial cell  
DMEM, 10 % FCS, 1% 1:8   10 µg/ml BS 
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line Pen/Strep every 3-4 days 
M210-B4 continuous bone 
marrow stromal cell 
line 
RPMI, 10 % FCS, 1% 
Pen/Strep 
1:4 
every 3-4 days 
 2,5 µg/ml BS 
SVEC4-10 continuous murine 
endothelial cell line, 
SV40 transformed 
DMEM, 10 % FCS,1 % 
Pen/Strep 
1:8 
every 3-4 days 
 10 µg/ml BS 
MEF primary murine 
embryonic fibroblasts 
DMEM, 10 % FCS, 1 % 
Pen/Strep 
1:2, on demand  
mES murine embryonic 
stem cells 
DMEM, 15 % FCS, 1 % 
NEAA, 
1 % L-glutamine, 
1 % Nucleosides, 
 0.1mM β-mercaptoethanol, 
 1 % Pen/Strep 
1 × 103 Units/ml murine LIF 
(Active Bioscience) 
change media 
daily 
 
split 1:6 
every 2-3 days 
 10 µg/ml BS 
 % in (v/v), 0.6 % (w/v) Penicillin/ 1.3 % (w/v) Streptomycin (Pen/Strep)  
3.3.2 Transfection of eukaryotic cells 
Lipofection 
Transfections of cell lines were routinely performed by lipofection with the reagent Transit3T3 
(Mirus) for all mentioned cell lines according to manufacturer’s instructions.  
Nucleofection 
Transfection of mES was performed by nucleofection with the AMAXA nucleofector (Lonza) 
according to manufacturer’s instructions (prog. A-013). 
3.3.3 Generation of stable cell lines with the pEPI vectors 
For the generation of stable cell lines, cells were seeded in 6-well plates one day before 
transfection to a confluence of 70 % at maximum. Cells were transfected with 1 µg freshly 
prepared plasmids via lipofection or mock transfected. The next day, transfection efficiency was 
controlled via fluorescence microscopy, either by the fluorescence marker encoded on the test 
plasmid itself or by a fluorescent transfection control. Cells of one 6-well were split onto a 10 cm 
dish and antibiotics added according to Table 5. Untransfected control cells typically died within 
one week. Cell lines were either kept as pools or cell clones were subcloned using limiting 
dilution. 
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3.3.4 Isolation of cell clones 
All cell clones in this work were obtained by limiting dilution with one exception; mES cell 
clones for blastocyst injections were gained by picking cell clones. For the isolation of cell clones 
by limiting dilution, cells were trypsinized, resuspended in appropriate medium and counted. Cell 
suspensions of 0.5 cells, 1 cell or 3 cells per 100 µl respecitively were made. These suspensions 
were seeded into 96 well plates, with 100 µl per well. Wells were controlled for single clones and 
grown up to stable cell lines under appropriate antibiotic selection.  
3.3.5 Cryoconservation of cell lines 
For long term maintenance of cell lines, cells were stored in liquid nitrogen. To this end, cells 
were incubated to 80 - 90 % confluence on 175 cm2 dish. Cells were trypsinized and pelleted by 
centrifugation at 800 × g for 5 min. The pellet was resuspended in 3 ml freezing medium and 
aliquoted in three cryotubes with 1 ml each. Cells were incubated at -80 °C for one day in special 
isopropanol-filled container that allow a slow cooling of the cells and then transferred to the gas 
phase of a liquid nitrogen tank. 
Freezing medium 
40 % FCS 
10 % DMSO 
50 % of the respective growth medium 
3.3.6 Mouse explants cultures 
For the cultivation of mouse explants tissue a protocol was established that combines the needs 
for simplicity and requirements of the different cell types. As explants cultures were taken from 
each mouse individually, only a very limited amount of cells was available. Successful explants of 
heart, kidney, lung, spleen, salivary gland, bone marrow and fat tissue were obtained.  
 One mouse at a time was sacrificed, fur disinfected with 70 % EtOH and eviscerated. 
Organs were washed with PBS several times to remove as much blood as possible. Heart, kidney, 
lung, spleen and salivary gland were minced into small pieces in 2.5 ml freshly prepared 
dissociation buffer, incubated at 37 °C for 30 - 60 min and dispersed by pipetting up and down 
with a wide bore pipette tip from time to time until a smooth homogenate was obtained. The 
homogenate was pressed through a 100 µm strainer and resuspended in 10 ml DMEM. Cells 
were centrifuged at 300 x g for 5 min at RT. Supernatants removed and resuspended in 5 ml of 
the appropriate cell culture medium. Cells were seeded on gelatine coated 75 cm2 tissue flasks. 
The same procedure was performed for fat tissue, with the exception that it was not minced and 
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cells containing a high amount of lipids do not pellet by centrifugation but were recovered also 
from the top of the medium. For the extraction of bone marrow, femure and tibia of one leg was 
removed and the tips clipped. The bone marrow was rinsed out with PBS, and cells resuspended 
in 10 ml DMEM. Cells were centrifuged as above and finally resuspended in 5 ml mmES-
Medium. Medium was exchanged daily for one week and then every third day. 
Dissociation buffer 
12.5 mM HEPES in PBS 
200 U/ml DNase I 
13 Wünsch U/ml Liberase 
 
Table 6: Media for mouse explant tissues 
medium ingredients  organ / cell type 
mmES 407.5 ml DMEM 
75 ml FCS 
5  ml Pen/Strep 
5  ml L-Glutamine  
5 ml non-essential amino acids (100x) 
3.5 µl β-mercaptoethanol 
2.5 ml Fungizone (1.25 µg/ml Amphothericin 
B) 
Heart, kidney, salivary gland, bone marrow, fat, 
muscle 
LSGS 402.5 ml DMEM 
 75 ml FCS 
 5 ml Pen/Strep 
 5 ml L-Glutamine 
 5 ml non-essential amino acids 
 3.5 µl β-Mercaptoethanol 
 2.5 ml Fungizone 
 5 ml 1 × LSGS (Invitrogen) 
 (1 µg/ml hydrocortisone; 
 10 ng/ml human epidermal growth factor; 
  3 ng/ml basic fibroblast growth factor; 
 10 µg/ml heparin) 
lung 
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Spleen - 
medium 
432.5 ml RPMI 1640 
50 ml FCS 
1 ml 1M HEPES  
5 ml Pen/Strep 
2.5 ml Fungizone 
spleen 
  
3.3.7 Flow cytometry 
Fluorescence based flow cytometry assay was performed for the analysis of expression profiles of 
fluorescent proteins in stable cell lines. To this end, at least 5 x 105 tissue cultured cells were 
harvested by Trypsin digest, washed with PBS and finally resuspended in 1 ml PBS with 2 % 
FCS. The parental cell lines were used as negative controls to determine the autofluorescence of 
the cells. Measurement was performed with the flow cytometer Epics XL-MCL (Beckman 
Coulter).   
3.4 Virological Methods 
3.4.1 Reconstitution of viruses from BACs 
The cloning of the MCMV genome as a bacterial artificial chromosome (BAC) allows the 
manipulation of the viral genome, its characterization and control of the modification in bacterial 
cells [64]. To obtain viruses from BAC encoded genomes, permissive cells were transfected with 
the corresponding BAC. As a positive control for reconstitution, the BAC pSM3fr-MCK-2fl 
encoding wt-MCMV genome was used. To this end, MEF cells or transgenic NIH3T3 cells were 
seeded in 6-well dishes one day before transfection. 1.5 µg freshly prepared BAC-DNA was 
transfected with the help of Mirus Transit3T3 transfection reagent. Cells were split the next day 
onto a 10 cm dish, whereby the old supernatant is added back. Plaques from reconstituted viruses 
arose typically at 4-5 days after. In case of attenuated viruses, plaque formation and lysis was 
delayed and cells were split with transferring the supernatants until lysis occured. After complete 
lysis of the cells, supernatants were stored at -80 °C for further processing.  
 To remove the BAC cassette from the virus genome, which tolerates some oversize, 
viruses had to be passaged on MEF cells. To this end, a 6 well of confluent MEF cells were 
infected with the viruses for 1 h and then supernatant was replaced by fresh medium and waited 
until cells were completely lysed. After four rounds of passaging, the BAC cassette, encoding a 
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bacterial origin of replication and the chloramphenicol resistance gene, was typically removed 
from the viral genome and virus stocks were produced. 
3.4.2 Production of virus stocks 
For production of high titer MCMV virus stocks, six 175 cm2 dishes of confluent M210-B4 cells 
were trypsinized, washed and resuspended in 400 ml medium. Cells were infected in suspension 
with an MOI of about 0.1 and plated on 20 × 175 cm2 dishes. Typically after 4 – 5 days complete 
cell lysis occured and supernatant as well as residual cells were harvested in 250 ml beakers. All 
steps for the preparation were performed on ice with pre-chilled material. The virus/ cell 
suspension was centrifuged at 6,500 × g for 15 min at 4 °C. The supernatant was collected and 
stored on ice. The pellet was resuspended and cells cracked by homogenization in a glass douncer 
to liberate intracellular virions. By centrifugation at 20,000 × g for 10 min, cell debris was 
removed and the supernatant pooled with the supernatant put on ice. Virions were than pelleted 
by centrifugation of the supernatants for 3 h at 25,000 × g and again homogenized by douncing 
in a volume of 4 ml DMEM. This homogenate was loaded on top of 10 ml 15 % sucrose cushion 
and centrifugation tubes (SW28) completely filled up with virus stock buffer (VSB). By 1h 
ultracentrifugation at 20,000 × g in a swing bucket rotor (SW28, Beckmann), purified virus 
particles were pelleted. Supernatants were discarded and the virions resuspended in 1.5 ml VSB 
by homogenization in a douncer. For virus stocks that were to be used in mouse experiments 
another centrifugation step was performed to clear the suspension. To this end, the virus stock 
was two times centrifuged at 1,300 × g at 4 °C for 2 min and the pellet was discarded. The virus 
stock was then aliquoted in 50 – 100 µl and stored at -80 °C. 
VSB (pH 7.8) 
50 mM Tris-HCl  
12 mM KCl 
5 mM EDTA 
autoclave 
 
3.4.3  Virus growth analysis 
Typically virus growth analysis is performed to compare growth kinetics of two different viruses. 
In this thesis, virus growth analysis was mainly performed to evaluate the productivity of 
different stable cell clones infected with the same virus.  
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 Cells of different cell lines were harvested, counted and the viability of the cells was 
checked. 1 × 105 cells were seeded per well of a 12-well plate, with three wells per timepoint were 
analyzed for virus titers and a fourth well was used to determine cell density. Cells were allowed 
to attach for 4 - 5 h before infection with wt-MCMV (or a fluorescence marker containing 
MCMV) at an MOI of 0.1 in a volume of 1 ml. Virus suspension was washed away after one hour 
incubation at 37 °C. Subsequently, virus suspension was replaced by 1 ml fresh culture medium. 
Supernatants from cells were collected at the respective time points of growth analysis and kept 
at -80 °C until plaque assay was performed to determine virus titer. In addition, uninfected cells 
were counted daily to monitor the cell density and thus growth properties of the different cell 
lines. 
3.4.4 Plaque assay 
Plaque assays were performed to determine virus titer of cell culture supernatants or virus stocks. 
To this end, serial 1:10 dilutions of virus supernatants were performed in 500 µl MEF-medium. 
200 µl of these virus dilutions, typically ranging from 10-1-10-7, were transferred to 48 well plates, 
seeded previously with a confluent MEF monolayer. After 1 h incubation at 37 °C, virus dilutions 
were removed and 400 µl carboxymethylcellulose-containing medium added. Due to the high 
viscosity of this medium, viral particles cannot diffuse through the medium and a local plaque 
will arise by cell-to-cell spread on the spot where a plaque forming unit (PFU) infected the MEF 
monolayer. Plaques were counted by a light microscope at day 4 post infection. 
 The virus titer is calculated by the following equation: 
)2.0(
)/(
mldilutionvirusplatedofvolume
factordilutionplaquescountedofnumber
mlPFUtitervirus
∗=   
Carboxymethylcellulose-containing Medium 
3.75 g Carboxymethylcellulose 
388 ml H2O 
to be autoclaved before supplementation with 
25 ml FCS 
50 ml 10 × MEM 
5 ml L-Glutamine 
2.5 ml non essential amino acids 
5 ml Pen/Strep 
24.7 ml NaHCO3 (7.5 %)  
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3.5 In vivo experiments 
All animals were housed at the animal facility of the Max von Pettenkofer- Institute or the animal 
facility of the department of Molecular Animal Breeding and Biotechnology, LMU, under 
specified-pathogen-free (SPF) conditions. Animal experiments were approved by the Regierung 
Oberbayern, the responsible office of the state of Bavaria.  
3.5.1 Generation of VIOLA mouse strains 
The mES cell line E14 was transfected with pEpibo-luc-ori by nucleofection. Positive cells were 
selected with 5 µg/ml BS for three days. Appropriate clones were selected after partial 
differentiation of the clones by removal of LIF and feeder layers to allow productive infection 
with MCMV [132]. Selected clones were injected into C57BL/6 blastocysts and implanted into 
foster NMRI mothers (Chair of Molecular animal breeding and biotechnology, LMU). Chimeras 
were backcrossed to 129X1/SvJ mice (Jackson) and analyzed for presence of the transgene by 
PCR with the primer P(SV40)-probe-for and pA(SV40)-probe-rev (4.4.2). Two lines were 
obtained, which were named VIOLA (virus inducible oriLyt-dependent luciferase animal) line A 
and B. 
129-VIOLA-A: derived from mES clone A3, backcrossed to 129X1/SvJ 
129-VIOLA-B: derived from mES clone B8, backcrossed to 129X1/SvJ 
3.5.2 Invasive bioluminescence detection 
As a pre-experiment, invasive analysis of bioluminescence was performed with the VIOLA-A line 
mice. To this end, two animals of VIOLA-A and two animals of the background strain 
129X1/SvJ were infected with 1 × 105 PFU wt-MCMV in a volume of 300 µl in PBS 
intravenously (i.v). One mouse of the VIOLA line and one of the background strain were not 
infected and served as background controls. Mice were sacrificed at day 2 or day 5 post infection. 
Organs and tissues (kidney, spleen, liver, lungs, heart, salivary gland, brain, fat and muscle) were 
harvested, homogenized by filtring through a cell strainer with a 100 µm pore size and 
resuspended in 5 ml MEF-Medium. One ml of the homogenates was pelleted by centrifugation at 
1,300 × g for 5 min. The supernatant was discarded and cells were washed with PBS. The 
centrifugation step was repeated and the pellet was finally resuspended in 1 × Passive Lysis 
Buffer (Promega). After 10 min lysis at 37 °C, FL expression of the lysates was measured with a 
bioluminescence reader (Berthold).  
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3.5.3 Non-invasive bioluminescence imaging 
For non-invasive bioluminescence imaging, VIOLA-A mice were infected i.v. with wt-MCMV or 
mock treated with PBS. As a positive control mice of the background strain 129X1/SvJ were 
infected with MCMV-luc, which constitutively expresses FL [71]. To measure the background 
bioluminescence, one measurement was performed before infection of the mice. To this end, 
3 mg Na-D-Luciferin in 200 µl PBS were injected intraperitoneal (i.p). After 5 min mice were 
anesthetized with 2.5 % isofluroan gas in a whole body chamber. Respiration and response to 
rear foot reflex stimulation was constantly monitored. When mice were fully anaesthetized, they 
were transferred to the IVIS Lumina measurement chamber onto nosecone inhalators. Isofluran 
concentration was set down to 1.5 %, a non-irritating eye cream was applied and measurement 
performed on 37 °C pre-warmed heating plates. 
 
3.6 Biochemical analysis 
3.6.1 In vitro Luciferase assay 
Bioluminescence measurements were performed to quantify induction of luciferase reporter gene 
expression under various conditions.  
3.6.1.1 Transient transfections 
Expression studies in transient transfection assays were performed with a dual bioluminenscence 
reporter measurement, whereby the expression of firefly luciferase (FL) under control of 
different promoters was normalized to a control vector constitutively expressing Renilla 
luciferase. To this end, NIH3T3 cells were seeded on a 12-well plate to 70 % confluence. Cells 
were transfected in duplicates with 1 µg test plasmid (e.g. pEpibo-P(SV40)-luc) and 100 ng 
control vector pTK-RL using the transfection reagent Transit3T3 (Mirus, Madison, USA) 
according to manufacturer’s instructions. Duplicate transfections were pooled and split on 8 wells 
of a 24-well plate the day after. Half of the wells were infected with MCMV at an MOI of 0.5. 
The other half was used as uninfected control. 24 h or 48 h after infection cells were lysed in 
100 µl 1 × Passive Lysis Buffer (Promega, Mannheim, D) on 37 °C for 10 min. Bioluminescence 
measurement was performed with 10 µl of the lysates in duplicates with the Microplate 
luminometer (LB960, Berthold). 40 µl of luciferin (Promega, Mannheim, D) and 20 µl of 
colenterazine (Promega, Mannheim, D) were injected into each well and light measured over 10 s. 
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For the evaluation of FL expression, corresponding relative light units (RLU) of Renilla luciferase 
was used for normalization. 
3.6.1.2 Stable cell lines 
Induction of FL expression by MCMV infection was analyzed in cells stably transfected with 
plasmids pEpibo-luc or pEpibo-luc-ori. Therefore, uninfected and infected cells were compared. 
To this end, 105 cells per well were plated in 12-well plates and allowed to attach for 3 – 4 hours. 
Half of the wells were infected with MCMV at an MOI of 0.5 and the other half left untreated. 
Cells were lysed 24 h or 36 h post infection performed as described above. 
3.6.2 Bradford Assay 
Protein concentration of cell lysates was determined by Bradford assay[133]. The principle of the 
assay is based on the ability of Coomassie-Brilliant blue to bind to proteins and the resulting 
absorption shift from 465 nm to 595 nm. Concentration of the cell lysates was correlated to a 
BSA standard curve. To this end, 1-10 µl cell lysates (harvested with Lysis Buffer B or Passive 
Lysis Buffer, Promega to be compatible with the assay) were mixed with 1 ml of 1:5 diluted 
Bradford Reagent (BioRad). After 5 min incubation, solutions where measured in the photometer 
at OD595 and concentration of the protein solution determined.  
Lysis Buffer B (pH 6.8): 
62.5 mM  Tris 
    6  M Urea 
10 % (v/v)  Glycerol 
  2 % (v/v)  SDS 
 
3.6.3 SDS-PAGE  
SDS-polyacrylamid gel electrophoresis (SDS-PAGE, [134] ) and western blot were performed to 
analyze the expression of recombinant proteins from cell lines and viruses. For the separation of 
proteins according to their molecular weight discontinuous SDS-PAGE with the buffer system of 
Fling & Gregerson [135] was used. For equal loading, protein concentrations were assessed by 
Bradford assay (see section 3.6.2).  Protein samples were denatured prior to loading in total lysis 
buffer or lysis buffer B and heated for 10 min at 95 °C. For very viscous samples with high 
gDNA content, 2 µl of Benzonase (Roche) was added to the samples and incubated for 30 min 
on ice. A prestained protein marker was loaded on each gel to correlate separation of the protein 
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samples to the size of the marker proteins (NEB, Prestained ColorPlus). Gels were cast as 
described in Table 7, and run for 15 min at 80 V, to allow a slow running into the stacking gel, 
and then for 60 min at 175V. In general, separated proteins were further processed by western 
blot analysis. 
Table 7: Composition of gels for SDS-PAGE 
 
 
reagent stacking gel resolving gel 
 5 % 10 % 12 % 15 % 
Acrylamid 30 % 830 µl 3.3 ml 4 ml 5 ml 
Gel Buffer 4x 1.25 ml 2.5 ml 2.5 ml 2.5 ml 
ddH2O 3.25 ml 4 ml 3.3 ml 2.3 ml 
TEMED 100 µl 100 µl 100 µl 100 µl 
10 % APS 20µl 5 µl 5 µl 5 µl 
Total Lysis Buffer 4 x Resolving Gel Buffer (pH 8.8) 
62.5 mM Tris 1.5 M Tris 
2 % (v/v) SDS 0.4 % SDS 
10 % (v/v) Glycerol  
6 M urea 4 x Stacking gel buffer (pH 6.8) 
0.01 % (w/v) bromphenolblue 0.5 M Tris 
0.01 % (w/v) phenolred 0.4 % SDS 
5 % (v/v) β-mercaptoethanol  
 5 x SDS loading buffer (pH6.8) 
10 × Laemmli buffer 300 mM Tris 
25 mM Tris 10 % SDS 
10 % SDS 30 % Glycerol 
250 mM Glycine 0.01 % (w/v) bromphenolblue 
 0.01 % (w/v) phenolred 
 5 % (v/v) ß-mercaptoethanol 
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3.6.4 Western blot 
Western blot analysis is a sensitive method to detect specific proteins by an immunochemical 
reaction. Proteins separated by SDS-PAGE were transferred by Semi-Dry electroblotting 
(BioRad, TransBlotSC) onto a activated PVDF-membrane (GE Healthcare, Hybond-P) in 
western blotting buffer with 19 V for 40-60 min, depending on the designated protein mass. 
Afterwards membranes were incubated with a suitable blocking buffer (5 % skimmed-milk or 
5 % BSA or 5 % FCS in TBS-T 0.1) for 1 h at RT under constant agitation. Primary antibodies 
diluted in blocking buffer were bound during o.n. incubation at 4 °C on a roller mixer. After five 
subsequent washes with washing buffer (TBS-T 0.1 or TBS-T 0.2.5) for 10 min each, membranes 
were incubated with an appropriate secondary antibody coupled to horse radish peroxidase 
(HRP) dissolved in blocking buffer at RT for 2 h. Unbound antibodies were washed off by five 
subsequent washes with washing buffer for 10 min each. Chemiluminescence induced by the 
HRP-tagged proteins was detected with ECLPLUS Western Blot Detection System (GE 
Healthcare) on an X-ray film (Hyperfilm ECL, GE Healthcare) according to manufacturer’s 
instructions. 
Western blotting buffer Washing buffer (TBS-T 0.1 or TBS-T 0.25) 
  25 mM Tris 150 mM NaCl 
192 mM glycine   10 mM Tris/HCl 
20 % (v/v) methanol 0.1 % or  0.25 % Tween-20 
 
3.6.5 Immunofluorescence 
For the detection of the immediate early protein 1 (ie-1) of MCMV, immunofluorescence analysis 
was performed. Cells grown on plates were fixed for 5 min with acetone/methanol (1:1) at RT. 
After three subsequent washes with PBS, primary antibody CHROMA101 (kindly provided by 
Stipan Jonjic, Croatia) was added 1:200 diluted in 5 % FCS/PBS to the cells and incubated for 
45 min at 37 °C. Cells were washed three times with PBS and incubated with a secondary anti-
mouse-Cy3 antibody 1: 5000 diluted in 5 % FCS/PBS at 37 °C for 1 h. After another three 
subsequent washing steps, nuclei of the cells were counterstained with 5 µg/ml Hoechst 333258 
(Invitrogen, Karlsruhe, D) in PBS for 1 min. Finally, cells were again washed three times and 
analyzed by fluorescence microscopy. 
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4 RESULTS 
4.1 Construction of an virus inducible system on the episomal vector 
pEPI 
Episomal vectors provide interesting features that were thought to be advantageous for the 
construction of the novel expression system. Most important, episomal vectors do not integrate 
into the host chromatin, thus are independent from positional effects of the surrounding host 
chromatin, which in turn results in more reliable expression rates and furthermore they possess a 
lower risk for insertional mutagenesis that limits their usage in vivo. 
 A non-viral episomal vector, namely pEPI-1 has been originally described by Piechaczek 
and colleagues [136]. Several follow-up studies underlined the previous findings and highlighted 
the benefits of this episomal vector. 
 
 
Figure 12: Vector map of pEpibo 
The gfp gene and the neomycin resistance 
gene of the original pEPI vector were 
replaced by mOrange and the blasticidin S 
resistance gene (bsr). The modified vector 
was termed pEpibo. P(hCMVie) = 
immediate early HCMV Promoter, 
S/MAR= surface matrix attachment region, 
MCS = multiple cloning site, P(SV40ie) = 
SV40 immediate early promoter/ori, 
pA(TK) = Thymidin kinase poly A site, f1 
ori = phage origin of replication, colE1 ori 
= bacterial origin of replication. 
 
 
 Fluorescence and antibiotic marker of the original pEPI vector were changed for this 
project; i.e. the gfp gene was replaced by the mOrange gene to distinguish its fluorescence from the 
dominant-negative protein GFPSCP, which was used at later time points of this study. 
Furthermore, the neomycin resistance was exchanged to a blasticidin S resistance gene (bsr), 
which allows improved selection in NIH3T3 cells. The resulting vector was termed pEpibo 
(Figure 12). 
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4.1.1 Trans-activation of viral promoters during infection  
Using inducible expression systems is a good way to avoid toxic side-effects, often associated 
with high and constitutive expression levels. It is known that many herpesviral promoters can be 
induced in trans, meaning that viral transcription factors bind and activate promoter sequences 
inserted into the host chromatin upon infection [137]. However, strength of expression levels as 
well as tightness of the promoters in the non-induced, meaning in this case the non-infected 
status, has not been assayed, yet.  
 As mentioned above (see section 1.3) herpesviruses proteins can be divided in three 
kinetic classes, according to the time point of protein production in the virus life cycle. The first 
proteins that can be detected after infection are termed ‘immediate-early’ proteins. The genes of 
these proteins are instantly activated by factors provided in the virion or are directly transcribed 
by the host RNA polymerase II. Some immediate-early proteins are transcription activators that 
in turn activate early genes and the gene products can be detected around 6 hours post infection. 
Late proteins arise after about 16 h post infection and can be divided in leaky-late and true-late 
proteins. True-late genes need in contrast to leaky-late genes DNA replication of the genome for 
transcription.  
 Several viral promoters, belonging to different kinetic classes were used to test if the 
intrinsic feature of the virus to activate its own promoters could be exploited to generate a virus 
inducible expression system. Thus different promoter sequences of MCMV together with a firefly 
luciferase open reading frame were cloned into the multiple cloning site of pEpibo. One 
promoter of an early gene, namely M143 [128], and two of late genes, namely M53 [138] and M94 
[100], as well as the strong human CMV immediate-early promoter (P(hCMVie)) and the minimal 
SV40 promoter were tested. Only for the promoter of M143, namely P(M143), a detailed 
promoter analysis was available [128] and length of the promoter region was adopted as 
described therein. For P(M53) and P(M94) a 500 bp long sequence upstream of the start codon 
was used. P(hCMVie) was derived from the vector pCR3 and the minimal P(SV40) from pGL3-
control.  
 First, induction of FL expression driven by the different promoters was tested. NIH3T3 
cells were co-transfected with one of the pEpibo-P(X)-luc plasmids, as well as the control 
plasmid pTK-RL encoding for Renilla luciferase for transfection normalization. After 
transfection, cells were split and infected with MCMV or were mock treated. FL expression was 
measured 24 h and 48 h p.i. and was normalized to Renilla luciferase expression. 
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 The minimal SV40 promoter was not induced by MCMV infection, neither at 24 h nor 
48 h p.i. (Figure 13). All other viral promoters were induced in trans. Nevertheless, none of the 
promoters was completely silent prior to infection and the overall induction level was quite low. 
The P(hCMVie), one of the strongest known promoters, drove the highest FL expression, as 
expected, and FL expression was enhanced 2.5-fold at 24 h p.i. and 5-fold at 48 h p.i. by MCMV 
infection. However, the basal constitutive expression in uninfected cells remained high. The 
highest ratio of induction was seen with the early promoter P(M143), where FL expression was 
increased 7.5-fold at 24 h p.i., but dropped to 2.5-fold after 48 h p.i. in accordance with the 
typical early gene expression pattern. While the late P(M94) showed already some response to the 
MCMV infection at 24 h p.i. and increased to 6.8-fold induction at 48 h p.i., the expression 
controlled by the second late promoter P(M53) did not increase at 24 h p.i. and only a 2-fold 
induction was measured at 48 h p.i. Furthermore, P(M53) was the weakest of all tested 
promoters. 
 
 
Figure 13: Trans-activation of herpesviral promoters by infection. 
NIH3T3 cells were transfected with either pEpibo-P(SV40)-luc, or the respective constructs with the human 
immediate early promoter P(CMVie), the early promoter P(M143) as well as the two late promoters P(M53) and 
P(M94). Firefly luciferase expression was normalized to the renilla expression by the co-transfection of pTK-RL. 
Cells were infected with MCMV at an MOI of 0.1 and 24 h (A, white) or 48 h p.i. (B, grey) and a bioluminescence 
assay was performed.  
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4.1.2 Construction and characterization of the replicon vector – Induction of gene 
expression by plasmid replication 
As the induction of the viral promoters by trans-activation (see section 4.1.1) was low, another 
possibility to increase gene expression was needed. Herpesviruses can replicate plasmids 
containing their lytic replication origins (oriLyts) in trans [45, 46]. Therefore, we tested if the 
addition of the MCMV oriLyt to the pEpibo-luc vector would cause vector replication and thus 
enhance gene expression during infection. Ideally, the transgene should act like a true-late gene 
and would not be transcribed before infection and replication (Figure 14).  
 
 
Figure 14: Concept of oriLyt-induced gene expression.  
While the gene expression from the episomal plasmid should ideally be silent in uninfected cells, infection with 
MCMV should activate DNA replication of the episome via activation of the incorporated MCMV oriLyt (blue) and 
replication of the plasmid, thus inducing and increasing reporter gene (luc) expression. 
 
 In order to construct such an episomal vector containing the oriLyt, the oriLyt-sequence 
had to be obtained from the MCMV genome first. The location of the minimal oriLyt region in 
the MCMV genome was published by Masse and colleagues in 1997 [46]. The borders of the 
region were not well defined and no further study of the oriLyt region has been performed. Yet, 
the oriLyt sequences of the CMVs are known to be complex, containing several inverted and 
direct repeats as well as several runs of identical nucleotides (see 1.4.2.2). This makes the oriLyt 
sequence a very difficult template for PCR reactions. To facilitate the cloning of the MCMV 
oriLyt from the viral BAC pSM3fr into a smaller plasmid, a ‛pick-up-strategy’ was designed. It has 
been described for other herpesvirus origins that additional sequences next to the minimal oriLyt 
can have enhancing effects on replication [139]. Therefore, a 3.9 kb DNA fragment rather than 
the minimal oriLyt sequence (1.7kb) was cloned. To do so, a PCR fragment containing the 
selective bacterial replication origin oriR6K together with a kanamycin resistance gene was 
amplified, which is flanked by MluI restriction sites as well as one NheI restriction site on the 5′-
site of the construct (Figure 15A). In addition, homologous sequences at both ends allowed the 
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recombination of the PCR fragment into the MCMV BAC genome into the 5′- site of the oriLyt 
sequence. The m58 gene partially overlaps with the oriLyt region, therefore the oriR6K-kan 
fragment was recombined into the ORF behind the start ATG, thereby disrupting the expression 
unit of m58. Another gene, namely m59, was originally annotated inside the minimal oriLyt 
region. However, later expression profiling indicated that this gene does not exist [140]. Correct 
insertion of the PCR fragment was analyzed by fragment length polymorphism of the respective 
BAC clones (Figure 15 B). As the MCMV genome encodes another NheI site on the 3'-site of the 
oriLyt sequence, the replication origin together with the PCR fragment could be excised by NheI 
restriction digestion. The DNA fragment was ligated to a functional bacterial plasmid, which can 
be selected by kanamycin and growth in the oriR6K specialized E. coli PIR1. From ten selected 
clones of the ligation reaction, nine did contain the plasmid p06kan-MCMV-oriLyt (Figure 15 C). 
 
Figure 15: Cloning of pEpibo-luc-ori. 
A pick-up-strategy was designed to clone the complex and repetitive oriLyt of MCMV into the transfer vector 
p06kan-MCMV-oriLyt. Homologous recombination was used to insert a PCR fragment containing a kanamycin 
resistance gene and a selective bacterial origin oriR6K flanked by MluI restriction sites and one additional NheI 
restriction site into the viral BAC pSM3fr encoding the entire MCMV genome. B) Successful insertion of the PCR-
fragment into pSM3fr was analyzed by restriction digest. (lane 1, 1kb Marker, lane 2 native pSM3fr digested with 
AseI, lane 3 pSM3fr-oriR6kan digested with AseI, lane 4 pSM3fr-oriR6kan with NheI). Additional bands due to the 
correct recombination are marked with an asterisk. C) After the recombination the oriLyt can be excised by a NheI 
digest together with oriR6K and kanR gene and ligated to the vector p06kan-MCMV-oriLyt. Due to the selection 
with the antibiotic and the growth in PIR1 E.coli that can maintain oriR6K vectors, plasmids obtained contained in 9 
of 10 cases the wanted vector. D) By a MluI digest the oriLyt could then be transferred into the pEpibo vector. 
Insertion of a FL reporter gene (luc) upstream of the oriLyt allowed a sensitive measurement of oriLyt induced gene 
activation. 
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 The MluI restriction sites initially flanking the PCR fragment now flanked the oriLyt 
sequence in the plasmid p06kan-MCMV-oriLyt after ligation. Thus the oriLyt sequence became 
transferable via these restriction sites into the pEpibo vector, resulting in the replicon vector 
pEpibo-MCMV-orilyt. To test whether oriLyt-mediated amplification of the replicon vector 
indeed increased gene expression a FL reporter gene (luc) was cloned into the vector (Figure 15 
D). This should allow sensitive and quantitative measurements of the transgene expression in a 
bioluminescence assay. The expression of the FL reporter gene was set under the control of the 
minimal SV40 promoter, as this promoter is not influenced by MCMV infection (Figure 13). The 
changes of gene expression in response to MCMV infection should thus depend entirely on the 
effect of the MCMV oriLyt-induced replication of the vector. The resulting replicon vector was 
named pEpibo-luc-ori (Figure 15 D).  
4.1.2.1 Infection can reactivate silenced gene expression of the replicon vector 
To test whether expression of the reporter gene from the replicon vector is enhanced upon 
infection, NIH3T3 were stably transfected with pEpibo-luc-ori. FL expression was measured in 
two stable cell pools, NIH3T3: luc-ori t1 and NIH3T3: luc-ori t2 (luc-ori t1, luc-ori t2) over time. 
In both a strong decline of bioluminescence was found during ongoing culture of the cell pools 
(Figure 16 A, plain bars). In one pool, i.e. luc-ori t1, the expression of the reporter gene dropped 
under detection limit after 16 weeks. If the same transfectants, however, were infected with 
MCMV at an MOI of 0.5 strong reporter gene expression was detected by bioluminescence after 
24 h p.i. (Figure 16 A, hatched bars). Reporter gene expression was up to a 1000-fold higher than 
in non-infected cells. While in the cell pool luc-ori t1 the ability to induce FL after infection 
declined over time, in the cell pool luc-ori t2 induction strength after 16 weeks was as strong as 
after the first week.  
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Figure 16: Infection with MCMV reactivates silenced reporter gene expression. 
In two stable NIH3T3 cell pools transfected with pEpibo-luc-ori (luc-ori t1, luc-ori t2) expression of FL was 
measured in relative light units (RLU) over time. Reporter gene expression is lost in uninfected cells over time. 
Infection of luc-ori t1 and t2 with MCMV (MOI of 0.5) however induced high expression of FL 24 h p.i.. NIH3T3 
served as control to determine background (BG) signal. (B) FL expression is inactivated by histone deacetylation. 
Cell clones derived from subcloning luc-ori t1 were subjected to treatments for 36 h with 25 µM 5′-azacytidine 
(5′Aza, gray bars), an inhibitor of CpG-methylation or 330 nM trichostatin A (TSA, black bars), an inhibitor of 
histone deacetylases. FL expression was analyzed in comparison to untreated control (mock, white bars). Recovery of 
FL expression was significantly enhanced by decondensing histone packaging through TSA treatment in three of 
four isolated clones. (*** p < 0.001, ns  p> 0.05, Two-Way-Anova, depicted is mean + SD). RLU (relative light 
units), p.i. post infection, weeks = weeks post transfection of pEpibo-luc-ori 
 
 To examine the mechanism of bioluminescence regulation in murine fibroblasts, four 
isolated cell clones that were derived from luc-ori t1 after 16 weeks of selection were treated with 
trichostatin A (TSA) or 5′-azacytidine (5′-Aza). TSA is a well known inhibitor of histone 
deacetylase thus indirectly lifting histone-dependent silencing mechanisms [141]. 5′-Aza is 
inhibiting methylation of cytosines after incorporation of the modified nucleotide into the 
genomic DNA [142]. In three of the four isolated cell clones (luc-ori cl. 1 to cl.3) a low FL 
expression level was detected in the untreated cells (Figure 16 B, white bars). If 330 nM TSA was 
added for 36 h, FL reporter gene expression increased by approximately 100-fold in the three cell 
clones (black bars). Bioluminescence in cell clone luc-ori cl.4 could never be detected in any 
condition. Changes in luciferase expression due to 5′-Aza treatment were not significant (grey 
bars) in the cell clones luc-ori cl.1 to cl.3. Therefore, the silencing of the transgene expression in 
the cell lines is most likely due to the inaccessibility of the gene for RNA polymerase due to 
condensed chromatin packaging, which was lifted upon MCMV infection (Figure 16A, hatched 
bars). 
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4.1.2.2 Immediate early proteins cannot remove silencing from pEpibo-luc-ori 
The previous experiments showed that the replicon vector was silenced in the stable cell lines by 
a histone deacetylase-dependent mechanism. For HSV-1 [143], HCMV [144] and MCMV [145] it 
has been described that viral immediate early proteins can inhibit de-novo silencing by histone 
deacetylase (HDAC), which prevents inactivation of incoming viral genomes. To assess whether 
the immediate early proteins of MCMV are, in the present case, able to recover reporter gene 
expression from the silenced cell lines, luc-ori cl. 1 cells were transfected with the plasmid pGPS-
ie1/ie3-ie2. This plasmid encodes the entire immediate early locus and should produce all known 
isoforms (kindly provided by K. Eisenächer). Expression of the ie1 and ie3 protein was 
controlled by immunofluorescence staining with an anti-ie1/3 antibody (Figure 17 A) and 
bioluminescence was measured in the treated and the untreated cells. The expression of the 
immediate early proteins did not result in an increase of reporter gene expression but rather in a 
slight decrease (Figure 17 B). Thus, the immediate early proteins are not directly involved in the 
removal of FL silencing on the pEpibo-luc-ori construct. 
 
Figure 17: Immediate early proteins do not induce luciferase expression. 
luc-ori cl. 1 cell were transfected with a plasmid encoding immediate early proteins ie1, ie2 and ie3 or were mock 
transfected. 52 h post transfection the presence of the ie1/3 proteins was analyzed by staining with the antibody 
CHROMA101. Cell nuclei where counterstained with DAPI. (B) Transfection of the ie proteins (black bar) alone 
cannot induce FL expression in luc-ori cl. 1 cells. Moreover, a significant drop in background expression compared 
to the mock transfected cells (gray bar) could be detected. (***: p < 0.001, ns: p >0.05, Students t-test, depicted is 
mean + SD) 
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4.1.2.3 Induction of reporter gene expression requires oriLyt sequence 
To test whether reactivation of reporter gene expression is dependent on the oriLyt sequence, 
NIH3T3 cells were transfected with pEpibo-luc-ori or pEpibo-P(SV40)-luc (see section 4.1.1) 
and stable cell pools were isolated. Both vectors differ only in the presence or absence of the 
oriLyt sequence.  
 
Figure 18: Only construct with oriLyt is activated by 
viral infection. 
Stable cell pools were generated by transfecting NIH3T3 
with pEpibo-luc (luc t1) or pEpibo-luc-ori (luc-ori t3). 
Cells were infected with MCMV at an MOI of 1 and 
bioluminescence analysis was performed 36 h post 
infection. Induction of FL expression was calculated as a 
ratio of RLU of infected and uninfected cells. The pool 
luc-t1 did not induce FL after MCMV infection, while luc-
ori t3 was inducible as previously shown, thus 
demonstrating that the oriLyt is needed for the activation 
of reporter gene expression. 
 
 After two months of culturing, the transfectants NIH3T3:luc t1 (luc t1, derived from 
pEpibo-P(SV40)-luc) as well as NIH3T3:luc-ori t3 (luc-ori t3, derived from pEpibo-luc-ori) were 
analyzed for their ability to induce FL expression upon MCMV infection. In both stable cell 
pools a low background signal of FL could be detected (data not shown). In the luc-ori t3 pool a 
> 40-fold increase of luciferase expression could be seen upon infection. Notably, reporter gene 
expression in the luc t1 cells did not change upon infection (Figure 18). Thus, the reactivation of 
the replicon vector from silencing was dependent on the presence of the MCMV oriLyt 
sequence.   
 The replicon system was tested in different cell types, murine stromal fibroblast cells 
M2-10B4, murine heart endothelial cells MHEC-5T and SV40 transformed murine endothelial 
cells SVEC4-10. Cells were transfected with the vector pEpibo-P(SV40)-luc or pEpibo-luc-ori. 
Stable cell pools were selected and reporter gene expression was measured in infected and non-
infected cells. Irrespective of the cell type, only cells transfected with the replicon vector, 
containing the oriLyt sequence, could be induced upon infection (Figure 19). All cells were 
infected with an equal virus load. However, the permissivity of the cell types for MCMV is 
variable, with the MHEC-5T cells being least infectable, which might explain the differences in 
the induction strengths. In summary, the replicon vector worked in all tested cell types.  
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Figure 19: Induction of the replicon vector in 
different cell types. 
NIH3T3, M2-10B4, MHEC-5T and SVEC4-10 were 
transfected with pEpibo-P(SV40)-luc (luc) or pEpibo-luc-
ori (luc-ori). Stable pools of the transfectants were 
selected. Cells were infected with MCMV at an MOI of 1 
and bioluminescence analysis was performed 36 h post 
infection. Induction of FL expression was calculated as a 
ratio of the RLU of infected and uninfected cells. In all 
different cell types, luc-ori cell pools could be induced 
upon infection with MCMV, while in luc cell pools 
infection did not influence FL expression.  
 
4.1.2.4  Virus specific activation of the oriLyt-expression system 
Herpesviruses usually are species specific and cannot productively infect another animal than 
their specific host. There are two herpesviruses that naturally infect mice, namely MCMV 
belonging to the β-herpesviruses and the murine herpesviruses 68 (MHV68), a γ-herpesvirus. No 
herpesvirus of the α-subfamily could be isolated from mice so far. All herpesviruses share the 
major six proteins needed for replication (see 1.4.1), but possess different oriLyt sequences and 
specific proteins for their activation. To examine if the MCMV-based oriLyt expression system 
can be non specifically activated by a herpesvirus of a different subfamily luc-ori cl. 1 cells were 
infected with MCMV or MHV68 at an MOI of 0.1 and induction of FL expression was measured 
36 h p.i. after (Figure 20).  
 
 
Figure 20 : MHV68 infection cannot activate MCMV 
orilyt-based expression system 
luc-ori cl. 1 cells were infected with MCMV or MHV68 at 
an MOI of 0.1. 36 h p.i. cells were harvested and 
bioluminescence was measured. Depicted is the ratio of 
infected to uninfected cells. While induction was at 1000-
fold by infection with MCMV, MHV68 infection resulted 
only in 5 to 10–fold induction of the MCMV oriLyt-based 
expression system. 
 
 
While MCMV induced luciferase expression by ~1000-fold, MHV68 infection resulted only in a 
5 to 10-fold increase of reporter gene expression. This is indicative for a highly specific activation 
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of the system that is dependent on the correct oriLyt sequence and its specific oriLyt activation 
protein.  
4.1.2.5 Activation is dependent on viral DNA amplification  
As the induction of reporter gene expression was dependent on the oriLyt sequence of the 
episomal vector, the necessity of viral DNA replication for the activation of the luciferase was 
addressed. To do so, the four luc-ori cell clones 1 to 4, as well as NIH3T3 as control were 
infected with MCMV at an MOI of 0.5 (hatched bars, Figure 21) or left untreated (full bars). 
Furthermore PAA, a specific inhibitor of the viral DNA polymerase, was added (black bars). 
Infection with MCMV induced gene expression in a range of 100 to 1000-fold in three of four 
cell clones (Figure 21), in accordance with the clones that could be reactivated with TSA (Figure 
16). Treatment of infected cells with PAA however blocked the induction of the reporter gene 
expression completely. The presence of the drug did not influence basal luciferase expression in 
uninfected cells. Therefore, not only the presence of the oriLyt in the sequence but also the 
functionality of the viral DNA polymerase is needed for the activation of the adjacent reporter 
gene. 
 
Figure 21: Induction of reporter gene expression depends on viral DNA amplification. 
Four luc-ori cell clones were tested for their response to MCMV infection. A low basal level of luciferase signal 
could be detected in three of four isolated cell clones (white bar). By infection with MCMV with an MOI of 0.5, FL 
expression was induced up to 1000-fold (white, hatched bar). To determine if the induction is dependent on viral 
DNA amplification, a specific inhibitor (PAA) was added to either uninfected (black bars) or infected (black, hatched 
bars) cell clones. While PAA did not have any influence on uninfected cells, it could block the increase of FL in the 
infected cells completely. Thus, the activation is highly dependent on viral DNA amplification. (p.i., post infection; 
BG = Background; ***: p < 0.001, ns: p >0.05, Two-Way-ANOVA, depicted is mean + SD) 
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 To find out if DNA replication or just the activation of the oriLyt is necessary for the 
induction, a time course (12, 15, 18, 21, 24 and 26 h p.i.) of reporter gene induction upon 
infection was performed. The co-translational folding of FL is very fast and lies in the range of 
20 min [146] and has a half-life of three to four hours [147], and thus does not contribute much 
to the shape of time course. The exact onset of MCMV DNA replication has not been analyzed 
in detail so far, but FACS measurement of total DNA content stained by propidium iodide in 
MCMV infected NIH3T3 roughly revealed the expected DNA replication onset at about 16 h p.i. 
[148]. Induction of luciferase expression was assayed under five conditions: either PAA was 
added directly after the infection, after 12 h p.i., 15 h p.i., 18 h p.i. or the measurements were 
performed in absence of the drug. If PAA was added prior to the onset of viral DNA replication 
(0 h p.i., 12 h p.i.) [149] no induction of FL was detected. If PAA was administered after DNA 
replication had just started, a reduced level of induction could be detected that was dependent on 
the elapsed time since addition. In infected cells without inhibitor an exponential increase of 
luciferase expression could be seen after 18 h p.i. Therefore, it can be concluded, that the 
activation of reporter gene expression in the stable cell lines requires viral DNA replication and 
increases further with ongoing replication. Furthermore it can be reasoned that the start of viral 
DNA replication in NIH3T3 probably takes place earlier than reported and begins already 
between 12 and 15 h p.i. 
 
Figure 22: Time course of FL induction. 
luc-ori cl. 1 cells were infected with wt-MCMV at an MOI of 0.5. At 12, 15, 18, 21, 24 and 26 h p.i. induction of FL 
was measured. In addition the replication inhibitor PAA was added after; either immediately at infection, at 12, 15 or 
18 h p.i. (indicated by the arrows). Induction without PAA, starts before 15 h p.i. and increases exponentially (black 
bars).  If PAA is added before viral DNA replication takes place, no induction of FL appears (white and light gray). 
Whereas induction can be blocked in a dose related fashion the later PAA is added to the infected cells (gray and 
dark gray).  
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4.1.2.6 MCMV infection amplifies replicon vector 
As the induction of reporter gene expression was dependent on viral DNA replication, it was 
reasonable to ask whether also the episomal plasmid itself was amplified by viral infection. 
Therefore, quantitative real time PCR was performed on uninfected (plain bars, Figure 23 A) and 
infected luc-ori cell clones (hatched bars, Figure 23 A). Amplification of the vector was measured 
by detection of the blasticidin resistance gene (bsr) on the vector pEpibo-luc-ori and normalized 
to the endogenous lamin B receptor gene (lbr). Results are presented as relative copies of the 
pEpibo-luc-ori vector per lbr. A significant increase of pEpibo-luc-ori copies of more than 50-
fold could be detected in the infected cell lines luc-ori cl. 1-3. Only in the luc-ori cl. 4 clone that 
was not responsive to viral infection there was no increase in copy numbers.  
 
Figure 23: Amplification of  pEpibo-luc-ori in infected cells. 
A) The vector pEpibo-luc-ori is amplified after infection. NIH3T3 or luc-ori cl. 1 to 4 were infected with wt-MCMV 
with an MOI of 1 (hatched bar) or left untreated (closed bar, mock). 36 h p.i. quantitative realtime PCR was 
performed to determine copy numbers of the PCR products bsr (Blasticidin resistance gene on vector) and lbr 
(cellular lamin B receptor gene). Shown is the mean of triplicates of bsr relative to lbr copy numbers with standard 
deviation. B ) and C) Strong induction of luciferase correlates with amplification of the vector. luc-ori cl. 1 cells were 
subjected to several treatments; cells were infected with MCMV (white hatched bars) or MHV68 (black hatched) bars 
at an MOI of 1 or 330 nM TSA was added to the cells. 300 µg/ml phosphonoacetic acid (PAA) or 100 µg/ml 
phosphonoformic acid (PF) was added to MCMV infected cells. Bioluminescence measurements (B) or qPCR (C) 
was performed.  
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 To strengthen the correlation between amplification of vector DNA and induction of 
reporter gene expression qPCR analysis under different conditions was performed. Luc-ori cl. 1 
cells were infected with MCMV or MHV68 at an MOI of 1 and additionally treated with the viral 
replication inhibitors PAA and phosphonoformate (PF) (Figure 23 B and C). Under these 
conditions, only luc-ori cl. 1 cells infected with MCMV induced strong FL expression of 2500-
fold, which correlated with an amplification of the vector DNA of 50-fold. In contrast, treatment 
with 300 ng/ml TSA partially resolved silencing, but did not lead to vector amplification. 
Accordingly, FL induction by TSA treatment was 100-fold less effective than infection. Thus, 
vector DNA replication is a prerequisite for strong expression of the reporter gene.  
 Southern blot analyses of uninfected and infected cell lines were performed to analyze 
the status of the pEpibo-luc-ori plasmid DNA before and after replication. Although the 
pEpibo-luc-ori plasmid could not be detected in the uninfected cells, strong specific signals were 
found for the three cell lines luc-ori cl. 1-3, which were also responding to MCMV infection with 
strong FL induction (Figure 16). The infected luc-ori cl.1-3 exhibited band patterns of amplified 
pEpibo-luc-ori vectors (Figure 24).  
 
Figure 24: Southern blot of uninfected and infected luc-ori cell clones. 
Amplification and conformation of the pEpibo-luc-ori vector were analyzed by Southern blotting. 10 µg genomic 
DNA of uninfected and infected (MOI of 0.5, 24 h p.i.) luc-ori clones cl.1 to 4 as well as NIH3T3 was digested with 
PstI. 10 ng and 1 ng of PstI-linearized plasmid DNA was loaded as control. The blot was treated with a dig-labeled 
probe directed against the luc gene. (* = single-unit, episomal plasmid; 1= concatemeric bands, 2 = probably 
supercoiled plasmid form) 
 
The strongest signal was detected at 11 kb, the same height as the linearized loading control of 
pEpibo-luc-ori. Yet, additional weaker bands appeared migrating at positions higher as well as 
lower as the single unit size. This indicated first, that the replicon vector replicates similar to the 
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MCMV genome and second exists as supercoiled and relaxed plasmid forms, as well as in the 
form of concatemers typical for herpesvirus genomes during replication. No specific bands could 
be detected in the non responsive clone luc-ori cl.4 (Figure 24).  
 
4.1.2.7 Induction of FL expression from the oriLyt based system in comparison to virus 
encoded FL expression 
In order to compare the expression strengths of the replicon vector system with direct transgene 
expression by the virus, luciferase expression encoded by MCMV-luc virus and the ori-luc cells 
was compared. The luc gene in the MCMV-luc virus is expressed by the strong CMVie promoter 
and starts with early kinetics after viral infection, thus also expressing the FL earlier than the 
replicon system. The expression of the replicon vector and the MCMV-luc were comparable at 
very low MOI, but the virus induces a stronger signal at higher infection doses.  Thus, although 
the replicon system induces strong and accumulating gene expression, it cannot completely 
compete with the FL expression encoded by the virus under early kinetics. Nevertheless, the 
differences were only 10-fold at an MOI of 0.5, which is quite small given that virus-encoded 
expression has a head start whereas replicon-derived expression of FL starts 16 h later. 
 
Figure 25: Comparison of expression strength of virus 
or luc-ori driven luciferase production. 
NIH3T3 cells were infected with MCMV-luc, a virus 
encoding a firefly luciferase under the strong immediate 
early hCMV Promoter, and luc-ori cl. 1 cells were infected 
with wt-MCMV at the indicated MOIs. 30 h p.i. cells were 
harvested and bioluminescence measured.  
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4.2 Intracellular immunization with the DN GFPSCP in the replicon 
system 
Previous attempts to realize intracellular immunization by the means of several other expression 
systems (data not shown) indicated that some important prerequisites need to be fulfilled. First of 
all, a strong expression of the inhibitory protein is necessary to block virus spread. Second, 
positional effects can be minimized by the usage of extrachromosomal elements. Initial 
experiments using the luciferase as reporter gene showed that the oriLyt-based replicon system 
combined both criteria. As a next step, the suitability of the replicon vector with respect to 
intracellular immunization was evaluated. To do so, the luc gene of the pEpibo-luc-ori episome 
was replaced by the inhibitory gene DN gfpscp (see section 1.8). While in permissive host cells 
MCMV multiplies and spreads to neighboring cells, in cells carrying the pEpibo-gfpscp-ori 
episome, viral DNA replication should strongly induce the gene expression of the viral 
dominant-negative fusion protein GFPSCP (see section 1.8) and appropriate expression levels of 
this inhibitor should block further budding of viral capsids from the nucleus into the cytoplasm 
resulting in the block of virus maturation and spread to uninfected cells (Figure 26).  
 
Figure 26: Schema of oriLyt induced expression of the dominant-negative protein GFPSCP. 
In MCMV-permissive cells, MCMV enters the cell and replicates its DNA in the nucleus. Viral capsids are filled with 
the virus genome and bud through the inner nuclear membrane. After acquiring the tegument in the cytoplasma, 
MCMV exhits by budding through the cell membrane. Gfpscp-ori cell lines, stably carrying the episome pEpibo-
gfpscp-ori, encoding a dominant negative version of the small capsid protein (SCP) of MCMV fused to the 
fluorescent protein GFP should be resistant to MCMV infection. During an infection with MCMV, pEpibo-gfpscp-
ori should be replicated and thereby the expression of the inhibitory protein should be induced, which in turn should 
block egress of viral capsids from the nucleus. 
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4.2.1 Validation of MCMV infection and spread on cell lines carrying the replicon 
pEpibo-gfpscp-ori  
To test the hypothesis of intracellular immunization on the basis of the oriLyt-based expression 
system, two MCMV-permissive cell lines NIH3T3 and M210-B4 cells were stably transfected 
with the plasmid pEpibo-gfpscp-ori and stable cell clones were isolated.  
 In contrast to NIH3T3 cells, MCMV spread was visibly reduced on gfpscp-ori cells. 
After infection with wt-MCMV at an MOI of 0.5, full lysis occurred at day 3 p.i. in NIH3T3 cells, 
while only small plaques were found in the gfpscp-ori cl.3 culture (Figure 27 A). Remarkably, 
silencing of the gfpscp gene happened much faster than the luc gene and within two weeks after 
transfection no fluorescence signal could be detected in uninfected cells (Figure 27 B). However, 
expression of GFPSCP was strongly induced by infection (Figure 27 B). In infected cells 
GFPSCP localizes to the cytoplasm and is then transported by the help of the major capsid 
protein into the nucleus, where it localizes in nuclear speckles. At very late stages of infection the 
induced GFPSCP production is so strong that the complete cell fluoresces brightly. 
 
 
Figure 27: Infection pattern of 
gfpscp-ori cl.3 
A) NIH3T3 and gfpscp-ori cl.3 
cells were equally infected with wt-
MCMV at an MOI of 0.5. Three 
days post infection brightfild 
microscopy pictures were taken. B) 
gfpscp-ori cl.3 cells were infected 
with wt-MCMV at an MOI of 0.5. 
Brigthfield and fluorescence micro-
scopy pictures were taken 5 d p.i. 
Uninfected cells do not express 
GFPSCP. After infection GFPSCP 
is induced. 
 
 
 To check whether and to what extend various gfpscp-ori clones were able to inhibit 
viral spread, they were infected with MCMV at an MOI of 0.1 and virus growth analysis was 
performed. In NIH3T3:gfpscp-ori cl. 3 and M210-B4:gfpscp-ori cl. 3 the system was inducible by 
MCMV infection and GFP fluorescence could be detected. In the other cell clones either a weak 
constitutive or no GFP expression at all was found. 
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 Only clones producing GFPSCP in response to MCMV infection were able to reduce 
viral spread. In case of NIH3T3:gfpscp-ori cl. 3 a reduction of ~ 250-fold virus titer could be 
detected on day 3 and 5 in comparison to the wt-NIH3T3 cells, which represents a 99.5 % 
inhibition of MCMV. In the M210-B4:gfpscp-ori cl. 3 also a strong reduction of 100-fold could 
be measured on day 3, which then dropped to a 10-fold reduction on day 5. All other clones 
possessed either very weak or lacked inhibitory potential (Figure 28).  
 
 
Figure 28: Virus growth analysis of wt-MCMV on NIH3T3:gfpscp-ori and M210B4:gfpscp-ori lines  
NIH3T3 or M210-B4 cells respectively were transfected with pEpibo-gfpscp-ori. Stable cell clones were isolated and 
tested for their potential to inhibit MCMV spread. One NIH3T3:gfpscp-ori clone (cl. 3 green bar, left) out of five (cl. 
1 to 5) could reduce MCMV titer up to  250-fold, meaning a 99.5 % inhibition of MCMV spread compared to the 
parental cell line (black bar). In the M210-B4: gfpscp-ori clones (cl. 1 to 4) also one clone (cl. 3, green bar, right) was 
able to reduce virus titer by 100-fold on day 3 and 10-fold on day 5. 
 
4.2.2 The vector pEpibo-gfpscp-ori is maintained as an episome 
As individual clones of NIH3T3:gfpscp-ori showed a different antiviral potential, the status of 
the vector DNA pEpibo-gfpscp-ori in cells was analyzed. To this end, Southern blot analysis of 
the stable cell clones was performed with a dig-labeled DNA probe detecting the gfpscp gene. In 
case of an episomal maintenance one band at the size of the full length plasmid is expected, when 
the genomic DNA is digested with an restriction enzyme that cuts only once in the plasmid. As 
control for the Southern blot experiment linearized pEpibo-gfpscp-ori plasmids were loaded. 
Three specific bands recognized by the gfpscp probe could be detected in gfpscp-ori cl. 3 (lane 3, 
Figure 29), the lowest band possessing the expected size of the linearized plasmid of 11.5 kb and 
two higher bands (red asterisks). 
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 In another independent clone (gfpscp-ori cl. 8, lane 5) that also responded with 
GFPSCP expression to infection the same pattern was detected. In cl. 7, however, a weak 
constitutively expressing clone, two bands at approximately 9 kb and 2.7 kb were marked by the 
probe (black asterisks, lane 4) indicating that the plasmid has partially integrated into the host 
genome. In cl. 1 (lane 2) no specific signal was detectable over background pattern of NIH3T3 
(lane 1). In this case an integration of only the bsr gene seems likely, as this clone did not express 
GFPSCP at all. Function or failure to inhibit MCMV spread thus seems to be associated with the 
genomic status of the pEpibo-gfpscp-ori plasmid.  
 
Figure 29: Southern blot of uninfected gfpscp-ori cell 
lines.  
To determine the status of the pEpibo-gfpscp-ori plasmid in 
the different NIH3T3 cell clones Southern blot experiments 
were performed. Genomic DNA of NIH3T3 (lane 1), gfpscp-
ori cl. 1 (lane 2), gfpscp-ori cl. 3 (lane 3), gfpscp-ori cl. 7 (lane 
4), gfpscp-ori cl. 8 (lane 5),  0,5 pg, 5,0 pg, 50 pg and 0,5 ng of 
pEpibo-gfpscp-ori (lane 6 to 9) was digested with PstI. A 1 kb 
Marker was loaded as size control (lane 10). Southern blots 
were hybridized with a dig-labeled probe against the gfpscp 
gene. Red asterisks mark bands additionally appearing to 
background of NIH3T3 in the lines that are responsive to 
MCMV infection. Black asterisks mark the bands that appear 
in the line NIH3T3:gfpscp-ori cl. 7 that constitutively 
expresses GFP but does not respond to MCMV infection. 
 
 
 
 
 The Southern blot hybridization detected three bands specific for the gfpscp-probe, 
whereas only one band was expected for the episomal state. Thus the plasmid status of pEpibo-
gfpscp-ori was further analyzed by fluorescence in situ hybridization (FISH). Thereby it should 
be clarified if the plasmid might was integrated in tandem repeats or whether bands resembled 
different conformation forms representing artifacts of incomplete restriction enzyme digest. 
 To detect different subregions of the plasmids at the same time, a multicolor FISH was 
performed. Probes were generated against the gfpscp gene (FITC-labeled, green), the bsr gene 
(Cy3.5-labeled, pink) and the oriLyt region (DEAC-labeled, red). All probes co-localized to 
extrachromosomal elements in the metaphase spreads of gfpscp-ori cl. 3 that could not be 
detected in the NIH3T3 control. In 18 metaphase spreads, on average two extrachromosomal 
spots were found. Note, that smaller DNA fragments can drift much further than chromosomes 
and thus might not have been attributed belonging to the spread of the analyzed cell. In many 
 
cases, the spots seemed to be close to centromeres or telomeres of the acrocentric mouse 
chromosomes. As mouse chromosomes are difficult to distinguish, it could not be completely 
determined whether the extrachromosom
However spots where clearly also found completely free and unconnected. This fits well to the 
published behavior of pEPI-1 episomes
linked to chromosomes [111]. In some metaphase spreads
also found. Although it has been publish
[108], the ratio in the gfpscp-ori cl.
Still, in the cell line gfpscp-ori cl.
is mainly in an episomal form. 
 
Figure 30: Fluorescence in situ hybridization of gfpscp
Metaphase spread of uninfected NIH3T3:
gfpscp gene (green), bsr gene (pink) or oriLyt
chromosomal spots, indicating an episomal persistence of pEpibo
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Figure 31: Fluorescence microscopy of NIH3T3:gfpscp
NIH3T3: gfpscp-ori cl. 3 was infected with MCMV
late promoter of scp at an MOI of 0.1. Three days post infection fluorescence microscopy was performed. Infected 
cells were detected by the red mCherry fluorescence
showing the typical ‘speckles’ pattern. A very high 
observed, speaking for the specificity as well as the efficiency of reactivation from the silenced 
 
4.2.4 Comparison of expression strength of GFPSCP driven by the oriLyt system or by 
the virus 
Considering the results that nearly all infected cells express 
entirely in NIH3T3:gfpscp-ori 
rather than the fidelity of activation. As 
viral spread completely when encoded as a second gene copy by the 
SVTgfpscp) [103], the expression strength of both systems w
were infected with wt-MCMV to determine background fluorescence or with the MCMV
SVTgfpscp and NIH3T3:gfpscp
Fluorescence pictures were taken 
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GFPSCP, the failure 
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it was found before that the DN GFPSCP
viral genome (MCMV
as compared. To this end, NIH3T3 
-ori cl. 3 cells were infected with wt-MCMV at 
16 h p.i. (Figure 32).  
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Figure 32: Comparison of GFPSCP expression from the inducible cell line and the inducible virus. 
Fluorescence and brightfield microscopy was applied to evaluate the expression strength of the inducible gfpscp-ori 
cl. 3 cell line in comparison to the infection of NIH3T3 with MCMV-SVTgfpscp, which expresses the inhibitory 
protein under control of a Tet-ON CMV/SV40enhancer-Promoter. A) As control NIH3T3 were infected with wt-
MCMV. B) gfpscp-ori cl.3 does not express GFPSCP in the uninfected state, but GFPSCP is induced upon 
infection. C) NIH3T3 were infected with an MCMV-SVTgfpscp. Without Doxycyclin (Dox) weak background 
expression of GFPSCP can be seen, indicating that the system is not absolutely tight. Under induction with Dox, a 
strong expression of GFPSCP that exceeds the level obtained from the NIH3T3: gfpscp-ori cell line can be seen. All 
infections were performed with an MOI of 1, fluorescence pictures were taken 16 h p.i.. 
 While a considerable expression of GFPSCP could be already detected from the cells 
infected with MCMV-SVTgfpscp in absence of doxycyclin needed for gene induction, indicating 
leaky control of the gene cassette, no expression of GFPSCP was found in uninfected gfpscp-ori 
cl. 3. However, doxycyclin induction of the viral encoded expression of gfpscp produced a much 
stronger signal than the viral induced gfpscp-ori cl. 3 cells. Similarly to the data obtained with the 
luc-ori and MCMV-luc comparison (see Figure 25), the cell line cannot cope with the expression 
strength of the virus at early time points. The expression strength increases during replication in 
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the oriLyt cells, so does expression of the viral-encoded gene. The GFPSCP DN was selected for 
proof-of-principle of the replicon vector, yet it may not be the optimal DN for intracellular 
immunization, which is reflected by the fact that the basal leaky expression of GFPSCP in the 
viral context was not even inhibitory for virus spread [103]. A protein target with a lower 
constitutive abundance than the wt MCMV SCP protein, close to 900 copy numbers per virion 
should be a better target for competitive inhibition [16]. 
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4.3 Trans-complementation of MCMV late viral proteins by the replicon 
vector 
True-late herpesviral proteins are expressed only after DNA replication has occurred and true-
late promoters need an oriLyt sequence in cis for appropriate timing. Thus, late protein 
complementation has been a difficult task. In order to test, whether the replicon system would be 
suitable to trans-complement late viral transgenes two exemplary genes, coding for MCMV 
proteins, were cloned into the pEpibo-oriLyt vector. One was the glycoprotein gO of MCMV 
and the other the transmembrane protein M50, which is involved in the egress of MCMV from 
the nucleus. No M50 trans-complementing cell line could be generated via traditional methods 
due to toxicity of the protein [150]. 
 
4.3.1 Trans-complementing MCMV∆gO on NIH3T3:gO-ori 
The glycoprotein O governs cell-type specific entry of MCMV, like its homologue in HCMV 
[22]. In fibroblasts MCMV∆gO is restricted to focal spread, meaning that the virus still infects 
the neighboring cell by cell-to-cell contact but is not able to spread via the supernatant. Deletion 
of gO in MCMV leads to a 100 to 500-fold reduction of total virus release into the supernatant. 
In order to trans-complement this growth defect, the cell line NIH3T3:gO-ori (gO-ori) was 
generated. 
  
 
Figure 33: Virus growth analysis of MCMV∆gO on the trans-complementing cell line NIH3T3:gO-ori 
NIH3T3 (striped bars) or NIH3T3:gO-ori (plain bars) were infected with wt-MCMV (white bars) or MCMV∆gO 
(black bars) at an MOI of 0.05 with centrifugal enhancement respectively. Supernatants of infected cells were 
harvested at the indicated time points post infection and infectious virus in the supernatants was analyzed by 
standard plaque assay. The cell line gO-ori can effectively rescue the deletion of gO of MCMV. 
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 The virus growth analysis was performed on NIH3T3 and NIH3T3:gO-ori to determine 
the ability to trans-complement MCMV∆gO on the replicon-based cell line. MCMV∆gO and wt-
MCMV grew to comparable titers on NIH3T3:gO-ori, thus the release defect of infectious virus 
could be completely rescued (Figure 33). Furthermore, the trans-complemented 
MCMV∆gO/trans gO virus was not restricted to the focal spread pattern as the deletion virus on 
NIH3T3, but spread like wt virus on gO-ori cells (Figure 34). 
 
Figure 34: Virus spread pattern of MCMV∆gO on NIH3T3 and gO-ori cells 
NIH3T3 and gO-ori cells were infected with MCMV∆gO or wt-MCMV respectively at an MOI of 0.05 with 
centrifugal enhancement. Five days post infection MCMV infected cells were stained with anti-IE1/3 antibody 
CHROMA 101. (bar = 100 µm) 
 
 As the replicon vector possesses homologous sequences to the viral genome, 
recombination due to homologous pairing could occur that would lead to reversion of the gO 
deletion. The m74 gene coding for gO overlaps with the coding region of gN. Thus m74 could 
only be partially deleted in MCMV∆gO leaving 782 bp of homologous sequence. To address the 
question whether recombination occurs, PCR analysis detecting the m74 gene coding for gO was 
performed on supernatants harvested from the virus growth analysis experiment on day 5 (Figure 
33) of MCMV∆gO on gO-ori and NIH3T3. In order to discriminate between the m74 gene on 
the replicon vector in the cells and the virus genome, supernatants were cleared by centrifugation 
and liberated cellular DNA was digested with Benzonase. Lack of cellular debris was controlled 
by amplifying the cellular gene lbr in the purified supernatants, while integrity of the viral DNA 
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was controlled by amplification of the M54 gene, coding for the viral polymerase. All 
supernatants were positive for the M54 gene and negative for the lbr gene (Figure 35). The m74 
gene however was detected only in wt-MCMV genomes, but not in MCMV∆gO whether or not 
it descended from NIH3T3 or gO-ori cells. Thus, no recombination within the m74 gene locus 
was detected by PCR analysis. Furthermore, a phenotypic reversion of MCMV∆gO, meaning loss 
of the cell-to-cell spread restriction was never observed (data not shown). 
 
 
 
 
 
Figure 35: PCR test for recombination of MCMV∆gO 
with pEpibo-gO-ori 
Supernatants of virus harvested from the virus growth 
experiment (Figure 33) were analyzed for the 
recombination between the viral genome and the replicon 
vector. M54 gene, indicating viral genomes, were 
amplified with PCR primers M54-for and M54-rev. As 
indicator for cellular debris PCR detecting lbr was 
performed with primers LBR-for and LBR-rev. Presence 
of the m74 gene in wt-MCMV and deletion viruses was 
performed with primers m74-for and m74-rev. 
 
 
 
4.3.2 Trans-complementing MCMV∆M50 on NIH3T3:M50-ori 
As a second proof-of-principle, the trans-complementation of the viral M50 protein with the 
replicon system was analyzed. The protein M50 belongs to the essential nuclear egress complex 
of MCMV. M50 is a type II membrane protein of approximately 35 kDa, which is located in the 
inner nuclear membrane and recruits viral as well as cellular partners [99]to promote the egress of 
viral capsids form the nucleus to the cytoplasm. Isolated constitutive expression of M50 was 
found to be toxic for the cell and thus no trans-complementing cell line could be constructed by 
conventional methods [150]. 
 For the generation of the M50-ori cell line a C-terminal HA-tagged M50 ORF was 
inserted into the vector pEpiNo-luc-ori, replacing the luc gene. NIH3T3 cells were transfected 
with the resulting vector pEpiNo-M50-ori and two stable cell pools were obtained two weeks 
post transfection by selection with G418. Western blot experiments were performed with the two 
cell pools M50-ori t1 and t2 under infection and mock conditions (Figure 36). Interestingly, no 
M50HA expression was detected in the uninfected state, already at this early stage of analysis, 
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indicating a very fast silencing process of the M50HA gene. However, infection did induce a 
strong M50HA signal in both cell pools. Loading of the blots was controlled by detecting actin 
and the viral infection rate by detecting IE1/3. Both cell pools expressed M50HA at comparable 
levels after infection. 
 
Figure 36: Western blot analysis of M50-ori cell pools 
Detection of the M50HA protein (~35 kDa) in cell lysates of NIH3T3, M50-ori t1 and M50-ori t2. To analyze the 
induction of M50HA, the respective cell lines were infected with wt-MCMV at an MOI of 1 or mock treated and cell 
lysates harvested 36 h p.i. Viral load was analyzed by detection of IE1/IE3 (76 kDa/89 kDa) and cellular load was 
analyzed by detecting actin (42 kDa). No expression of M50HA could be detected in uninfected cells, whereas a 
strong induction of the protein was observed after infection of the M50-ori t1 and t2 cell pools. 
 
 M50 is an essential protein for MCMV. To assess the ability to trans-complement a M50 
deletion virus, the BAC pSM3fr-∆1-16-∆M50-F (MCMV∆M50), which encodes a gfp gene at the 
endogenous position of M50 and as a late fluorescence marker mCherry with an IRES site behind 
the endogenous scp ORF, was transfected into M50-ori t1, M50-ori t2 and NIH3T3. The parental 
BAC without M50 deletion served as positive control (MCMV-mCherry). At three days post 
transfection first plaques of MCMV∆M50 were detectable in the M50-ori t1 and t2 cell pools but 
not in NIH3T3. At five days post transfection, full lysis of the cells by the reconstituted viruses 
occurred. In contrast, MCMV∆M50 could not be reconstituted on NIH3T3 cells, due to the lack 
of the essential M50 protein, and no plaques were detectable up to the end of the experiment 
four weeks post transfection. This indicates a very effective reconstitution of the deletion virus in 
the M50-ori cell pools. 
RESULTS 
82 
 
 In order to assess the reversion of MCMV∆M50 to a wt-MCMV virus, supernatants of 
M50HA trans-complemented MCMV∆M50 (MCMV∆M50/M50HA) were harvested one day 
after full lysis occurred in the reconstitution plates and titrated on M50-ori and NIH3T3 cells by 
TCID50. Remarkably, the viral titer of 2 × 107 TCID50/ml of the trans-complemented virus was 
comparable with viral titers obtained with wt-MCMV. However, genetic reversion did also occur, 
as few plaques could be detected after infection of NIH3T3 or MEF cells with 
MCMV∆M50/M50HA at high titers. This recombination could be detected in 1 out of 104 to 105 
PFU when complemented on the M50-ori cell pools. 
 The subcloning of the cell pools led to a variety of clones, which showed major 
differences regarding their performance, as already seen with the other replicon constructs. From 
twelve subcloned M50-ori cell lines, three clones failed to reconstitute pSM3fr-∆1-16-∆M50F 
(MCMV∆M50 BAC). In six cell clones only a slow reconstitution compared to the wt controls 
was observed, as seven days post transfection only very small plaques were detectable and 
reconstituted virus spreaded very slowly in these cultures. In three further subclones M50-ori cl 
1.7, M50-ori cl 1.8 and M50-ori cl. 2.1 a very efficient and fast reconstitution of the MCMV∆M50 
BAC was found. Serial dilution of MCMV∆M50/M50HA derived from M50-ori cl 2.1 on 
NIH3T3 and M50-ori showed again a very high titer of the reconstituted virus of 5.4 × 107 
PFU/ml. Fluorescence microscopy detecting the reporter protein mCherry of 
MCMV∆M50/M50HA indicated an effective spread on M50-ori cl 2.1 cells, while infection 
stopped after initial infection on NIH3T3 cells (Figure 37). Thus the rate of recombination of the 
virus on M50-ori cl 2.1 cells was much lower than recombination rates of viruses reconstituted 
on the M50-ori cell pools.  
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Figure 37: Fluorescence imaging of MCMV∆M50-mCherry/trans M50HA on NIH3T3 and M50-ori cells 
Supernatants derived from the reconstitution of MCMV∆M50-mCherry on M50-ori cl.2.1 cells were serially diluted 
and used to infect NIH3T3 and M50-ori cells. Fluorescence images were performed detecting the mCherry signal 
derived from the reconstituted virus. While on M50-ori cells, the trans-complemented virus spreaded to neighboring 
cells and formed plaques after 5 days of incubation, the same supernatant only initially infected NIH3T3 cells, but d 
spread to neighboring cells.  
 
 With aging of the cell clones even better performances regarding viral titers and smaller 
recombination rates were observed. Virus reconstitution on M50-ori 1.7, 1.8 and 2.1 in parallel 
resulted again in very high titers of reconstituted viruses. Especially the clone 2.1, performed 
extremely well with a titer of 3.4 × 108 TCID50/ml, while recombined viruses titrated on NIH3T3 
were under the detection limit of the assay with 8,3 × 101 TCID50/ml (Table 8). Although 
recombination rates were sometimes extremely low, no cell clone was isolated whose progeny did 
not form any plaque in NIH3T3 cells, meaning that recombination could not be entirely 
excluded. 
 
Table 8 : Reconstitution of MCMV∆M50 on various M50-ori cell lines  
BAC pSM3fr-∆1-16-∆M50-F was reconstituted on different M50-ori cell lines. After full cell lysis, supernatants were 
harvested and titrated on M50-ori (the respective cell line) or NIH3T3 cells via TCID50. (n.d.= not detectable). 
experiment cell line for 
reconstitution 
titer of reconstituted virus detection limit 
on M50-ori cells on NIH3T3 cells 
(reversion rates) 
No. 1 M50-ori t1 5.4 × 106 TCID50/ml 1.2 × 103 TCID50/ml 4.3 × 102 TCID50/ml 
M50-ori t2 2.5 × 107 TCID50/ml 1.2 × 103 TCID50/ml 4.3 × 102 TCID50/ml 
No. 2 M50-ori t1 2.5 × 107 TCID50/ml 1.2 × 103 TCID50/ml 4.3 × 102 TCID50/ml 
M50-ori t2 7.9 × 107 TCID50/ml 7.9 × 102 TCID50/ml 4.3 × 102 TCID50/ml 
M50-ori 2.1 5.4 × 107 TCID50/ml 7.9 × 102 TCID50/ml 4.3 × 102 TCID50/ml 
No. 3 M50-ori cl. 1.7 1.1 × 107 TCID50/ml n.d. 8,3 × 101 TCID50/ml 
M50-ori cl. 1.8 2.3 × 105 TCID50/ml n.d. 8,3 × 101 TCID50/ml 
M50-ori cl. 2.1 3.4 × 108 TCID50/ml n.d. 8,3 × 101 TCID50/ml 
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4.4 In vivo analysis of the replicon system- generation of the transgenic 
mouse line VIOLA 
In order to test if the induction principle of the oriLyt-expression system can be eventually used 
for intracellular immunization principles in transgenic animals, the system had to be evaluated in 
the in vivo situation. So far, the episomal vector pEPI-1 has not been used for the generation of 
transgenic mice. Successful establishment of episomes was demonstrated in transgenic pig fetuses 
generated via sperm mediated gene transfer [151]. This technique of gene delivery is not 
commonly applied for the generation of transgenic mice, where the use of either microinjection 
of DNA into the pronucleus of fertilized oocytes or the injection of embryonic stem cells (ES) 
into blastocysts are common procedures. As the latter one allows the pre-selection of suitable 
transgenic ES cells, generation of transgenic replicon-carrying mice was performed by this 
technique.  
 Firefly luciferase (FL) is a non-toxic and very sensitive expression marker. Therefore, FL 
was preferred over the DN GFPSCP as a transgene for the first generation of the transgenic mice 
to test functionality in vivo. The general outline of the strategy followed the scheme presented in 
Figure 38. ES cells were transfected and isolated cell clones were selected for virus-induced 
expression of FL. Responding ES cells were then used for the transfer into blastocysts and 
generation of chimeras. Progeny of the chimeras were subsequently checked for germ line 
transmission of the pEpibo-luc-ori plasmid and the resulting mouse lines were evaluated for their 
ability to express FL upon MCMV infection. The newly generated mouse line was termed 
VIOLA for virus induced oriLyt-dependent luciferase animal. 
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Figure 38: Outline of VIOLA generation and selection 
Generation of virus inducible oriLyt-dependent luciferase animal (VIOLA). mES cell clones were transfected with 
pEpibo-luc-ori and (1.) pre-selected for their induction capacity by MCMV infection in vitro. (2.) Mouse lines were 
analyzed for expression of FL before and after infection in explant cultures of several organs. 
 
4.4.1 Transfection and selection of mES clones for the generation of transgenic mice 
Murine embryonic stem cells (mouse line 129 14.1, [124]) were transfected with pEpibo-luc-ori 
by nucleofection (Amaxa). Two different conditions for further culture and selection were tested. 
mES cells need to be grown on feeder cells to maintain their pluripotent state. Either mES cells 
were grown on mitomycin-inactivated luc-ori cl.4 cells (carrying the bsr restistance gene, 
condition A) or mitomycin-inactivated MEF feeder cells (condition B).To select for positively 
transfected mES cells, Blasticidin S was added to the culture medium. In case of condition B 
selection of transfected mES cells with Blasticidin S kills also the feeder layer cells, whereas under 
condition A feeder cells survive due to the integrated bsr copy, but might not provide all 
necessary factors to keep the cells pluripotent.  
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Figure 39: Differentiation of transfected mES clones. 
As mES cell clones cannot be productively infected with MCMV, cells were differentiated according to the protocol 
of Matsukage et al. [132]. Undifferentiated mES cell cultures (upper row) are differentiated by withdrawal of the 
Leukemia inhibitory factor (LIF) and feeder cells. Differentiate cultures formed spikey fibroblast like cells 
surrounding mES colonies after three weeks. Feeder layers in condition A are NIH3T3:luc-ori cl.4 and MEF in 
condition B. 
 Four cell clones of each condition were picked, grown up and splitted in two parts. One 
part was frozen for later blastocyst injection, the other one expanded for in vitro-testing of the 
clones. MCMV can infect mES cells only after differentiation, therefore cells were differentiated 
first. Cells were differentiated by removing feeder cells and LIF according to the protocol of 
Matsukage et al. [132]. After three weeks of continuous culturing, morphology of the mES cells 
changed to a fibroblast-like appearance (Figure 39) 
 Clones were then infected with MCMV and a bioluminescence assay was performed 
36 h post infection.  As permissivity to MCMV is dependent on differentiation status of the cells, 
the results are only semi-quantitive. Nevertheless, cells either responded to MCMV infection 
(even only in the range of two-fold) or did not express luciferase at all. Two clones, A3 and B8, 
one from each condition, were selected for the generation of the transgenic animals as they 
showed a clear FL induction upon infection. 
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Figure 40: Selection of transfected mES clones by inducibility upon MCMV infection. 
A) Differentiated mES clones were mock treated (white) or infected with MCMV (hatched). In three clones A10, B1 
and B9 no expression of FL could be detected (BG: Background of substrate luciferin). In all other clones induction 
of FL could be detected upon MCMV infection. B) The fold induction of luciferase expression was calculated as 
ratio of the RLU of infected to non-infected cells. Three clones A3, B8 and B11 showed an explicit induction upon 
MCMV infection. Clones A3 (VIOLA-A) and B8 (VIOLA-B) were chosen for the generation of transgenic mice. 
 
4.4.2 Testing of the generated VIOLA- mouse lines 
4.4.2.1 Inheritance of pEpibo-luc-ori in the mouse line VIOLA 
Viable chimeras were born from both blastocyst transfers of mES clones A3 and B8. Agouti 
coat-color indicated a successful germ-line transmission in the C57BL6 blastocyts (black fur) in 
the first generation (F1), and mice progeny were screened by PCR for the presence of the luc 
transgene (Figure 41). From both transfers one mouse line each could be bred that transferred 
the luc gene to its progeny. The lines were termed VIOLA (virus-inducible oriLyt dependent 
animal) line A or B respectively. 
Figure 41: Genotyping PCR of VIOLA mice. 
Depicted is a typical result from a genoytyping PCR of the 
VIOLA-A line. Genomic DNA was extracted from 
mouse tail pieces and subjected to PCR analysis with the 
primer P(SV40)-probe-for and pA(SV40)-probe-rev, 
which amplifies the 2.2 kb luc gene. Genomic DNA from 
luc-ori cl. 1 line was used as positive control (+). 
 
 VIOLA lines inherited the luc transgene stably over several generations. Surprisingly, it 
followed a typical mendalian pattern, as around the half of the progeny carried the transgene 
when crossed to a non-transgenic background mouse (Figure 42). 
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Figure 42: Pedigree of VIOLA-A line.  
Yellow symbols represent animals positive for the 
luciferase transgene. Black symbols represent wt animals. 
Round symbols indicate female mice, squares male mice. 
42.1 % of the progeny of the chimera were positive for 
the transgene. 
 
 
4.4.2.2 Southern blot analysis of pEpibo-luc-ori status in VIOLA 
In this study, the first transgenic mouse based on the episomal pEPI vector system was 
described. Therefore, the replicon vector was analyzed regarding its maintenance type in the 
VIOLA mice genomes. Genomic DNA of uninfected mice was extracted from mouse tails and 
was subjected to Southern blot hybridization. A probe detecting the luc gene was used for the 
detection of the vector. Linearized pEpibo-luc-ori vector served as positive control and for the 
estimation of vector copies. Two mice of the VIOLA-B line and five of the VIOLA-A line were 
analyzed. For episomal persistence of the replicon vector only a single band was expected. Yet, in 
all mice, two bands with equal and lower size than the linearized vector were obtained after 
restriction digestion with an enzyme that cuts only once in the pEpibo-luc-ori plasmid. Thus, 
signals in all mice corresponded to a pattern typical for vector integration (Figure 43). While the 
signal for unique length was present there was also a band of lower size detectable with the same 
signal strength. The presence of episomal vector copies cannot be formally excluded but the 
presence of additional bands with the same intensity as the unique size band, indicate a mainly 
integrated presence. Hybridization signal of the 100 pg control and the signals obtained from the 
mice had comparable signal strength, thus the vector copy number can be roughly determined to 
be between 1-10 copies per cell. 
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Figure 43: Southern blot analysis of VIOLA lines.  
Genomic DNA of 129X1/SvJ or two VIOLA- B and five VIOLA-A mouse tails (of the 3rd and 4th generation) was 
extracted and digested with PstI. As control the vector pEpibo-luc-ori was linearized with PstI and loaded at different 
amounts (100 ng, 10ng, 1 ng, 100 pg, 10 pg, 1 pg). Asterisks mark specific bands probed with an anti-luc-dig probe, 
indicating an integration of the pEpibo-luc-ori constructs in the VIOLA lines.  
 
4.4.2.3 Non-invasive bioluminescence imaging of VIOLA-lines 
As the luciferase gene should be activated by infection in the replicon system, the VIOLA lines 
were infected with MCMV and analyzed by non-invasive bioluminescence imaging. To determine 
whether the VIOLA mice would produce bioluminescence signal after infection, three mice of 
the VIOLA line were infected i.v. with 1×106 PFU wt-MCMV into the tail vein. As controls the 
background line 129X1/SvJ was also infected with wt-MCMV or, for a positive control with 
MCMV-luc with 1 × 105 PFU, respectively. Bioluminescence signal was measured daily over a 
period of five days. To determine the background FL signal, bioluminescence images were taken 
from all mice before infection. No bioluminescence signal could be detected in any of the non 
infected VIOLA mice (data not shown). Bioluminescence signals in the positive control mice, 
129X1/SvJ, infected with MCMV-luc followed a typical infection pattern (Figure 44).  
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Figure 44: Non-invasive imaging of VIOLA-lines and controls 
From left: 129X1/SvJ infected with 1 × 105 PFU/ml MCMV-luc, 129X1/SvJ infected with 1 × 106 PFU/ml wt-
MCMV, or VIOLA infected with 1 × 106 PFU/ml wt-MCMV. Depicted is one exemplary VIOLA mouse of three 
animals in the experiment. Mice were injected with 300 µl 50 mM Luciferin and anesthetized with 2 % isofluran gas. 
Bioluminescence images were taken with the IVIS Lumina imaging system, with 5 min exposure time and highest 
binning rate of 8 pixels. 129X1/SvJ mice infected with MCMV-luc served as positive control and followed a typical 
MCMV infection pattern. Depicted are images taken one, two and three days post infection. VIOLA mice did not 
produce infection specific bioluminescence signals.  
 
 A local infection of the tail and also the liver as well as the spleen was monitored at the 
first days of infection (Figure 44). At day 3 and 4, infection of kidneys can be seen (data not 
shown). Infection of the lungs can be monitored from day 3 on. Very weak signals can be also 
detected in salivary glands at day 5 (data not shown). No bioluminescence signal was detected in 
the negative control mouse 129X1/SvJ infected with wt-MCMV at any time point. Unexpectedly, 
also all VIOLA mice did not show any bioluminescence signal as response to infection at any 
time point.  
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 In order to exclude that the mice were not sufficiently infected, virus titers were 
determined in several organs of VIOLA mice infected with 1 × 106 PFU wt-MCMV and 
bioluminescence assays were performed in the organ homogenates in parallel. Again, no 
bioluminescence signal was detectable in infected organs of VIOLA mice. Determination of virus 
titers in the organ homogenates revealed normal virus titers according to the typical course of 
dissemination. Thus failure of FL expression is not due to a lack of MCMV infection in the 
transgenic mice. 
  
Figure 45: Virus titers in infected VIOLA mice 
In order to exclude that failure of bioluminescence 
induction is due to lacking infection in the transgenic 
mice, viral titers in organ homogenates were determined. 
VIOLA mice were infected with 1 × 106 PFU/ml wt-
MCMV and sacrificed at day 5. Organs were 
homogenized and virus titers determined with standard 
plaque assay. Titration of the organs revealed normal 
viral loads (black squares). (DL = detection limit of each 
organ respectively; depicted is the standard deviation) 
 
 
4.4.2.4 Ex vivo analysis of VIOLA explants cultures 
To analyze the lack of induction in more detail, explants cultures of mice were made. To this end, 
a simple and versatile protocol for the extraction and cultivation of different organ and tissues 
from individual mice had to be developed (see 3.3.6). Lungs, kidney, heart and fat tissue of four 
VIOLA mice, two of the 2nd and two of the 3rd generation, as well as a 129X1/SvJ were extracted 
and explanted. Cultures were grown until at least two confluent 6 well dishes could be obtained. 
Explant cultures of the majority of organs were obtained, however, as the protocol was not 
optimized for each organ specifically, some extractions failed. Cultures were infected with wt-
MCMV at a calculated MOI of 0.5 or left untreated. Infection density was always lower than the 
calculated dose, as permissive as well as non-permissive cells were extracted. As the proportion of 
these cells were not equal, infection density could not be equalized. Thus results reflect only 
semi-quantitative data. In contrast to the bioluminescence assays in infected animals and their 
organ extracts we found induction of FL in tissue cultures derived from these mice (Figure 46). 
In one mouse induction of 500-fold could be detected in one organ, and no induction could be 
seen in cells from another organ of the same mouse, which reflected the different permissivity of 
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MCMV to certain cell types. FL expression correlated typically with the presence or absence of 
rounded cells, a marker for CMV infection (data not shown). 
 
 
Figure 46: Induction of FL in VIOLA explant cultures upon MCMV infection. 
Mice of the second and third generation of VIOLA-A were sacrificed and various organ and tissues were explanted. 
Shown are explants cultures of lung, kidney, fat and heart that were infected with MCMV or left untreated (not for 
all animals all organ explants were successful). Due to the inhomogeneity of the explants cultures infection could not 
be equalized therefore RLU values represent only semi-quantitative results. Notably, in almost all tissues and 
cultures, FL expression could be induced after infection although no signal could be detected in uninfected cells. 
(BG: Background of luciferin) 
 
 In addition, bone marrow, heart, muscle, fat, spleen and salivary gland tissue were 
explanted of a mouse of the fourth VIOLA generation. Again, specific signals could be obtained 
from extracted tissues. However induction strength was altogether very low in all assayed organs 
(Figure 47), which might be due to the loss of episomal persistence of the replicon vector. Thus, 
the VIOLA mice could be specifically induced upon infection, meaning that the replicon 
expression system can be transferred into the mouse model. However, the induction was only 
detectable in explant cultures but not in vivo. 
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Figure 47 Induction of FL in explant cultures of 
various organs from the 4th generation of VIOLA 
Explant cultures of bone marrow (BM), heart (He), 
muscle (Mu), fat tissue (Fa), spleen (sp) and salivary 
gland (Sg) of a VIOLA mouse of the 4th generation was 
infected with wt-MCMV and bioluminescence assay was 
performed. Signal strength of the induction was very 
low, but induction of FL expression could be detected in 
any of the explanted organ. (BG = background of 
luciferin) 
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5 DISCUSSION 
The replicon system established herein offers a wide application range: successful 
implementations were shown for the study of herpesviral DNA replication, intracellular 
immunization, and trans-complementation of late herpesviral genes. 
 
5.1 Advantages and disadvantages of non-viral episomal plasmid pEPI 
for the generation of stable cell lines  
Pre-experiments (data not shown) indicated that episomal maintenance is an interesting feature 
for the establishment of stable cell lines. Especially, the independence of positional effects 
appeared favorable for reliable expression rates. The major disadvantage of episomal expression 
vectors is the unfaithful distribution of vectors during cell division. In contrast to this, the reliable 
once-per-cell cycle and even distribution to daughter cells is one of the key features of pEPI 
vectors. The essential element of these vectors is the cellular surface matrix attachment site 
(S/MAR) sequence that regulates the episomal maintenance of the vector (see chapter 1.9).  
 While in many human cell types, transgene expression derived from pEPI vectors was 
stable and not subjected to CpG-dependent silencing [109], transgene expression was always 
silenced in all cell types tested in this thesis. In accordance with the results from Jenke et al. [109] 
methylation-dependent silencing was not found in the replicon vectors, as cells did not respond 
to 5'-azacytidine treatment. In contrast, expression of the reporter gene through the replicon 
vectors was strongly silenced by a HDAC-dependent mechanism. This stands in line with results 
from Papapetrou et al. [118], who found also a HDAC-dependent silencing of a pEPI vector in 
murine MEL cells. Detailed studies on transgene expression of pEPI vectors in MEL cells 
revealed strong regulation at the chromatin level [120]. The vector is heavily chromatinized with 
histone H3 that becomes acetylated after treatment with TSA, leading to transcriptional 
activation (as also seen with the replicon vector). Therefore, Tessadori et al. concluded that pEPI-
derived vectors are regulated ‘remarkably’ similar to host genes and are also responsive to histone 
modulation. Interestingly, inactivation of reporter gene expression on pEPI in MEL cells or the 
replicon vectors in the NIH3T3 cells did not result in vector loss although an active transcription 
unit was reported to be a crucial pre-requisite for vector maintenance [112]. Tessadori et al., 
however, also found regulation by H3K9 methylation and direct methylation of DNA. The 
literature regarding methylation of pEPI vectors is, however, contradictory [109, 113, 118]. 
Differences in chromatin modifications indicate a species-specific or cell type-specific mode of 
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action of pEPI vectors and S/MAR elements. Interestingly, the kinetic of silencing was 
dependent on the type of transgene, as the genes for the toxic M50 and the GFPSCP proteins 
were much faster inactivated than the luc gene. This indicates once more the influence of the host 
chromatin on the regulation of the replicon vector in order to inactivate ‘unwanted’ genes.  
 While transgene silencing points to a limited use of the standard pEPI vectors in murine 
cells, the reliable inactivation of the vector served as tool for viral trans-activation of gene 
expression in the replicon system. Stable cell clones with the replicon vector were kept under 
continuous antibiotic selection pressure in this work. Failure of the antibiotic in one case did 
result in loss of the vector (data not shown). This is contradictory to published results in which a 
silenced pEPI vector remained stable without selection [118]. By transcribing the antibiotic 
resistance gene, even at low levels during selection, the S/MAR site might promote stronger 
association to chromatin as proposed by Jenke et al. [110]. This would explain the genomic 
integration of the replicon vector in mice lacking selection pressure. Silencing of the episome 
would thus result in poor maintenance of the vector, as no transcription would run into the 
S/MAR element and hold it in an open, meaning active, conformation. 
 Transgenic mice on the basis of the pEPI vector have not been generated so far. 
However, transient gene therapy studies with the pEPI vector have been described in mice. 
Intravenous injection of pEPI-1 into mice did not result in prolonged transgene (luciferase) 
expression or DNA persistence when compared to a conventional plasmid [152] indicating that 
the vector is not automatically maintained as an episome in mice. In the original pEPI vector an 
hCMVie promoter controls the transcription unit running into the S/MAR site. In several 
studies, including this one, this promoter has been found to be prone to epigenetic silencing [113, 
153]. However, change of the hCMVie promoter to cell type-specific promoters, as alpha 1-
antitrypsin, or novel synthetic promoters, as CMV-EF1α hybrid promoter, offers the possibility 
to influence the duration of transgene expression and with it maintenance of the derivative vector 
[152, 153]. Thus, transgene expression and vector stability are closely linked properties. In this 
replicon system, however, silencing of the transgene expression was important for transgene 
regulation. Inhibition of silencing would prevent the usage of cell-toxic transgenes. This leads to 
a dilemma, as discontinuous expression seems to be detrimental for stability but favorable for 
expression of toxic proteins. Murine S/MAR sites, as identified in the α-globin gene [154], and 
constitutive promoters could enhance transgene expression and thereby also the stability of the 
vector. It needs to be tested, if the second transcription unit downstream of the S/MAR site, 
which harbors the transgene, might be still silenced in this case or not. As S/MAR sites do also 
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work as insulators [155], individual transcription units on the replicon vectors could principally be 
regulated independently. This hypothesis is supported by the fact that the antibiotic resistance 
gene was always active ex vivo in this study by continuous addition of antibiotics to the cell culture 
while the reporter gene was inactivated. Still, balancing the two effects might be difficult to 
achieve in vivo. 
 
5.2 Induction of transgene expression through DNA replication 
The herpesviral expression profile is determined by a cascade of gene induction, with sequential 
immediate-early, early and late gene expression. This cascade is (besides other elements) achieved 
by usage of different viral transcription activators that possess specific binding sites in promoters 
of genes. Therefore, it was reasonable to assume that by using viral promoters the specific 
induction of a gene can be obtained. Several studies showed the possibility to activate herpesviral 
promoters in trans [137]. Here, five representative viral promoters were tested for their 
responsiveness to MCMV infection. To this end, the promoters P(M143), P(M53) and P(M94) as 
well as the control promoters P(hCMVie) and P(SV40) were cloned upstream of an firefly 
luciferase ORF into the vector pEpibo. The FL expression under control of the minimal P(SV40) 
was unaffected by MCMV infection and thus was used as control henceforth to dissect additional 
regulatory effects in further experiments. For the MCMV promoters, induction could be 
detected, which corresponded to the expected kinetic profile. Nevertheless, the overall induction 
levels were quite low, limiting their usage for further studies. However, the expression driven by 
isolated late herpesviral promoters in trans does not reflect the expression kinetics in the viral 
context and the expression from such constructs is started under early kinetics. In the context of 
viral infection, the dependence on DNA replication in cis for true-late gene expression is a well 
known phenomenon and defines a true-late viral protein. The mechanism of this ‘cis-dependent’ 
regulation, however, is not yet understood. 
 Replicon expression aimed at very strong expression to cope with expression levels 
reached during natural viral infection. It is known that plasmids containing herpesviral origins of 
replication-sequences can be replicated in trans [156]. However, it was not known whether 
combining an oriLyt sequence to an expression unit has an enhancing effect on transcription. 
There are controversial opinions about the cooperativity of replication and transcription. It has 
been stated that DNA replication and transcription are two exclusive mechanisms, which would 
hinder each other as the DNA sequence is occupied by the respective binding proteins [157]. The 
other opinion supports the view that DNA replication enhances adjacent gene transcription 
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[158]. As herpesvirus true-late gene expression is dependent on DNA replication of the viral 
genome it was unlikely that amplification of the replicon vector would hinder the expression of 
the encoded transgenes. Indeed, MCMV infection, more precisely viral DNA replication, induced 
the expression of the encoded transgenes in replicon vector-transfected cells. Experimental 
evidence was given by inhibition of the viral DNA polymerase by a drug, which blocked 
induction of the transgene, while the presence of the oriLyt sequence in the vector was necessary 
to obtain induction. This supports an obligatory role of DNA amplification of the replicon 
construct for transgene induction. Due to this feature, the oriLyt-containing pEPI constructs 
were coined here as replicon vectors. 
 The induction of gene expression from replicon vectors was generally remarkably high, 
up to 1,000-fold induction of FL expression at 36 h post infection in independently isolated cell 
clones. Already the mere amplification of the template could account for this effect. On the other 
hand, DNA replication and replication forks could change chromatin structures, which would 
make the gene more accessible to the transcription apparatus. In the present tests, the induction 
of the transgene upon infection was around 10 to 100-fold higher than by reactivating the 
construct from silencing by trichostatin A, even if the maximal non-toxic concentration of TSA 
was added (data not shown). Thus, both aspects account for the induction of the replicon vector, 
as the vector is released from silencing, and the number of vector copies that means the 
transcription templates is increased. 
 In many herpesviral oriLyt sequences functional or cryptic promoters have been 
identified. Therefore, adjacent ORFs can be principally transcribed by activation of oriLyt 
promoters. Yet, the influence of an unknown promoter in the MCMV oriLyt sequence on the 
replicon vector can be excluded, as the oriLyt is positioned downstream of the transgene 
expression unit. Another possibility for induction of the transgene could be the existence of an 
enhancer element within the oriLyt sequence. In this case, the enhancer is either directly activated 
by DNA replication or the trans-acting factor that activates the enhancer is a viral late protein in 
order to explain the inhibitory effect of PAA. Although PAA acts directly on the DNA 
replication apparatus by mimicking the pyrophosphate leaving group of the nucleotide transit 
reaction [159], PAA inhibits not only DNA replication but also all subsequent DNA replication-
dependent steps like late gene expression. True-late proteins are not expressed under PAA 
treatment. Therefore, the inhibition of the transgene expression on the replicon vector using 
PAA can in principle reflect the lack of a late viral protein. Therefore, it cannot be formally 
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excluded that the presence of certain (late) trans-acting transcription factors suffices for induction 
of gene expression, without the need to replicate the construct. 
 In the γ-herpesvirus MHV68, viral proteins were identified that are essential for late 
viral transcription. Deletion of these genes causes inhibition of late gene transcription while 
DNA replication is not affected [160, 161]. These findings, therefore, partially refute the dogma 
of late gene transcription and replication forming an inseparable unit. Recently, the deletion of 
UL79 of HCMV has been found to cause the same phenotype as seen in MHV68 [162]. The 
HCMV protein UL79 shares 51 % amino-acid sequence identity with the yet uncharacterized 
M79 protein of MCMV. It is likely, that the proteins present functional homologues. In this case, 
it might be interesting to see, whether the replicon system could be activated by an MCMV∆M79 
virus and how or if the transgene expression might change. 
 To obtain clarity if DNA amplification or induction of a late gene is the trigger for 
activation of the reporter gene, the MCMV replication proteins, especially the oriLyt activating 
protein, need to be identified. If cells carrying the replicon can be induced solely by the replicator 
proteins, DNA replication and with it the change of the chromatin state should be sufficient to 
activate adjacent gene transcription. If these proteins cannot activate the transgene, it would be 
more likely that activation is dependent on, or due to, a late viral transcription factor. CHIP 
analysis could help in both cases to identify the viral proteins bound to the replicon vector.  
 Induction of genes adjacent to replication origins is not limited to viral genomes. An 
interesting observation has changed the former static view of replication origins. In metazoa 
several classes of replication origins exist, of which some are activated very early during S-phase 
and others activated later on [163]. Usually early-firing replication origins are found in actively 
transcribed regions but are not limited thereto. Furthermore, not all potential origins are used 
during DNA replication as initiators for the replication fork. Some are only passively duplicated 
like any other DNA sequence [164]. Remarkably, some replication origins are only used during 
certain stages of development of the organism. This implicates regulatory effects between 
replication origins on gene expression and effects of transcription on origin usage [165]. A simple 
model for the activation or desilencing of genes during DNA replication was described by Wolffe 
in 1991 [166]. Every nucleosome is displaced in front of the replication fork. With ongoing time 
the newly synthesized DNA is again packed in nucleosomes. In excess of transcription factors 
that can bind to the promoter elements of the deliberated DNA, further packaging into tighter 
nucleosome structures is inhibited. Thereby, replication opens a window of opportunity to 
reorganize epigenetic imprinting and transcription factor binding on the replicated genes [158, 
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165]. Similarly, incoming herpesviral genomes are rapidly packaged by histones that are again 
removed during DNA synthesis [167], which might contribute to the DNA replication-
dependent expression of true-late genes. Furthermore, this model could also explain the 
desilencing effect of the replicon vector after DNA replication. (Figure 48)  
 
Figure 48: Model of the disruption and reassembly 
of nucleosomes during DNA replication. 
In order to facilitate DNA replication nucleosomes are 
disrupted in front of the replication fork. First original 
H3-H4 histones are reassembled in a random fashion 
and can be exchanged by H3-H4 molecules with 
different posttranslational modified marks (PTM) 
(picture taken from [168]). This replication dependent 
removal of nucleosomes thus opens the opportunity to 
modify the epigenetic landmark or by access of 
transcription factors might even inhibit formation of 
nucleosomes. 
 
 
 A genome-wide study in Saccharomyces cerevisiae revealed that most genes are transcribed 
without being influenced by DNA replication [169]. However, in 3.5% of the genes DNA 
replication was necessary to start gene expression, e.g. genes coding for histones are highly 
upregulated by DNA replication. This indicates that DNA replication or origin activation could 
have an impact on adjacent gene expression even in higher eukaryotes. Still, regulation via this 
way is apparently only rarely used. 
5.3 Intracellular immunization with the replicon vector 
Herpesviruses are important pathogens for humans as well as for livestock. For some livestock 
specific vaccines were successfully constructed, which prevent disease in the animals. However, 
cases of vaccine failures and emergence of more virulent virus strains have been reported in 
vaccinated livestock, because such vaccines do not eradicate the virus but rather prevent 
symptoms of the disease. Herpesviral vaccines stay latent in the host, a basic feature of 
herpesviral infection, and are able to spread within the flocks [83]. This led to the prohibition of 
vaccination for some of the livestock species such as pigs and cattle [170]. The use of dominant-
negative proteins to block virus infection, also termed intracellular immunization, has been 
proposed as an alternative to generate resistant animals. Yet, previous attempts to realize this 
concept have mainly failed due to toxicity of the constitutively expressed viral DN proteins 
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(summarized in section 1.7.2). In the present study several expression systems were evaluated. To 
this end, a replicon system was constructed offering for the first time the possibility to induce 
expression of transgenes, activated by viral wild type infection and concomitantly to produce high 
amounts of transgenic protein. Besides the advantages of an inducible system regarding health 
and safety, acceptance for such transgenic animals by consumers is likely to increase as the 
protein is not expressed in the uninfected animal. 
 Previous studies with DN proteins of HSV-1 were hampered by the strong toxicity of 
the transgenes. There were also attempts to generate inducible expression systems, either by 
usage of herpesviral promoters or by chemically inducible systems. Sheppard et al. tried to 
circumvent the toxicity of an HSV-1 DN mutant by using the ICP4 promoter of HSV-1, which is 
activated by herpesviral transcription factors [94]. Nevertheless, constitutive expression of the 
DN was found already in absence of infection and the toxicity of the transgene could not be 
avoided. Similar results were obtained in the present study, when MCMV promoters of different 
kinetic classes were used. Although all promoters were inducible by infection and the expression 
correlated to the expected time of activation, none of the promoters was inactive in uninfected 
cells. Usually, only short promoter stretches of 500 bp were used to ‘preliminary’ define the 
promoter regions, however, there is only little information about regulatory elements in these 
promoters and adjacent regions. Lack of inhibitory transcription factor binding sites or silencers, 
in the minimal 500 bp promoters, might result in the uncontrolled leaky expression of the 
isolated promoters. Due to overlapping coding sequences, borders of genetic elements, especially 
promoters are hard to define. Usage of longer promoter sequences might help to get tighter 
regulations, but bears the risk to include genetic elements of overlapping or the complementary 
strand sequences.  
 Obviously, herpesviruses are able to strictly control the timing of gene expression and 
protein production during infection. Recent data from Marcinowski et al. (personal 
communication) point to an even more complex mechanism to regulate gene expression, as the 
transcription of true-late genes can be found during a short period at immediate-early time points 
although no protein can be detected at this stage. Viral post-transcriptional regulation, however, 
has so far not been analyzed at large and might be difficult to translate into an expression 
cassette. 
 A major improvement to the regulation of dominant-negative proteins for intracellular 
immunization was achieved by the replicon vector system. The host-mediated silencing of the 
expression cassettes was highly reproducible in all assayed cell types in this study, although the 
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time period, until complete inactivation was reached, was dependent on the individual transgenes. 
‘Harmful’ proteins were, in general, inactivated much faster than non-toxic proteins. For 
example, the regulation of the GFPSCP was extremely tight, as no fluorescence could be detected 
in uninfected cells. The infection of the GFPSCP-ori cells with MCMV-mCherry revealed a high 
correlation of the infection marker mCherry and induced GFP fluorescence. Although the 
correlation was calculated to be greater than 95 %, this number might even be underestimated as 
the fluorescence signals of mCherry are typically higher than the GFP signals and ‘negative’ cells, 
carrying only one fluorescence signal could be possibly re-evaluated at later stages of infection. 
The mCherry gene was set under control of the late SCP promoter; still the timing might not be 
completely identical, although the replicon system is also activated under late kinetics, which 
might lead to a miscalculation of fluorescence correlation. 
 Although the replicon expression system drives a very strong gene expression, MCMV 
spread could not be completely blocked in GFPSCP-ori cell lines. In contrast to the cell lines, a 
recombinant virus encoding the DN protein in the viral genome was not able to spread [103]. In 
this case, expression of the DN occurred in early kinetics and thus the inhibitory protein had a 
headstart before the onset of expression of the wt scp gene. The DN was more abundant 
compared to the wt protein and could occupy binding sites before the wt protein is even present. 
As the replicon system is activated in late kinetics, it is much harder to out-compete the wt SCP 
protein. Note that SCP is one of the most abundant proteins in the viral capsid [171]. The 
GFPSCP protein was only selected to demonstrate proof-of-principle, as the expression of the 
DN is simple to monitor by the marker. Other DN proteins, which are less abundant, might be 
better targets to inhibit MCMV spread.  
 Most remarkable, the replicon system having on average two copies per cell reached the 
same inhibitory potential as another previously tested episomal papilloma virus-derived vector 
system B45, which is maintained with 50 to 100 copies per cell and constitutively expresses 
GFPSCP (data not shown). The low copy number of replicon vectors in cells is probably 
advantageous to reduce potential side effects. As 2 to 10 copies of pEPI-vector were typically 
found per cell and in particular 2 copies of the DN replicon vector in the GFPSCP-ori cl. 3 
clone, it is possible that cell lines with a higher initial vector load might result in a stronger 
inhibition of MCMV spread. In this case, it is unlikely that the presence of few more replicon 
vectors will cause stronger side effects, as the additional DN genes are most likely subjected to 
silencing as well. 
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  Generation of virus-resistant animals is the aim of intracellular immunization. As a first 
test of functionality of the replicon vector in vivo, a firefly luciferase transgene was used to 
generate transgenic mice. In the resulting VIOLA mice (standing for virus-inducible oriLyt-
dependent luciferase animal) the bioluminescence of the transgene is easier to monitor and to 
quantify compared to an inhibitory DN protein, which should be used in the end. Testing the 
replicon vector in vivo led, however, to unexpected results. In particular, the expression of the 
replicon vector encoded transgene was detectable only after infection in explant cultures but not 
in the living animal. Furthermore, the replicon vector was not stably maintained as an episome in 
the VIOLA mice. Rather integration of the replicon vector was found. Without having 
explanations and answers to these findings, it had no point to generate transgenic animals with 
the GFPSCP containing replicon.  
 To gain more information on these peculiar results, it has to be completely ruled out 
whether the total FL signal in VIOLA was too weak to be detected due to a rather low infection 
density in mice compared to the tissue culture experiments or whether there was really no 
induction of transgene expression upon infection in vivo. If the former assumption is correct, the 
induction in individual infected cells could still inhibit viral spread. Unfortunately, the vector 
integrated in the genomes of VIOLA mice. This, however, makes the expression dependent on 
positional effects of the integrated vector. Positional effects might thus also explain the failure of 
the VIOLA-B line in contrast to the VIOLA-A line, which showed also different integration 
patterns in the Southern blot experiments. Large numbers of animals will be needed to screen for 
expression of the transgene before and after infection using an integrating construct. Therefore 
optimization of the vector for episomal maintenance is necessary before applying the replicon 
system. The fact that episomal maintenance was found in transgenic pigs with the pEPI-EGFP 
vector [151] opens however a window of opportunity to directly translate the replicon system to 
the pseudorabies virus, which is an important veterinary pathogen (see section 1.7). Therefore, if 
the pEPI-vector is already suitable for the usage in swine, further adaptation of the replicon 
vector to mice seems not to be essential. Notably, the sequence of the origin of replication of 
pseudorabies virus is well defined [172] and should be thus easily transferable to the replicon 
system. 
 
5.4 Usage of the replicon vector to study MCMV oriLyt function 
DNA replication of the β- herpesvirus subfamily is not completely understood yet. While some 
work has been published on human CMV (HCMV), almost no data is available for any of the 
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other cytomegaloviruses used as models for HCMV disease, like rat CMV, guinea pig CMV or 
MCMV. While eleven proteins are necessary to replicate an oriLyt-containing vector in HCMV, 
no information is available, which proteins are necessary for the DNA replication of MCMV, 
although the core set of proteins is conserved [30]. The study of DNA replication on MCMV 
might be of special interest as HCMV, like MCMV, does not harbor a special latent origin of 
replication. Moreover, only one replication origin has been identified for cytomegaloviruses in 
contrast to other herpesviruses, which harbor up to three origins of replication. Still, HCMV 
resides latently in actively replicating cells as for example myeloid stem cells [173]. To prevent the 
loss of the viral genome during division of the host cell an active DNA replication process 
appears to be necessary. Therefore, the oriLyt of HCMV, like that of MCMV must provide the 
factors for latent DNA replication. Although there is no sequence homology between the oriLyt 
of MCMV and HCMV, the structural composition and functional elements, such as direct and 
indirect repeats, A/T-rich regions, Y-block and transcription factor-rich binding sites are shared 
[45, 46]. Studying HCMV latency in humans is extremely difficult: information on time-point and 
course of infection in patients without pathological findings and availability of tissue-samples is 
restricted. Therefore a detailed knowledge of MCMV DNA replication and in vivo studies might 
be helpful to elucidate the general mechanism of replication in latency. 
 Identification of the proteins necessary for DNA replication of HSV-1 has been 
performed by a method proposed by Challberg [156]. Viral genome fragments were ligated, cells 
transfected with the plasmids, and super-infected with the respective herpesvirus. Amplification 
of the plasmid with the potential origin of replication was analyzed by Southern blot 
hybridization and several oriLyt sequences were identified by this way [45, 46, 63, 174-177]. Later 
on, plasmids containing oriLyt sequences were co-transfected with several plasmids containing 
herpesviral genes, to clarify which individual proteins were necessary for the amplification [156]. 
Although often successful, this strategy is very tedious and time consuming. In this work, a strict 
correlation of DNA replication and induction of gene expression of the replicon vector was 
found. Applying the replicon vector principle would simplify the identification all replication 
proteins. Superinfection of the luc-ori cells and subsequent bioluminescence assays would 
simplify the procedure. While the Challberg-method relies on Southern Blot analysis as read-out 
of DNA amplification, the DNA replication of the replicon vector is simply monitored by FL 
expression. Southern blot experiments extend over a period of four to five days, a 
bioluminescence assay of the replicon vector system can be performed in less than one hour. 
Optionally, quantitative PCR, which is also the more precise and direct proof for DNA 
amplification compared to the bioluminescence experiments can be added to verify findings from 
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the bioluminescence assay. Yet, the bioluminescence assay is cheaper and less prone to errors 
compared to qPCR, which makes it very interesting for a fast high-throughput screening.  
 Notably, even the minimal oriLyt sequence of MCMV has been mapped only roughly 
and no key elements have been assigned yet. The HCMV oriLyt possesses two important regions, 
whereby one region can be replaced by an SV40 promoter [52]. The replicon vector contains also 
a SV40 promoter close to the oriLyt sequence. This could contribute to the connection of 
replication and gene induction, if the SV40 promoter directing FL expression would mimic part 
of the oriLyt sequence. Several viral as well as cellular transcription factor binding sites have been 
mapped to the HCMV oriLyt sequence, but none of these have been analyzed in detail. 
Mutagenesis of the oriLyt sequence in the replicon vector instead of mutagenesis of the viral 
genome should give clearer results, as there is no risk of analyzing side effects due to overlapping 
ORFs or promoters. A RNA/DNA hybrid has been found in the HCMV oriLyt [178], thus it 
would be interesting to know if MCMV possess also RNA/DNA hybrid regions and how these 
elements regulate DNA replication. Furthermore, miRNAs have been identified close to the 
oriLyt [179]. There is no information about their role, yet. Again, these questions can be 
addressed in the replicon system using the FL expression of the pEpibo-luc-ori vector as a simple 
read-out. 
 The induction of DNA replication varies between the herpesvirus subfamilies. While 
the mode of action is very well analyzed in α-herpesviruses only little knowledge is available for 
the other subfamilies. The origin binding protein of the α-subfamily and also that of the 
roseoloviruses initiates DNA replication by forming a cruciform/hairpin structure by 
complementary intrastrand base pairing, which leads to strand separation and recruitment of the 
core replication proteins [180]. In γ-herpesviruses a hairpin structure is also a key element to the 
initiation of DNA replication. There, an imperfect preformed hairpin within a repetitive element 
is recognized by a viral transcription factor and is an important feature of DNA replication 
initiation [181]. A common herpesviral mechanism of DNA initiation based on the formation 
and stabilization of such secondary elements has been proposed [36]. In cytomegaloviruses no 
hairpin structure has been identified yet, although there are several inverted repeats that would 
allow such a conformation. DNA conformation analysis of the oriLyt might be more easily 
accessible in the replicon vector than in the large MCMV genome, with a size of about 230 kb. 
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5.5 Trans-complementation of late viral proteins with the replicon vector 
Protein trans-complementation is an important tool to study mutant herpesviral genomes carrying 
deletion of essential or non-essential genes. To analyze and control the effect of a targeted 
deletion, in order to exclude additional unwanted mutations in the viral genome, revertants of the 
generated mutants are generated. Genetic reversion is a common procedure, where the original 
sequence is reintroduced into the deleted region. This bears, however, the risk to ‘overlook 
construction flaws’ [182] that originate from overlapping gene or regulatory regions, which will 
be also corrected by genetic reversion but not by trans-complementation. Therefore additional 
information may be gained by reversion of a virus mutant phenotype through trans-
complementation. Furthermore, transient complementation of a mutant virus can help to study 
the function of the protein. 
 Especially the trans-complementation of late herpesviral proteins is a difficult task. 
Improper timing and expression levels on the one hand can hamper the correct localization of 
the proteins, while on the other hand isolate expression, i.e. without the co-expression of viral 
binding partners, can lead to toxicity. Particularly, construction of correctly timed expression is 
hindered by the very nature of herpesviral late gene expression. Only limited information about 
the regulation of true-late gene expression is available. As discussed earlier (see section 5.2) one 
remarkable feature is their dependency on DNA replication for the induction of gene expression 
[183]. Removal of late gene promoters from the viral genome and their insertion into the cellular 
genome resulted in wrong, namely early, expression [184]. Correlation of DNA replication and 
late gene expression was demonstrated by the fact that incoming genomes, which were not 
replicated yet, cannot serve as template for late gene expression [183]. Moreover, late gene 
expression could be restored if a late gene promoter or a minimal promoter was present together 
with a lytic origin in cis [185, 186]. Deviations from this principle exist in that some late gene 
promoters were dependent on DNA replication in trans [187]. Although trans-complementation of 
late herpesviral protein is so difficult to achieve with the constitutive expression cassettes, 
nobody has tried to construct an expression cassette mimicking herpesviral late gene expression 
to our knowledge. 
  ‘Toxic’ proteins have to be expressed via conditional systems. The most common 
inducible expression systems are the Tet-ON/Tet-OFF system [67] or the FKBP12 [68] system, 
which rely on the administration of small chemical compounds. By the addition of the 
compound, activation takes place synchronously in all cells in the culture. This activation is 
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independent from the state of virus replication in all cells. In contrast the oriLyt-based system 
uses viral DNA replication as signal for the induction. Moreover, the expression of the transgene 
follows the natural route of late kinetics in the replicon system as the expression increases in 
proportion with the amplification of the vector DNA. Thus each cell is activated individually 
upon infection with incoming virus, which leads to appropriate and correct timing of the late 
transgene. It has to be noted, that due to the replication dependency the system is only suitable 
for trans-complementation of late but not of early viral transgenes. 
 The TET-regulatory system has been successfully used to trans-complement the late 
protein M94 of MCMV [71]. In this case, the M94 gene in the viral genome was replaced by the 
gene encoding the tetracycline transcription activator (tTA) and a cell line encoding the M94 gene 
under control of the tetracycline response element (TRE) was constructed. In this setting the 
virus lacking M94 induces the expression of M94 upon infection in this cell line. By this elegant 
way the tTA protein is produced at the time point the endogenous M94 protein would be 
activated and binds to the TRE element, which leads to the transcription of the transgenic M94. 
In this case, the protein is produced at the correct time point. However, an increase of transgene 
expression as it is achieved with the replicon system does not take place here. While the tTA-
TRE method allowed trans-complementation of the essential M94 protein, the mutant production 
in large scale was tedious (personal communication, C. Mohr). A further disadvantage of the 
system is the necessity to modify the viral genome for presence of bacterial elements in the 
inducing expression cassette within. Especially for vaccine production, bacterial sequences within 
the viral genome should be avoided. The replicon system, in contrast, is activated by wt virus and 
thus allows more possibilities for the design of virus mutants. Moreover the system is not marred 
by the presence of ‘foreign’ DNA elements. 
 Usage of the replicon system for protein trans-complementation was demonstrated with 
two viral proteins, namely gO and M50. In case of the non-essential glycoprotein O, the deletion 
of the gene causes a 2 to 2.5 fold order of magnitude smaller amount of virus in supernatants and 
a strict cell-associated spread. Growth on the complementing cell line gO-ori of the MCMV∆gO 
mutant restored the phenotype, meaning that the virus is no longer restricted to a focal spread 
pattern and releases similar amounts of virus compared to the wt situation. Thus the replicon 
system was suitable to trans-complement even such a difficult transgene like a glycoprotein. Due 
to the host-mediated silencing of the transgenes, the question whether the system is also suitable 
to trans-complement a toxic protein was addressed. Previous attempts to generate M50-
complementing cell lines via common methods failed [150]. In contrast, the creation of M50-
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complementing cell line with the replicon system was very successful. No difference to any other 
non-toxic transgene was detectable regarding efficacy of cell line generation. This was due to the 
fast host-mediated shut-off of the M50 transgene expression. Western Blot analysis revealed the 
absence of the protein in uninfected cells and a high induction of the protein in infected cells. 
Very high titers of MCMV∆M50 virus could be grown on the M50-ori cell lines speaking for the 
high efficacy of trans-complementation. Furthermore, reconstitution of ∆M50 virus from 
transfected BACs was just as quick as the reconstitution of wt virus.  
 Trans-complementation bears the risk of reversion of the mutant virus to wt sequences 
due to recombination of homologous sequences. Viral genes are often organized in an 
overlapping fashion in the genome. Therefore deletion of an open reading frame is not always 
possible, as the neighbouring gene would be affected as well. Furthermore, the replicon vector 
carries the oriLyt-sequence, which of course is present in the viral genome as well. While no 
recombination of MCMV∆gO could be detected when propagated in the gO-ori cells, reversion 
of the M50 deletion was found after propagation on the M50-ori cells. In both cases there were 
complementary sequences in the replicon vector and the viral genome as the genes could not be 
completely deleted due to overlapping coding sequences. However, the selection pressure on 
MCMV-∆M50 is much higher, as the gene is essential for virus spread. The deletion of gO causes 
only a reduction in viral release and a change in the mode of virus entry. The detection of 
recombination is however much more sensitive in case of M50 as a few recombined genomes 
have a growth advantage on non-complementing cells, as these are the only virus mutants that 
are able to survive. The recombination rate in the cell pools was high with 1 of 104 viruses. Yet, 
the recombination rate in the isolated M50-ori cell clone 2.1 was very low with less than 1 of 108 
viruses. Maybe, the presence of non-functional cells in the cell pool, i.e. cells only having the 
resistance marker integrated but not the transgene as seen in the luc-ori cl.4 line, increases the 
selection pressure towards recombined genomes. In case of gO, recombination via phenotypic 
assays is much more difficult to detect as the protein is not essential for virus amplification. Yet, 
even PCR analysis could not detect any recombination of MCMV∆gO with the replicon vector. 
Furthermore, no recombined viruses where found by immuno-histology in mice infected with 
trans-complemented MCMV∆gO (personal communication B. Adler), where recombination 
would provide a major growth advantage and selection pressure would be also very high. It needs 
to be determined what favors recombination with the replicon vector and how it might be 
prevented. 
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 Single cycle viruses (see section 1.6) are of rising importance for vaccine development 
[71, 188]. A single cycle virus is a virus lacking an essential gene in its genome but is trans-
complemented with the respective protein in order to allow the infection of the host. Still, the 
virus cannot spread further to neighboring cells. The major advantage of this vaccination strategy 
is the presentation of almost all antigens and the high safety in comparison to attenuated 
vaccines. A major limitation with single cycle viruses for vaccination is the necessity to trans-
complement the missing protein. Vaccine production needs to be safe as well as efficient in order 
to be applicable. The trans-complementation of essential genes with the replicon vector system 
might help to improve the latter point, as the titers that were obtained after trans-complementing 
mutant viruses in replicon cell lines were comparable to wt titers. Yet, the degree of 
recombination of the vector might limit the usage of the system for vaccine production at this 
stage.  
  
5.6 Difference between ex vivo and in vivo performance of the replicon 
vector system 
While the replicon vector could be very successfully used in tissue culture, its performance in 
mice was disappointing. The question remained why the bioluminescence signal upon infection 
could be easily detected in explanted tissue culture but not in the living animal. A simple solution 
would be to hold the detection limit of the non-invasive bioluminescence signal to account for 
the lack of the FL signal. However, measurements were performed with maximal sensitivity 
settings. Under such conditions it has been possible to detect even as few as 500 to 1000 
bioluminescent cells in vivo [189]. Regarding the infection dose of 1 × 106 PFU wt-MCMV, the 
initial amount of infected cells is much higher as the cell number in the former mentioned reports 
― without even taking further dissemination in account. The high bioluminescence values in 
tissue culture were obtained with an MOI of 0.5; this infectious density is not reached in vivo in 
the first place. However, when amplification and spread takes place high titers can be locally 
obtained, which should have resulted in detectable FL signals. Furthermore, also low MOI 
infection as 0.01 gave a measurable signal in the luc-ori cells.  
 Even invasive bioluminescence assays on organ homogenates were not successful either 
(data not shown), although the sensitivity is here even much higher, as the signal is not blocked 
by fur or tissue. The induction of gene expression was however readily detectable in explanted 
tissue cultures of the VIOLA mice. Still, the bioluminescence values were rather low, compared 
to the data of the luc-ori cell line. One possible explanation for the low induction is the 
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integration of the replicon vector into the host genome. Although the general opinion of 
herpesviral replication proposes the initiation of replication from circular genomes, the 
hypothesis has been challenged as the lytic replication may originate from linear templates [190]. 
Replication of integrated origin of replication sequences of HSV-1 (oriS) has been reported [191]. 
Previous experiments with an oriS associated with an expression unit in an integrated vector, 
proposed that the replication origin had no influence on gene expression [192]. However, as the 
data obtained in that study was derived from integrated constructs, the two data sets, namely with 
and without oriS, were not directly comparable as the influence of positional effects was not 
taken into account. In the line with this, also integrated replicon constructs might be subjected to 
positional effects. This could cause failure of the system or lower induction strength in general. 
Yet, in case of the VIOLA mice, this does not explain the difference between in vivo and ex vivo 
experiments, as the construct has always the same genomic position even if the integration 
decreases full replicon strength. 
 The curious difference of the replicon system in the VIOLA mice is reminiscent to the 
behavior of herpesviral genomes. The hallmark of herpesvirus infection is establishment of latent 
infection. In the latent infection almost no gene expression occurs and no viral progeny is 
produced. A reliable observation is the reactivation of herpesviruses from latently infected cells 
after explantation of tissue [193, 194]. Interestingly, addition of histone deacetylase inhibitors like 
TSA can enhance the reactivation rate. Thus, it can be concluded that the chromatin state of the 
herpesviral genome is involved in the establishment and maintenance of latency. During 
explantation major epigenetic changes occur, which release the latent genomes from the silenced 
state. A similar effect might be active with the replicon vector as well. It might be that the vector 
is in a chromatin state that is inaccessible for the DNA replication machinery of MCMV and 
therefore the induction of gene expression is hindered in vivo. During explantation, a less tight 
meta-stable chromatin status may be established, which can be than resolved during infection. To 
address this question, the epigenetic status of uninfected and infected cells from mice and 
explanted tissue needs to be analyzed. CHIP experiments should show different histone marks to 
proof this hypothesis. 
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5.7 Concluding remarks 
In this study, a herpesvirus lytic origin of replication was combined with the transcription unit 
from an episomal vector to generate a novel inducible expression system, namely the replicon 
vector, which is induced by infection with wt virus. Transgene expression of the replicon vector 
was reliably silenced in all tested cell types. However, upon viral infection, de-silencing and 
activation of the replicon vector led to a >1000-fold increase in induced gene expression. The 
novel and major advantage of the replicon system over other inducible system resides in the 
usage of fundamental viral processes. Wt virus infection suffices and no chemical compound has 
to be added in order to achieve induction of transgene expression. Instead, the DNA replication 
of the infecting virus does also lead to the DNA amplification of the replicon vector, which, in 
turn, releases the vector from silencing and activates gene expression. Due to the increase in 
vector templates a remarkably strong induction of transgene expression was achieved. Therefore, 
the expression of the transgene was much stronger when compared to conventional expression 
systems and can almost cope with the strength of viral expression itself. Moreover, fluorescence 
imaging revealed a nearly perfect correlation of infected cells and cells expressing the marker 
protein. Thus, the transgene is only expressed in the virus infected cell, which undergoes a lytic 
infection cycle. This, of course, prevents toxic side effect by unwanted expression of the 
transgene protein and thus solves the major problem that marred previous applications like 
intracellular immunization and trans-complementation of toxic proteins.  
 The non-viral episomal vector system pEPI offered an interesting opportunity for the 
construction of the replicon vector. Previous reports highlighted the stable expression and 
maintenance of the vector in the absence of antibiotic selection pressure. Silencing of the 
encoded transgene was, however, found in all cell types tested, while FISH analysis revealed the 
mainly episomal persistence of the vector in vitro. Although, this limits the usage of the pEPI 
vector for other purposes were a reliable constitutive expression is needed, it was very 
advantageous for the goal of this study, as an extremely low or no background expression could 
be detected. The generation of transgenic mouse lines based on the non-viral and episomal pEPI 
vector background can be reported herein for the first time, although unfortunately, the vector 
failed to persist in the episomal state in vivo. This emphasizes, while pEPI vectors are used for 
gene therapy in many other studies, which were mainly in vitro, that translation of such system to 
the living transgenic animal certainly needs further (re-) evaluation to consider the demands on 
the vector for reliable performance and to finally proof the concepts in vivo. In other words, the 
results shown herein demonstrate – not for the first time – that data obtained from in vitro 
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experiments are not directly translatable to the living animal. Thus, further studies and re-
evaluation of the in vivo findings made herein are needed. It remains open if and how a transgenic 
mouse stably homing an episomal vector can be generated.  
 Yet, the data obtained in this study, helped to solve important aspects on the way to 
implement intracellular immunization to livestock. A major improvement was the lack of toxic 
side effects seen with constitutively expressed dominant-negative transgenes by using a suitable, 
i.e. an inducible, system. The trigger to activate the inducible system must rely within the virus 
itself to achieve a fast inhibition of the infection and, moreover, prevent further spread of the 
virus. Trans-activation of viral promoters was considered as one possibility to obtain a virus-
specific induction, however, with respect to the strength of expression, the activation of viral 
promoters (encoded in the host chromatin) by transcription factors provided by the viral 
infection in trans was rather low. Yet, high expression of the dominant-negative protein is 
necessary in order to block viral spread. The replicon vector provides here the basis for extremely 
high expression levels that can partially cope with levels obtained during viral infection. 
Nevertheless, full inhibition of virus spread could not be achieved with the DN GFPSCP used in 
this study. Targeting proteins, that have lower abundance than the small capsid protein, with 900 
copies per virion, might shift the DN to wt ratio resulting in stronger inhibition. An interesting 
late protein target could be e.g. the portal protein, which is present only twelve times per capsid. 
 The expression and especially the trans-complementation of late herpesviral protein was a 
difficult task as true-late viral proteins are only expressed after viral replication has taken place. 
Out of the viral context, true-late promoters are generally activated with an early kinetic. This 
wrong expression timing often caused problems in trans-complementation resulting in low virus 
yields. This is an unwanted side effect in vaccine production, for example. With the replicon 
vector system viruses lacking the glycoprotein O or the toxic transmembrane protein M50 could 
be successfully trans-complemented to high virus titers. Thus, the replicon system closes the gap 
for production of such virus deletion mutants.  This would allow, if transferable to viruses 
infecting man, to generate spread-deficient vaccines. These should be promising candidates for 
vaccination against infection and/or reactivation of human herpesvirus infections. 
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7 APPENDIX 
7.1  Abbreviations 
BAC  Bacterial artificial chromosome 
BHV-1 Bovine herpesvirus -1 
Bsr Blasticidin S resistance gene 
BS Blasticidin S 
BSA Bovine serum albumin 
CAM Chloramphenicol 
DEAC Diethylamincoumarin 
DN Dominant negative 
DNA Deoxyribonucleic acid 
DR Direct repeats 
dNTP Desoxynucleotide triphosphate 
EBV Epstein-Barr virus 
FCS Fetal calf serum 
FL Firefly luciferase 
gDNA Genomic DNA 
H Hour 
HCMV Human cytomegalovirus 
h p.i. Hours post infection 
i.p. Intraperitoneal 
i.v. Intravenous 
IR Inverted repeats 
KAN Kanamycin 
KSHV Kaposi’s Sarcoma virus 
LB Luria broth 
Lbr Lamin B receptor gene 
LIF Leukemia inhibitory factor 
Luc Firefly luciferase gene 
MCMV Murine cytomegalovirus 
MDV Marek’s disease virus 
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MHV68 Murine herpesvirus 68 
min  Minutes 
MOI Multiplicity of infection 
NEAA Non-essential amino acids 
NTP Nucleoside triphosphates 
OBP Origin binding protein 
o.n. O.n. 
Ori Origin of replication  
oriLyt Origin of lytic replication 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PRV Pseudorabies virus 
qPCR Quantitative PCR 
RFLP Restriction fragment length polymorphism 
RT Room temperature 
SB Sleeping Beauty 
TGN Trans-Golgi network 
URR Upstream regulatory region 
Wt Wild type 
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